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Nedocromil sodium is a high dose anti-allergic drug currently formulated as a pressurised 
metered dose inhaler for the prophylactic treatment of bronchial asthma. There are 
currently no marketed dry powder inhalation formulations, which is due in part to a poor 
understanding of the physicochemical properties of nedocromil sodium and how these 
properties affect the interparticle interactions governing the aerosol performance of the 
powder systems. Therefore, the physicochemical properties of micronised nedocromil 
sodium trihydrate (NST) were characterised and are described.
Low temperature scanning electron microscopy (LTSEM), a technique considered novel to 
the characterisation of pharmaceutical particulate systems, is described. LTSEM provided 
useful information as to the particle size and shape of fully hydrated micronised NST as 
well as enabling the drug particles’ distribution within carrier based powder systems to be 
characterised. The techniques of energy dispersive X-ray analysis (EDAX) and 
environmental scanning electron microscopy (ESEM), as they relate to the characterisation 
of this high dose dry powder inhalation systems, are also described.
NST was not amenable to conventional methods of dry powder inhaler formulation, 
including the preparation of coarse carrier and aggregated powder systems. The in-vitro 
aerosol performance of both systems was governed by the cohesive drug/drug interactions. 
Therefore, alternative powder formulation strategies (novel to NST) were developed in an 
attempt to physically disrupt the cohesive drug interactions and promote more efficient
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regeneration of fine particle material upon aerosolisation. Further manipulation of these 
systems enabled excellent flow properties to be restored without adversely affecting the 
improved aerosol performance of the systems. Following each formulation procedure, 
improvements in the in-vitro aerosol performance of the systems, together with supportive 
LTSEM and ESEM images, were related to changes in the interparticle forces presumed to 
be governing the mixing and aerosolisation of the systems.
It was concluded that the efficient regeneration of fine particles of NST could be achieved 
by the intercalation of fine particle lactose within the aggregated NST system.
By comparing the milled and micronised NST (physicochemical and in-vitro aerosol 
performance), the strong cohesive interactions governing the aerosol performance of both 
carrier based and pure drug aggregated systems were related to the ultrafine nature of the 
micronised material. Imaging of the milled and micronised materials using LTSEM 
together with optimisation of the particle size measurement techniques, enabled alternative 
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Inhalation is now the principal route of administration for drugs whose site of action is 
the lungs (Asking and Olsson, 1997), having several recognised advantages over 
alternative routes of drug administration. Medication for the treatment of respiratory 
diseases reaches the site of action directly, allowing for a rapid and predictable onset of 
action (Timsina et al. 1994). The large pulmonary surface area and extensive blood 
supply provide an excellent site for drug absorption (Timsina et al. 1994). The hepatic 
first pass effect and degradation within the gastrointestinal tract are avoided. Therefore, 
lower doses are generally required reducing the potential for unwanted side effects 
(Newman and Clarke, 1983).
Currently, the main uses for medicinal aerosols are for the immediate and prophylactic 
treatment of asthma and chronic irreversible obstructive airway diseases (chronic 
bronchitis and emphysema) (Smith and Bernstein, 1996). The ultimate goals of asthma 
drug therapy are prevention of symptoms (by controlling bronchial hyperresponsiveness 
and inflammation) and preservation of lung function (Smith and Bernstein, 1996). The 
treatment of acute symptoms involves the use of selective ^-adrenergic agonists, 
anticholinergic agents, theophylline and other xanthine oxidase inhibitors. Long term 
control of asthma usually involves the use of anti-inflammatory preparations containing 
corticosteriods and/or the antiallergic drugs, cromolyn sodium or nedocromil sodium 
(Holgate, 1996; Smith and Bernstein, 1996).
Recent advancements in biotechnology have led to a large increase in the number of 
large molecule drugs available (proteins and peptides). Due to their poor oral
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bioavailability, the majority of these drugs are currently delivered by injection. 
However, many proteins and peptides are relatively well absorbed from the lung (Niven, 
1995; Patton, 1996; Smith, 1997), making it a potential target for the delivery of locally 
and systemically acting biotherapeutics (Berressem, 1999).
Drugs for inhalation can be dissolved in aqueous based formulations for nebulisation or 
in liquefied propellant-based systems for delivery by a pressurised metered dose inhaler 
(MDI). Alternatively, fine drug particles can be formulated as suspensions (MDIs) or as 
dry powder inhaler (DPI) systems, reducing the problems associated with drug 
solubility and stability (Johnson, 1997).
Each of the delivery systems has advantages and disadvantages. MDIs are very 
compact and portable. However, the relatively large size and high initial velocity of the 
delivered droplets can lead to considerable drug loss in the oropharynx (Leach, 1999). 
These problems can be reduced by using auxiliary spacer devices which, provide 
additional time for reduction of the primary droplet size (by evaporation of the 
propellant) (Holzner and Muller, 1994), decrease droplet velocity (Vidgren et al. 1987a) 
and improve the patient’s ability to co-ordinate actuation with inhalation.
Most currently marketed MDIs use chlorofluorocarbons (CFCs) as the system 
propellants. The potential adverse environmental effects of CFCs and the international 
regulations phasing out their production (Tansey, 1997) has led to the development of 
alternative systems for aerosolised drug delivery (Leach, 1995 and 1999). Despite 
significant formulation challenges (Tansey, 1997), MDIs containing alternative “ozone 
friendly” propellants (hydrofluorocarbons) have been developed (Leach, 1999). The
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elimination of CFCs from MDIs has provided the opportunity to more optimally target 
formulations to the deep lung, whilst decreasing oropharynx drug deposition (Leach, 
1999).
However, in addition to the formulation challenges, there continue to be issues relating 
to patients who find it difficult to co-ordinate their inhalation with the actuation of the 
MDI device (Crompton, 1982) although breath actuated MDIs are now available 
(Hickey and Dunbar, 1997; Newman et al. 1991a).
As a result of the problems associated with MDIs, a great deal of effort has been 
directed at improving the efficiency of DPI systems. Advantages associated with DPIs 
include the ease of operation (synchronisation of aerosol discharge with inspiration is 
inherent) and the formulations generally do not require the extensive use of excipients 
(Timsina et al. 1994).
Investigations in the present study have focused on factors influencing the performance 
of dry powders formulated for inhalation. The following sections review some of the 




The particle size is considered to be the most critical factor determining the degree and 
site of drug deposition within the lung (Hinds, 1982; Staniforth, 1996). Particles for 
inhalation can be spherical, fibrous or complex aggregates of smaller particles with a 
highly irregular shape. Therefore, when characterising the properties of particles in an 
aerosol cloud, the aerodynamic equivalent diameter (Dae), a parameter that considers the 
particle size, shape and density is used. The Dae is defined as the diameter of a sphere of 
unit density (1000 m3 kg'1) which has the same terminal settling velocity in still air as 
the particle examined (Gonda, 1988). Assuming the particles do not deviate 
significantly from sphericity, the Dac can be estimated by multiplying the volume 
median diameter (VMD) by the square root of the effective particle density (Hickey, 
1990).
Therapeutic aerosols are generally polydisperse and are described by a log normal 
probability size distribution characterised by two parameters; the count mean diameter 
(CMD) and the geometric standard deviation (GSD) (Gonda, 1988). However, for 
biological applications where the mass of drug is related to activity, the particle size 
distribution is more meaningfully expressed according to particle mass or volume. The 
mass median diameter (MMD) is the particle diameter above which 50% of the aerosol 
mass is contained.
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1.3 Factors Influencing the Deposition of Dry Powder
Aerosols
For drug delivery using a DPI system, the quality of the aerosol cloud is governed by 
three interdependent factors; the patient, the design of the device and the dry powder 
formulation (Ganderton, 1992; Timsina et al. 1994; Zanen et al. 1992).
1.3.1 The Patient
Anatomy o f the Respiratory Tract
The anatomical and physiological features of the respiratory tract as well as the patient’s 
inhalation technique have a significant influence on the aerodynamic behaviour and 
hence the deposition of the inhaled particles (Auty et al. 1987; Vidgren et al. 1988a).
The human respiratory tract is composed of a series of branching airways which can be 
divided into three anatomically distinct regions; the upper respiratory tract or 
oropharyngeal region, the tracheobronchial or conducting airways and the alveolar or 
pulmonary region (Gerrity, 1990).
Particle deposition within the respiratory tract is a complex process caused principally 
by inertial impaction, gravitational sedimentation and diffusion mechanisms (Hinds, 
1982).
Aerosol deposition in the upper airways occurs mainly due to inertial impaction. As the 
inspired air changes direction, the larger aerosol particles (Dae > 5 pm) impact on the 
upper airway walls due to their increased momentum. It is generally accepted that for
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deposition in the tracheobronchial and pulmonary regions of the lung, drug particles in 
the Dae size range of 1-5 pm are required (Gonda, 1992; Hinds, 1982). Particle 
deposition in these regions is governed by gravitational sedimentation and diffusion 
(Hinds, 1982). The large surface area of the bronchioles and alveoli facilitate the rapid 
absorption of the inhaled drug and it is deposition in these regions that is generally 
assumed to be therapeutically important. Excessively small particles (Dae <0.5 pm) have 
such a low terminal velocity that they hardly deposit within the deep lung and are 
therefore mainly exhaled (Zanen et al. 1994).
Mode o f Inhalation
All DPIs in current use are breath actuated and the inhalation flow rate is critical to the 
operation and efficiency of the device. An increased inspiratory flow rate improves the 
deaggregation of the powder, increasing the generation of potentially respirable particles 
(Newman et al. 1991b). This benefit may to some extent be countered by the increased 
velocity and hence greater orophamygeal impaction of the drug particles in the upper 
respiratory tract (Vidgren, 1994).
1.3.2 Device Design
The design of the DPI device has a significant effect on the deaggregation and 
subsequent fine particle deposition within the respiratory tract (Moren, 1992). A 
turbulent airflow is considered more effective for dispersing powder mixtures. 
However, the design principles employed to increase turbulence generally increase the 
resistance of the DPI device and therefore the inspiratory effort required of the patient 
(Clark and Hollingworth, 1993a).
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A large number of dry powder inhalers are currently available, each with different 
designs and operating principles (Bell et al. 1971; Brindley et al. 1995; Steckel and 
Muller, 1997a; Wetterlin, 1988). Hickey and Dunbar (1997) provide a review of 
currently marketed DPI devices and possible future developments.
1.3.3 The Formulation
Powder Mixing
The early theory of powder mixing was based on a concept known as random mixing, 
suggested by Lacey in 1943 (Staniforth, 1987). Random mixing requires there to be no 
particle interactions between the components of a powder mix, assumptions which may 
have been approximately valid when mixing very coarse and dense powders (Staniforth,
1987).
However, when considering finer, less dense pharmaceutical powders, the assumption 
that the component particles are non-interacting is no longer valid (Staniforth, 1987). 
Fine particles have been shown to adhere onto the surface of coarser carrier particles 
(Travers and White, 1971) and this phenomenon has been described as ordered mixing 
(Hersey, 1975).
The fundamental difference which distinguishes an ordered mix from a random mix is 
the nature of the forces influencing the interparticle interactions (Staniforth, 1981). 
Particles in a random mix are mainly influenced by the force of gravity (in a totally 
random mix there will be no cohesive or adhesive interactions between particles). In an 
ordered mix, the fines particles are bound to the larger coarser particles by interparticle 
forces that result from electrostatic, van der Waals or surface tensional interactions. The
ordered units are however still influenced by gravity. However, in the ordered mix the 
gravitational force is weak in relation to the cohesive/adhesive interparticle interactions, 
in the random mix the reverse is true.
However, the formation of ideal random or ordered mixes probably never occurs in 
pharmaceutical powders (Staniforth, 1982). Staniforth (1981) suggested that the two 
mechanisms, ordering and randomisation, exist in a dynamic equilibrium and proposed 
the concept of total mixing. Total mixing encompasses situations in which particles are 
mixed randomly, non-randomly, by ordering, by partial ordered randomisation or by any 
combination of these mechanisms (Staniforth, 1981). Intermediate forms of total mixes, 
in which ordered units containing different number of adherent particles and total mixes 
containing discrete particles as well as ordered units (partially ordered random mixes) 
probably occur most frequently in pharmaceutical systems (Staniforth, 1982).
The area of contact between the two interacting particles governs the strength of the 
interparticle force. This is in turn influenced by the size, shape, separation distance and 
surface properties of the particles (Hickey et al. 1994).
The ultimate aim of all powders formulated for inhalation is the delivery of drug 
particles in the Dae size range 1-5 jim by manipulating the powder system and/or 
optimising the design of the device. However, drug particles in this size range exist as 
cohesive powder systems with poor flow and adverse processing characteristics. 
Furthermore, the drug system is difficult to disperse upon patient inhalation due to the 
highly cohesive nature of fine particles (Hickey et al. 1994). Therefore, particles have
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to be sufficiently fine for deep lung deposition but a coarse particle system helps ensure 
effective powder processing and efficient DPI discharge.
Where a formulation approach has been used to address this issue, two general strategies 
have been adopted. In the first (figure 1.1), the micronised drug particles are blended 
with coarse (e.g. 30-100 pm) excipient carrier particles. This manipulation of powders 
is traditionally considered to result in the formation of an ordered system (Hersey, 1975) 
in which micronised drug particles are bound at active sites on the carrier substrate 
surface (Staniforth, 1996). The inclusion of a coarse carrier also overcomes the problem 
of dose metering and dose uniformity when low dose potent substances are to be 
administered (Ganderton, 1992). The carrier particles are generally designed to have a 
size such that after inhalation, most of them remain in the inhaler or deposit in the 
mouth and upper airways. In order to reach the lower airways, drug particles must 
therefore dissociate from the carrier particles and become re-dispersed in the airflow.
For most drug substances this is an inefficient formulation strategy because: (1) most of 
the drug particles are not liberated from the coarser carrier when the patient inhales and 
(2) drug particles which separate from the surface can often exist as agglomerates which 
are themselves too large to enter the lower lungs.
An idealised interactive mix may be expected with many potent low dose drugs (having 
a drug to carrier ratio typically between 1:50 and 1:500) (Wong et al. 1995a). The 
mixing process may result in a monolayer of drug particles adhered onto the carrier 
surface. However, for high dose drug systems where the drug to carrier ratio is far 
greater (typically 1:1 to 1:10), a pure interactive mix is not possible. The active powder
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in the carrier formulations may be present in a variety of possible states: a) individual 
drug particles; b) drug-drug agglomerates; c) drug particles bound to individual carrier 
particles in mono- or multi-layer configurations and d) as combined drug and carrier 
agglomerates (French et al. 1996; Wong et al. 1995b). The coarse components may 
assist in the mixing process by breaking down aggregates of fine powder, thus allowing 
the adhesion of single fine particles to the surface of the coarser constituents (Yeung and 
Hersey, 1979).
In the second strategy (figure 1.2), interactions between primary drug particles are 
modified using processing conditions selected to encourage the formation of 
agglomerated units of pure drug (Bell et al. 1971; Trofast and Falk, 1996; Wetterlin, 
1988).
Both formulation strategies improve the flow properties of the drug system ensuring that 
downstream processing and subsequent device emptying are efficient. However, 
adhesive forces developed between the drug and carrier particles or the internal cohesive 
drug-drug interactions observed in agglomerated formulations may be of a magnitude 
that prevents efficient regeneration of the primary drug particles under clinically 
achievable inspiratory conditions (Zanen et al. 1992).
The aerosol performance of carrier based and agglomerated dry powder formulations is 
predominately influenced by the particle characteristics and interactions within these 
systems.
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a) micronised drug 
particles and the 
coarser carrier 
lactose particle
b) micronised drug particles adhere 
to the surface o f the lactose 
carrrier to reduce free surface area 
and hence the surface free energy 
of the system
(a)
c) drug particles should 
detach from the carrier 
surface upon patient 
inhalation
(c)
Figure 1.1 Diagrammatic representation o f a coarse carrier based powder system
Controlled
Aggregation
Figure 1.2 Diagrammatic representation of an aggregated powder system.
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1.4 Interparticle Forces
The current generation of aerosol therapies has failed to fully exploit the potential of the 
pulmonary route for drug delivery (Hindle et al. 1998), due in part to a poor 
understanding of the interparticle forces dictating the performance of the systems.
Powder mixing, flow, fluidisation and dispersion are influenced by particle interactions 
(Stewart, 1986). For the majority of DPI formulations, powder deaggregation and 
dispersion currently relies solely on the energy harnessed by the device upon the 
patient’s inhalation. To improve the effectiveness and reproducibility of the aerosol 
performance, a better understanding of the interparticle forces that govern the behaviour 
of drug powders formulated for inhalation is required.
Micronised drug particles present in DPI formulations are thermodynamically unstable, 
possessing excess surface free energy. The exposed surface area can be decreased by 
self-agglomeration or adhesion of the drug particles to the surface of a coarser carrier 
component (Staniforth, 1987).
The total force of interaction in a mixture will consist of a number of force components 
(Stewart, 1986). Particle interactions are primarily dictated by: van der Waals, 
electrical, electrostatic (coulomb) and capillary forces (Stewart, 1986, Visser, 1989). 
The relative contribution of these components to the total adhesion/cohesion in a 
particle system will depend on the interacting materials, environmental humidity and 
processing factors (Padmadisastra et al. 1994a). The size, shape, rugosity, hardness and
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chemical composition of the interacting particles influence these interactions (Hickey et 
al. 1994).
1.4.1 Van der Waals Forces
Three types of van der Waals interactions exist; dipole, induction and dispersion or 
London-van der Waals forces (Com, 1966). Of these examples, London-van der Waals 
interactions provide the major contribution to molecular forces (Com, 1966).
London-van der Waals forces arise due to the random movement of electrons within an 
atom or molecule giving rise to the formation of temporary dipoles, which in turn 
induce complementary dipoles in nearby molecules (Visser, 1989). Attractive forces 
arise between the dipoles and the induced dipoles (Visser, 1989). Because of their 
limited charge, these forces have a very short distance of activity (Hiestand, 1966). 
However, when integrated over all the molecules in the contacting particles they are the 
major cause of particle cohesion (Visser, 1989). The van der Waals force (Fvdvss) 
acting between spherical particles of identical diameter separated by a distance (h) is 
given by;
Ar
F vdwss = Y2h2 Equation 1.1
Where r is the particle radius and A is the Hammaker constant.
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A more appropriate model for low dose carrier based powder formulations is to consider 
the attractive interactions between a spherical particle and a flat surface;
F -  —  vdwSp ~  ^ 2  Equation 1.2
where Fvdwsp is the van der Waals force acting between a sphere and a flat plane. The 
Hammaker constant is a material property that can be directly related to the molecular 
properties on the interacting particles (Visser, 1989).
Van der Waals forces are only noticeable when the particles become sufficiently close, 
i.e. separation distances of 0.2 to 1 nm (Visser, 1989). The magnitude of the van der 
Waals attraction becomes negligible compared with that of the gravitational force when 
the particle size exceeds a certain value. This value is of the order of a few microns 
(Visser, 1989).
Under “standard” conditions, i.e. no electrical charging and humidities <65% RH, the 
cohesive interactions of fine particles formulated for inhalation will be governed by the 
van der Waals interactions (French et al. 1996; Staniforth, 1995). The van der Waals 
interactions are very much dependent on the separation distance, the particles’ 
properties (Hammaker constant) and the region of interaction (Visser, 1989). The 
separation distance (h) between fine particles is the single most important factor 
governing the van der Waals attraction (equation 1.1 and 1.2) therefore, any means to 
increase the interparticle distance will reduce the attractive forces.
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Any effect that increases the area of contact between particles, without increasing the 
separation distance, will lead to an increase in interparticle interactions. Extended 
contact areas are found in particles having a partly flattened surface that may be due to 
their inherent structure, e.g. crystalline material.
1.4.2 Electrostatic Forces
Electrostatic forces can be formed by triboelectric charging (sliding/frictional forces 
involved) or by the formation of a potential difference when two dissimilar materials 
make and then break contact (Kulvanich and Stewart, 1987a). The charge that results 
from such processes will depend on the nature of the material, surface properties and 
environmental conditions (Mackin et al. 1993). The direction of charge transfer is 
governed by the difference in electron affinity of the two interacting materials 
(Kulvanich and Stewart, 1987a; Staniforth and Rees, 1982).
Triboelectrification is determined by many factors, such as particle properties (size, 
shape, physicochemical properties of the contacting surfaces), atmospheric conditions 
and processing parameters (particle motion, processing time) (Bailey, 1984). In most 
pharmaceutical processing conditions, the relative movement/collisions of particles 
provide an ideal environment for the development of contact potential or electrostatic 
charge (Kulvanich and Stewart, 1987a). Processes that may induce triboelectrification 
in pharmaceutical powders include; the preparation of fine particles (mechanical 
micronisation and spray drying), mixing and fluidisation in a turbulent airstream. 
During mechanical micronisation, the particle size is reduced by means of collisions 
between coarse particles so that the larger particles are broken up and fine particles are
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produced. These collisions may produce high electrical charges on the micronised 
particles (Bailey, 1994).
Triboelectric charging and ionisation methods have been used to increase the stability of 
powder mixes (Staniforth and Rees, 1982). It has been reported that excipient powders 
generally charge negatively when contacted with metal or glass surfaces whereas many 
charge positively when contacted with plastic surfaces (Staniforth and Rees, 1982). 
Most pharmaceutical excipients have a low resistivity and therefore rapidly lose the 
electric charge. However, the short lived increase in electrical interactions may 
facilitate closer surface contact between interacting particles causing a more permanent 
increase in van der Waals forces (Staniforth, 1987, Visser, 1989).
Electrostatic charge and charge decay of both the drug and carrier material may also 
affect drug delivery from DPI systems (Peart, 1996).
At low humidities (<30% RH), electrostatic effects markedly influence the degree of 
interaction. However, at increased humidities (>65% RH), capillary forces arising due 
to water vapour condensation at the interface of the particle become more predominant 
(Kulvanich and Stewart, 1988).
1.4.3 Surface Tensional Forces
The RH influences the type of interparticle interactions predominating in the powder 
mix (Kulvanich and Stewart, 1988). The presence of moisture in a powder system can 
impair the flow properties of the material, adversely affect stability and influence the 
aerosol performance of the formulation (Genus et al. 1997; Zografi, 1988).
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At a particular temperature and humidity, the amount of water associated with a solid 
will be dependent on its chemical affinity for the solid and the number of available sites 
for interaction (Konty, 1988). Water may be adsorbed onto the solid surface and/or may 
be absorbed into the bulk solid structure (Brittain et al. 1988; Khankari and Grant, 
1995). In hydrates, water occupies definite positions in the crystal lattice usually 
forming hydrogen bonds and/or co-ordinate covalent bonds with the anhydrate drug 
molecules (Khankari and Grant, 1995).
For non-hydrating, crystalline materials, the moisture associated with the particles at 
low humidities is adsorbed water vapour (Coelho and Hamby, 1978a). At increased 
levels of humidity, water vapour condensation at the interface of the interacting particles 
may give rise to capillary forces (Coelho and Hamby, 1978a; Kulvanich and Stewart,
1988). The critical relative humidity at which condensation first occurs ranges from 65 
to 80% (Coelho and Hamby, 1978a). As the critical humidity is reached, liquid bridges 
become stable and capillary forces should become the main component of the 
interparticle interaction (Coelho and Hamby, 1978b). In addition, if the material is very 
water soluble, formation of bridges of solid material at particle-particle contacts can 
occur as the liquid evaporates from the capillary region (Padmadisastra et al. 1994b).
When both adsorption and absorption occur, the term sorption is used.
Adsorbed moisture may increase the van der Waals interactions as the adsorbed layer 
may be regarded as part of the particle thus causing a decrease in the interparticle 
separation distance (Coelho and Hamby, 1978a). However, adsorbed moisture will 
reduce the electrostatic forces as humidity causes the surrounding air to become
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conductive and therefore facilitates rapid discharge of the particles (Coelho and Hamby, 
1978b).
1.4.4 Measurement of Interparticle Interactive Forces
Forces of adhesion/cohesion are generally determined by two approaches. In the first, 
measurements are based on the behaviour of a large number of particles and include, 
angle of repose determinations, vibration assessments (Staniforth, 1984; Staniforth and 
Rees, 1982 and 1983), shear stress and packing density measurements (Hiestand, 1966).
The second approach employs methods that determine the interparticle forces acting 
between individual powder particles and surfaces, e.g. pendulum impaction techniques 
(Concessio et al. 1988) and centrifugal methods (Kulvanich and Stewart, 1987b and 
1987c; Staniforth et al. 1981).
The interactions of fine drug particles bound to larger carrier particles (or glass beads) 
have been assessed using a modified centrifuge cell (Kulvanich and Stewart, 1987b and 
1988; Staniforth et al. 1981). More recent designs have used a scattering of coarse 
particles fixed to the centrifuge cell with drug particles then added to the experimental 
surface (Peart, 1996; Podczeck et al. 1995 and 1997). Centrifugal techniques have also 
been used to assess the influence of RH on the adhesive properties of model drug-carrier 
interactive systems (Kulvanich and Stewart, 1988; Podczeck et al. 1996 and 1997).
The removal of individual particles from carrier surfaces can be studied using the 
atomic force microscope, potentially allowing greater characterisation of the isolated 
sites of adhesion (Bowen et al. 1998; Mizes, 1994).
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1.5 Pre-Formulation Aspects of Dry Powder Aerosols
A number of physicochemical properties of the constituent particles must be optimised 
to ensure efficient powder processing and effective aerosol performance (Staniforth,
1995). These properties include particle size, density, morphology and surface 
composition (including adsorbed moisture) (Edwards et al. 1997; Hickey et al. 1990; 
Staniforth et al. 1996).
1.5.1 Physical Properties of the Drug Particles
Drug particle size is the most important parameter governing the efficient and effective 
performance of DPI formulations (Staniforth, 1996). The particle size is a primary 
determinant not only of the fraction of aerosol deposited but also of the deposition site 
itself.
It is difficult to specify an ideal size for aerosol particles, partly because it is not certain 
where the particles should be deposited within the respiratory tract and partly because of 
the difficulty in predicting the aerodynamic behaviour of the inhaled particles. The 
deposition pattern can be complicated by hygroscopic growth (Byron et al. 1977), 
particle agglomeration and particle charge (Balachandran et al. 1991).
However, it is generally considered that to promote deposition within the deep lung, 
powders containing drug particles with an Dae <5 pm must be employed (Ganderton and 
Kassem, 1992). Studies using liquid aerosols (where aerodynamic and geometric 
diameters are comparable) have demonstrated that an Dac window of 1-3 pm is optimal
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for inhalation drug delivery (Adjei and Garren, 1990; Clay et al. 1986; Zanen et al. 1994 
and 1995).
In two separate studies, Zanen et al. (1994 and 1995) found that monodisperse aerosols 
of salbutamol sulphate and ipratropium bromide with a particle size of 2.8 pm, 
produced greater bronchodilation than droplets of a larger size (5 pm). These findings 
were supported by Clay et al. (1986) who found that a terbutaline aerosol (Dae: 1.8 pm) 
induced a stronger bronchodilation in asthmatics than aerosols containing droplets of a 
larger size (Dae: 4.6 or 10.3 pm).
However, when considering DPI formulations, consideration must not only be given to 
the optimal particle size for deep lung penetration but also to the effects of the increased 
cohesive interactions acting between the fine drug particles (Byron, 1986). To date, few 
studies have investigated the optimal drug particle size <5 pm for dry powder systems 
in terms of the contribution of the various interparticle forces on the degree of particle 
deaggregation. It is considered that these interactions will be especially important when 
considering the deaggregation and aerosolisation of pure drug or high dose carrier based 
powder formulations. In these systems, drug-drug inteiparticle interactions would be 
expected to govern the aerosol performance of the formulation.
Persson and Wiren (1989) found that the bronchodilator response was increased when a 
greater mass of terbutaline particles <5 pm (Dae) were delivered. Altounyan (1985) 
found that small particles of disodium cromoglycate (DSCG) (94% <10 pm) produced 
improved clinical effects compared with larger particles (99.5% >10 pm).
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Curry et al. (1974) found a greater response to DSCG when administered in a size range 
around 2.0 pm compared with particles of a larger size (6.0 and 11.7 pm), findings 
supported by Godfrey et al. (1974). Similar observations have been made by Rees et al. 
(1982) who showed greater bronchodilation with terbutaline particles less than 5.0 pm 
compared with inhaled particles in the size range 5-10 pm or 10-15 pm.
However, Wong et al. (1995b) demonstrated a two-fold increase in the generation of 
potentially respirable nedocromil sodium trihydrate (NST) particles, formulated as a 
high dose powder system (50% w/w), when apex-milled drug particles (10.17 pm: VMD) 
as opposed to micronised drug particles (5.01 pm: VMD) were employed. The 
improvement in dispersion and subsequent fine particle deposition was attributed to a 
reduction in the cohesive interactions operating within the milled NST system.
Edwards et al. (1997) studied the in-vivo and in-vitro deposition of particles possessing 
low mass densities and consequently larger geometric particle size distributions such 
that the mean Dae was still considered potentially respirable. The increased particle size 
resulted in a decreased tendency of the particles to aggregate which in combination with 
the low mass density, enabled a more efficient aerosolisation.
Drug Particle Shape and Surface Properties
The morphology of the interacting surfaces will have a significant effect on the 
interparticle interactions influencing the performance of agglomerated or carrier based 
systems. Drug particle shape is largely determined by the method used to prepare the 
powders, e.g. comminution, screening, spray drying, crystallisation etc. The interaction
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between two spherical particles (a) would be expected to be less than between smooth 
flat particles (b) due to the decreased area o f intimate contact (figure 1.3).
Figure 1.3 Diagrammatic representation o f possible interparticle interactions.
Hiestand (1966) suggested that cohesive interactions between fine particles might vary 
due to differences in surface textures. Powders with smooth surfaces (figure 1.3a) 
would be expected to produce higher true areas o f contact compared with irregular 
particles (figure 1.3c) therefore, display an increased cohesive interaction. However, it 
could also be envisaged that the size and distribution o f the asperities might encourage 
maximum contact (figure 1.3d).
The influence o f drug particle shape on the aerosol performance has not been fully 
evaluated however, it has been shown to alter the interparticle interactions in powder 
systems (Wong and Pilpel, 1988; Wong and Pilpel, 1990). When considering the 
adhesion o f fine particles (calcium carbonate) onto the surface o f a coarser carrier 
(lactose), it was demonstrated that the more irregular fine particles tended to adhere 
more strongly to lactose crystals than equivalent more regular particles (Wong and 
Pilpel, 1988). The practical significance o f this is that by exercising control over the 
shapes o f the fine particle, it should be possible to produce an ordered mix that is stable 
towards de-mixing and segregation.
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The effects of drug particle shape on the aerosol performance of powder systems 
formulated for inhalation was investigated by Wong et al (1989) who found that the FPF 
of DSCG was not significantly altered by varying the drug particle shape.
Applications of spray drying to powder formulations for inhalation have appeared in 
several articles (Ampratwum et al. 1997; Chawla et al. 1994; Edwards et al. 1997; 
Vidgren et al. 1987b, 1988a, 1988b, 1989 and 1991). Vidgren et al. (1987b) concluded 
that spray dried DSCG deaggregated more completely to particles within an Dae size 
range of 0.3-3.3 pm compared to micronised particles. Following physicochemical 
characterisation of the micronised and spray dried DSCG material, it was concluded that 
the more spherical spray dried particles experienced decreased cohesive interactions 
compared to the irregular particles of the mechanically micronised material (Vidgren et 
al. 1987b). However, the presented data revealed that there was no significant 
difference in the percentage of particles deaggregating to a size <7.1 pm. Due to the 
smaller particle size of the spray dried material, no conclusions can be drawn regarding 
the regeneration of discrete drug particles since the 3.3 pm cut-off would in theory 
restrict a proportion of the discrete micronised particles reaching the lower stage of the 
impactor. The improved in-vitro aerosol performance of the spray dried DSCG 
compared to the micronised DSCG (based on regeneration of discrete particles), can 
only be attributed to the spray dried material having a smaller particle size and not to 
any changes in the cohesive interactions suggested by the physical analysis of the 
materials.
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Other techniques for the generation of powders for inhalation containing microfine 
particles include supercritical fluids processes (Phillips and Stella, 1993; York and 
Hanna 1996; York et al. 1998) and novel condensation technology (Hindle et al. 1998).
The effects on the deaggregation performance of DSCG particles surface treated with a 
series of saturated fatty acids has been investigated (Fults et al. 1997; Hickey et al.
1992). An increase in stage-2 drug deposition (Dae <6.4 pm) was observed following 
lauric acid and stearic acid treatment (two and three fold respectively) when compared 
to non-treated DSCG. It was concluded that a change in particle morphology of the 
treated DSCG contributed to the improved deaggregation of the drug system (Fults et al. 
1997).
1.5.2 Physical Properties of the Carrier Particles
The particle size and surface morphology of the carrier component influence the powder 
performance of carrier based systems during powder preparation, processing and 
following aerosolisation. A number of different carriers particles have been used 
(Braun et al. 1996; Mackin et al. 1997) although lactose is most frequently employed 
(Timsina et al. 1994).
Drug dispersion is dependent upon the size and shape (French et al. 1996; Robertson, 
1997) and surface morphology (Kassem and Ganderton, 1989) of the carrier particles. 
The size of the carrier can influence both the entrainment of powders and the force 
required to liberate drug particles from surfaces (Akiyama and Tanijri, 1989; Kassem, 
1990; Lord, 1993; Steckel and Muller, 1997b).
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Because adhesion o f particles is a surface phenomenon, the morphology o f the surface 
will have a significant effect on the adhesion o f drug particles (Staniforth et al. 1982). 
Staniforth (1981) concluded that rougher surfaces (associated with deeper energy traps) 
produced higher adhesion profiles than for the same adherent particle component 
blended with smoother carrier crystals. Figure 1.4a depicts particles that are lodged 
between the surface asperities, resulting in stronger adhesive interaction due a larger 
area o f surface contact and a reduction in the interparticle separation distance. 
Therefore, carriers that possess a more porous surface may form stronger interparticle 
bonds due to the entrapment o f  the fine drug particles within surface clefts and 
indentations (Kawashima et al. 1998a).
(a) (b) (c)
Figure 1.4 Diagrammatic representation o f  the possible effects o f the carrier surface 
on the adhesion o f finer drug particles.
The interparticle contacts depicted in figure 1.4b occur only at the tip o f the carrier 
surface asperities. This may result in a decreased interparticle interaction due to a 
decrease in surface contact and an increase in the separation distance. Carrier particles 
with a low surface roughness (figure 1.4c) have been shown to facilitate a more 
effective re-dispersion of drug particles in an inhaled airstream (Kassem and Ganderton, 
1989; Robertson, 1997; Kawashima et al. 1998a).
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Ideally, the surface should be optimised, possessing sufficient adhesion so that ordered 
systems do not segregate in the handling and filling processes but release most of the 
drug substance upon patient inhalation.
1.5.3 Ternary Components
Manipulation of the particle interactions in a dry powder aerosol system can also be 
achieved by the addition of ternary components to the formulation (Lord and Staniforth,
1996). It has been demonstrated that the addition of fine particle lactose (FPL) (Lord 
1993, Lucas, 1998a; Zeng et al. 1998), magnesium stearate (Kassem, 1990; Peart, 1996) 
and L-leucine (Peart, 1996; Staniforth, 1996) can improve the separation of the drug 
from the carrier, improving the aerosol performance of the formulation.
Mechanistically the action of fine particle excipients cannot be unequivocally explained. 
However, according to the ordered mixing theories of Hersey (1975), it is to be expected 
that upon blending, the FPL would occupy the most active binding sites on the carrier 
lactose surface (Staniforth, 1996). In this case, only more passive sites would remain 
available for adhesion of drug particles (Staniforth 1996).
It has also been shown that some drug particles can adhere to the FPL to form drug/FPL 
multiplets (Lucas et al. 1998a). It is considered that the formation of these multiplets 
improves the aerosol performance as liberation of drug or protein particles from the 
surface of FPL can occur more readily than from coarser particles (Lord, 1993; 
Ganderton, 1992). This would be expected since smaller particles have a lower degree 
of surface roughness that restricts opportunities for contacts at clefts and asperities on
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the surface of the substrate. A proportion of the drug/FPL multiplets may also be 
potentially respirable.
1.6 Characterisation of Aerosol Performance
In-vivo methods for determining the efficiency of inhaled drug delivery along the 
respiratory tract include, monitoring clinical changes (Basran et al. 1984; Edwards and 
Chambers, 1989; Persson and Wiren, 1989; Vidgren et al. 1991) and the 
pharmacokinetic assessment of blood and/or urine drug concentrations (Altounyan, 
1985; Hindle et al. 1995). Gamma scintigraphy and single photon emission computed 
tomography have also been used to assess in-vivo aerosol deposition (Biddiscombe et al. 
1993; Newman and Wilding, 1998; Summers et al. 1996). Vidgren et al. (1987b, 1988a, 
1988b, 1989 and 1990) has used gamma scintigraphy to characterise the in-vivo aerosol 
deposition of spray dried DSCG particles.
However, clinical studies are expensive and time consuming. Therefore, alternative 
methods have been developed to assess the potential aerosol performance of powder 
formulations for inhalation. Size measurements on impacted particles using optical 
microscopy have been conducted to characterise the properties of the aerosol cloud 
(Evans, 1993; Hallworth and Hamilton, 1976). However, these techniques do not take 
into account the anatomical structure of the human respiratory tract or the aerodynamic 
behaviour of the particles. Therefore, inertial separation techniques that determine the
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size distribution of aerosol particles based on their mass and velocity are perhaps the 
most appropriate in-vitro methods to assess the potential in-vivo deposition.
However, although inertial impaction methods are based on the principle mechanism 
relevant to the fractionation of aerosols within the respiratory tract, in-vitro aerosol 
assessments can not directly predict the lung dose in-vivo. This is in part due to the 
primitive design of impactors compared with the anatomical complexity of the 
respiratory tract and the fact that many in-vitro deposition studies do not try to mimic 
temperature and humidity conditions within the lungs (Martin et al. 1988). The 
potentially respirable dose as determined by current particle impactors, almost always 
overestimates the actual amount of drug deposited in the lungs (Vidgren et al. 1988a). 
Vidgren et al. (1988a) found a greater in-vitro fine particle deposition (0.3-7.1 pm) of 
spray dried DSCG (39.4 ± 1.6%) compared with in-vivo results (16.4 ± 3.9%). 
Nevertheless, cascade impactors can provide a useful measure of the aerodynamic 
particle size distribution with which to compare devices and formulations.
1.6.1 Impactor Theory
Cascade impaction is based on the principle that a particle/droplet moving in an 
airstream will impact on a surface placed in its path, provided that the inertia of the 
particle/droplet is sufficient to overcome the drag force that tends to keep it in the 
airstream. By successively increasing the velocity of the airstream as it passes through 
the stages of the impactor, the particles are separated into various size fractions. The 
increase in velocity is accomplished by successively decreasing the jet size at each stage 
of the impactor. A pre-separator is often included to collect the larger particles whilst
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the last stage is generally followed by a filter to capture all particles less than the final 
cut-off size.
1.6.2 Apparatus A (BP, 1998)
Apparatus A of the British Pharmacopoeia (1998) is an inertial aerosol classifier also 
referred to as the twin stage impinger (Hallworth and Westmoreland, 1987). The 
aerosol cloud deposits on three impaction surfaces. Following impaction on the back of 
the glass throat, the particles then pass through a liquid impinger (upper impinger) that 
has an effective cut-off diameter (ECD50%) of 6.4 pm at the prescribed flow rate of 60 ± 
5 litres min'1 (Hallworth and Westmoreland, 1987). This has more recently been 
verified (Miller et al. 1992). The last impaction surface is in the lower impinger, which 
traps the remaining drug although Miller et al. (1992) report that a significant fraction of 
sub-micron material may escape this final stage. The throat and upper impinger are 
defined as stage-1; the lower impinger is defined as stage-2.
Apparatus A (BP, 1998) functions simultaneously as a particle sizing device and as a 
means of assessing total drug output. The disadvantage is that the total sample is 
divided into only two size categories and separation between the two fractions is not 
sharp (Hallworth and Westmoreland, 1987; Miller et al. 1992). Since the aerosol cloud 
is only segregated into two fractions, no information is provided on the distribution of 
particle sizes above and below the selected cut-off.
Apparatus A has been used extensively to characterise and compare aerosol systems 
formulated as MDIs and DPIs (Jashnani and Byron, 1996; Jashnani et al. 1993; Lucas et
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al. 1998a and 1998b; Phillips et al. 1990). Various studies have compared its use with 
other inertial impaction techniques (Holzner and Muller, 1995; Olsson et al. 1996).
1.6.3 Cascade Impaction
Cascade impactors provide a useful aerodynamic measure of the particle size 
distribution, which can be used to compare devices and formulations. The impactors 
available vary in their complexity, particle size resolution capabilities and their 
collection efficiencies. The reliability of the impactor data can be influenced by factors 
such as inter-stage wall losses, particle bounce/blow-off, particle deagglomeration or 
break up and the nature of the collection surfaces (Hickey, 1990; Hindle et al. 1996; 
Nasr et al. 1997).
Three different impactors are to be included in the Pharmacopoeias for the evaluation of 
therapeutic aerosols, the Anderson Mk II impactor (ACI), the Marple-Miller Impactor 
(MMI) and the (5-stage) Multi-Stage Liquid Impinger (MSLI). However, none of the 
three impactors are ideal and future work is concentrating on further developing each 
impactor to improve their versatility (Olsson et al. 1998).
The performances of the MMI and ACI with regards the characterisation of therapeutic 
aerosols are discussed by Hindle et al. (1996), Marple et al. (1995) and Vaughan (1989).
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(5-Stage) Multistage Liquid Impinger
The original, all glass, multistage liquid impinger was constructed by May (1966) and 
has since been modified, incorporating additional stages and modified to a metal/glass 
construction to more fully and reproducibly characterise the aerosol cloud (Asking and 
Olsson, 1997; Bell et al. 1973a; Ganderton, 1996).
The upper stage of the MSLI serves as a pre-separator, having a high capacity for 
powder retention (Olsson et al. 1998). The MSLI impinges the aerosol onto wetted 
glass sinters. The trapping liquid used on the impaction stages allows high drug loading 
with minimum risk of re-entrainment (Asking and Olsson, 1997). All the important 
surfaces are easily rinsed therefore, there is no significant wall losses (Asking and 
Olsson, 1997). However, the MSLI is particularly weak as a classifier of fine aerosols 
at low flow rates therefore, an additional liquid stage (ECD50% of 0.7 pm at 60 litres 
min'1) has been designed, calibrated and performance tested to be possibly incorporated 
into the existing 5-stage compendial model (Olsson et al. 1998).
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1.7 Nedocromil Sodium
Nedocromil sodium (NS) (disodium 9-ethyl-4, 6-dioxo-10-propyl-4H, 6H-pyrano[3,2- 
g]quinoline-2, 8-dicarboxylate) (figure 1.5) is a hydrophilic drug (Khankari et al. 1998) 




Figure 1.5 The Chemical Structure of Nedocromil Sodium
Preliminary work on the preparation and physicochemical properties of various 
nedocromil sodium hydrates of NS have been reported (Khankari et al. 1995 and 1998). 
NS has been found to exist in the following hydrate phases; the heptahemihydrate 
(NSHH), the trihydrate (NST), a monohydrate (NSM) and an amorphous phase which 
contains variable amounts of water (1.5-3 moles) (Khankari et al. 1998). The ranges of 
stability for the crystalline hydrate phases at 22°C are: NSM 0-6.4%; NST 6.4 to 79.5% 
and NSHH 80 to 92.9% RH (Khankari et al. 1998). At a RH of 92.9%, NS forms a 
saturated solution whereas at RH > 92.9%, NS forms an unsaturated solution (Khankari
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et al. 1998). The optimum RH conditions for storage at 22°C are: 50% RH (ambient) 
for NST; 90% RH for NSHH and 0% RH for NSM (Khankari et al. 1998).
The monohydrate is the form used in the marketed MDI formulation (Tilade®). 
However, the monohydrate is extremely hygroscopic and rapidly converts to the 
trihydrate at RH > 6.4% RH at 22°C (Khankari et al. 1998). The trihydrate has 
previously been investigated when considering the formulation of powder systems for 
inhalation (Wong et al. 1995a and 1995b).
NST converts to the heptahemihydrate at RH > 80% therefore, when particles of NST 
are inhaled they have the potential to take up moisture in the RT and change their 
particle size and aerodynamic properties by hygroscopic growth (Byron et al. 1977).
The crystal structures of the trihydrate (Freer et al. 1987) and the heptahemihydrate 
(Khankari et al. 1995) of NS have been described but that of the monohydrate has not 
yet been reported (Khankari et al. 1988).
Different Salt Forms o f Nedocromil
Mixing aqueous solutions of NS and water-soluble salts of bivalent metal cations 
produce nedocromil salts of lower solubility than NS (Zhu et al. 1997a). The crystal 
structures and physicochemical properties of various bivalent salts of nedocromil have 
been published; nedocromil zinc (Zhu et al. 1997a; Ojala et al. 1996), nedocromil 
magnesium (Ojala et al. 1996, Zhu et al. 1996) nedocromil calcium (Zhu et al. 1997b) 
and other metal ions (Macrae, 1992). These salts have a much lower solubility in water 
than the sodium salt therefore, rapid water uptake due to hygroscopicity and particle size
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changes due to crystal growth would not be expected. Therefore, more predictable drug 
delivery to the RT may be achieved by selecting a suitable salt form. However, the 
toxicological profile of the salt may limit the usefulness of this approach (Zhu et al. 
1997a). Both zinc and magnesium ions at low concentrations are acceptable for use in 
pharmaceutical applications not involving the lung whereas only the sodium ion is 
suitable in systems formulated for use in the lung (Ojala et al. 1996).
The free acid form of nedocromil has been prepared and the physicochemical (Chan and 
Gonda, 1995) and aerodynamic properties characterised (Chan and Gonda, 1993). The 
free acid of nedocromil shows practically no moisture uptake below 80% RH (<1 % w/w) 
and minimal uptake even at prolonged exposure of the particles to 99.2% RH at 37°C 
(3.5% w/w) (Chan and Gonda, 1995). The elongated particles of the free acid (Dae~l pm) 
may therefore offer advantages for increased pulmonary deposition (Chan and Gonda,
1993).
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1.8 Aims of the Study
Nedocromil sodium is an anti-allergic drug administered in the prophylactic treatment 
of bronchial asthma. There is currently no marketed dry powder inhaler formulation for 
nedocromil sodium, which is due in part to a poor understanding of both the 
physicochemical properties of the micronised drug and the interparticle forces 
governing the aerosol performance of high dose inhalation systems.
Therefore, an attempt was made to formulate model DPI systems and assess the 
interparticle intercations governing the mixing behaviour and aerosol performance of 
these powder mixes.
A study was initiated to characterise the physical properties of the micronised drug 
particles, in particular the size and shape of the crystals, important parameters when 
considering the aerosol performance of powder systems.
Difficulties arise when characterising NST using conventional scanning electron 
microscopy (SEM) techniques, possibly due to the hydration state of the drug material. 
Therefore, it was considered essential to develop alternative microscopic techniques to 
fully characterise the particle size and shape of the micronised material. It was hoped 
that the techniques would enable characterisation of the drug particles’ distribution 
within dry powder formulations.
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By assessing the mixing and in-vitro aerosol behaviour of NST formulations, it was 
hoped that a more fundamental understanding of the interparticle forces governing the 
performance of this high dose powder system would be gained. By correlating the 
deaggregation and subsequent fine particle deposition of the powder systems following 
the various formulatory procedures, it was hoped that the contribution of cohesive 
(drug/drug) and adhesive (drug/carrier) interparticle interactions to the performance of 
nedocromil sodium as a high dose aerosol system could be established.
The cohesive interactions operating within the powder systems were assessed indirectly 
by measuring the deaggregation and subsequent fine particle generation using either a 
modified version of Apparatus A or a multistage liquid impinger.
It was hoped to characterise the effects of storage humidity on the physicochemical 
properties and in-vitro aerosol performance of nedocromil sodium to assess the 
contribution, if any, of adsorbed and absorbed moisture on the cohesive interactions 
operational within the pure drug system.
Finally, based on literature reports suggesting differences in the aerosol performance of 
milled and micronised NST (Wong et al. 1995b), studies to fully characterise the two 
materials (physicochemical and in-vitro aerosol properties) were initiated to increase 








Methanol and cyclohexane were HPLC grade.
Water was freshly distilled (Fisons Scientific Equipment, Loughborough, U.K.). 
Hydrochloric acid (1.0 M) and lecithin were obtained from BDH Ltd., Poole, U.K.
Table 2.1 details the materials used to produce saturated salt solutions and table 2.2 
details the materials used in the detection of fine particle lactose.
Salt Supplier
Potassium chloride BDH Laboratory Supplies, Poole, U.K.
Sodium chloride BDH Laboratory Supplies, Poole, U.K..
Magnesium nitrate BDH Laboratoiy Supplies, Poole, U.K.
Potassium acetate BDH Laboratory Supplies, Poole, U.K.
Lithium chloride Sigma Chemical Co., St. Louis, MO, U.S.A.
Table 2.1 Details of the salts used to produce the saturated salt solutions.
Material Supplier
Glycine powder Aldrich Chemical Company, Dorset, U.K.
Sodium hydroxide pellets BDH Laboratory Supplies, Poole, U.K.
Methylamine 
(40% w/v in water)
Aldrich Chemical Company, Dorset, U.K.
Sodium sulphite BDH Laboratory Supplies, Poole, U.K.
Table 2.2 Details of the materials used for the detection of fine particle lactose.
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2.1.2 M aterials used in the Formulation o f the Powder Systems
Table 2.3 details the formulation materials used in the study.
Classification Material Batch Supplier
Coarse carrier 

















Rhone Poulenc Rorer, 
Cheshire, U.K.
Rhone Poulenc Rorer, 
Cheshire, U.K.
Astra Draco AB, Lund, 
Sweden
Table 2.3 Details of the materials used in the formulation of the powder systems.
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2.2 General Methods
2.2.1 Preparation of Lactose Carrier Sieve Size Fractions
A vibratory sieve shaker (Fritsch ‘Analysette’, Christison, Gateshead, U.K.) with a set 
of standard brass test sieves (Endecotts, London, U.K.) was used for preparing sieve 
size fractions of a-lactose monohydrate. The sieves were assembled in ascending order 
of aperture diameter and approximately 20 g of the powder sample placed on the top 
sieve. The powders were vibrated for approximately 10 minutes, the contents of each 
sieve discharged and the sieve carefully brushed to unblock the mesh. The powder 
fractions were then returned to the sieves from which they were originally removed and 
vibrated for a further 10 minutes. The following sieve size fractions were produced: 
<45 and 63-90 pm.
The 63-90 pm sieve fraction was air-jet sieved (AJS) to try and remove adherent lactose 
fines from the coarse carrier surface. An Alpine air jet sieve (Augsburg, Germany) and 
a brass test sieve of 63 pm were used to remove the undersize fraction. Following 10 
minutes of sieving, the sieve was cleaned in the manner described previously. The 
contents were then replaced on the sieve and the air jet sieve operated for a further 10 
minutes.
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2.2.2 The Control of Relative Humidity
Storage o f the Drug and Excipient Powders
Environments of a fixed humidity were maintained within glass desiccators by 
preparing saturated salt solutions (table 2.4) from freshly distilled water. The 
desiccators were stored over the temperature range 20-25°C (Gallenkamp cooled 
incubator, U.K.) and the RH within the desiccators confirmed using a dial hygrometer.
Salt
Temperature °C
15 20 25 30
Relative Humidity (%)
Potassium chloride 87 86 • 85 84
Sodium chloride 76 76 75 75
Magnesium nitrate 56 55 53 52
Potassium acetate 23 23 22 22
Lithium chloride 13 12 12 12
Table 2.4 Saturated aqueous solutions of the salts (in contact with excess solute)
in an enclosed system produce the humidities indicated.
(Pharmaceutical Handbook, 1980)
Unless otherwise stated, all drug and excipient powders were stored in desiccators over 
a saturated solution of magnesium nitrate at 20-25°C (53-55% RH).
Experiments investigating the effects of humidity on the physicochemical (section 7.2) 
and in-vitro aerosol properties of NST (section 7.3) employed alternative saturated salts 
solutions to produce the desired RH conditions.
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Formulation Procedures
Unless otherwise specified, all formulation procedures (powder screening, size 
classification and mixing) were conducted under ambient laboratory conditions. The 
humidity and temperature within the laboratory for the year 1998 were recorded and 
ranged from 19 to 63% RH and 16 to 29°C.
Following processing, the powder systems were stored at 53-55% RH and 20-25°C. All 
formulations were generally characterised (physicochemical and in-vitro aerosol 
investigations) within a month of preparation.
Storage o f Hard Gelatin Capsules
The moisture content has a marked effect on the visco-elastic properties of gelatin 
capsules (Konty and Mulski, 1989). Konty and Mulski (1989) concluded that capsules 
stored < 40% RH exhibit brittleness at ambient temperature whereas at RH > 85% the 
gelatin sorbs considerable moisture causing swelling and altering the physical properties 
of the capsules.
Initial investigations, revealed that the mechanism of capsule piercing within the 
Cyclohaler® was an important factor influencing the deaggregation and dispersion of the 
powder system. Brittle fracture of the capsule allowed the powder formulation to 
“escape” from the capsule/device without being efficiently deaggregated by the shear 
forces generated upon aerosolisation of the powder system. Therefore, hard gelatin 
capsules (Davcaps®, Hertfordshire, U.K.) were stored in a desiccator at 53-55% RH for 
at least 24 hours before being used in the in-vitro aerosol investigations.
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Several studies have reported on the transfer of moisture between gelatin capsules and 
the contents of the capsules including: Bell et al. (1973b) and Strickland and Moss, 
(1962). The transfer of moisture from the capsules to their contents may render the 
capsules brittle whereas moisture transfer to the capsules may cause capsule swelling 
and stickiness. The accumulation of moisture in an encapsulated powder may also lead 
to chemical decomposition, hydrate formation, moisture binding and cementing of the 
capsule contents.
Therefore, the capsules were removed from the desiccator (53-55% RH) and filled with 
the powder formulation immediately prior to in-vitro aerosol assessment. By filling 
capsules immediately before aerosol characterisation, it was hoped that any moisture 
transfer effects would be minimised. This was considered especially important when 




Metal meshes of defined aperture size (Endecotts sieves, London. U.K.) were used for 
all size classification and screening procedures. Fine particle material (NST, TS and 
FPL) was screened through a 355 jim aperture mesh prior to all formulation studies to 
remove any large agglomerates.
Hand Blending (HB)
Unless otherwise specified, HB was performed by mixing the powders for 15 minutes 
with a metal spatula in a glass mortar. A metal spatula was used in preference to a glass
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pestle in an attempt to control the shear forces generated during the mixing process. 
The powders were screened (355 pm) at the mid-point of the mixing process to 
reduce/destroy any agglomerates and improve blend quality (Lord, 1993; Lucas et al. 
1988a; Wong et al. 1995a).
Turbulent Tumbling Mixer (TTM)
Powders were mixed at 42 rev. min'1 in a glass container (250 ml) using the TTM 
(Turbula T2C, Bachofen, Basel, Switzerland). Studies that investigated the effects of 
extended mixing times and the introduction of additional screening stages on the drug 
content uniformity within the powder blends are described in section 4.2.1. The TTM 
was also used to further promote the aggregation of the NST/FPL powder systems 
(section 6.2).
Rotary Bladed Blender (RBB)
The powders were mixed in a RBB (Kenwood Mini Chopper, CHI00, Kenwood Ltd., 
Havant, Hants, U.K.) at a constant blade speed. At intervals of 2 minutes, the blending 
process was stopped and the plastic mixing chamber emptied. Adhered powder was 
discharged from the wall using a soft powder brush. This procedure was adopted to 
minimise heat generation, by allowing the mixing chamber time to cool, and regularly 
re-introduce adhered powder (from the walls and metal blade of the mixing unit) back 
into the bulk powder bed.
2.2.4 Assessment of the Drug Content Uniformity
Unless otherwise specified, the drug content uniformity of the blends was assessed by 
removing ten powder samples (20 mg) from various parts of the powder bed using a
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metal spatula. The samples were diluted with an appropriate volume of solvent using 
volumetric flasks. The size of the powder samples analysed and the dilution factor were 
dependent on the concentration of drug formulated and were chosen to allow accurate 
quantitative drug analysis. Details of the analytical techniques employed to detect the 
drug compounds are described in section 2.4.
2.3 Physical Characterisation of Materials
2.3.1 Particle Size Analysis
The particle size distribution of all materials used throughout the study was determined 
using the techniques of low angle laser light scattering (LALLS) and time-of-flight 
aerosol beam spectroscopy (TOFABS).
2.3.1.1 Low Angle Laser Light Scattering
Instruments operating on the principle of LALLS calculate the particle size distribution 
(by volume) from the pattern and intensity of scattered light from a cloud of droplets 
traversing a laser beam. The Mastersizer X (Malvern Instruments Ltd., Malvern, U.K.) 
employs a helium-neon laser beam (k = 633 nm) which is shone through a cell in which 
the powder particles are suspended (Diffraction Training, 1993). The scattering of the 
particles is predicted by Mie theory and the information is used to calculate the particle 
size (Diffraction Training, 1993). The Mie scattering theory considers the optical 
properties of the material (Zhang and Xu, 1992) which is important when characterising 
particles <10 pm (Etzler and Sanderson, 1995; Nathier-Dufour et al. 1993). The
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theoretical particle size, which most closely fits the experimental pattern, is presented 
by the instrument (Diffraction Training, 1993).
Materials and Methods
LALLS investigations were performed using the Malvern Mastersizer X in conjunction 
with either the dry powder feeder (DPF), the small volume stirred cell (SVC) or the 
large volume circulating cell (LVC).
Particle Size Characterisation o f NST
The particle size distribution of micronised NST was determined using the SVC. The 
particle size distribution was measured using two dispersant solutions: a) cyclohexane 
and 0.1% w/v lecithin and b) a saturated solution of NST dissolved in cyclohexane and 
0.1% w/v lecithin. Both solutions were filtered (Type A/E glass 76 mm diameter, 
Gelman Sciences, Michigan, U.S.A.) before use. The refractive properties of the two 
dispersant solutions were measured and an appropriate programme presentation 
selected.
The SVC was filled (15 ml) with one of the two dispersant solutions, the optics in the 
instrument aligned and the diffracted light measured with no sample present to establish 
a background reading. A small test tube was half-filled with one of the dispersant 
solutions and a small sample of NST added (approximately 1 mg). The tube was 
manually agitated to facilitate wetting and then placed in an ultrasonic water bath to 
disperse the solid particles. The temperature of the ultrasonic water bath was 
maintained between 20 and 25°C throughout the investigations by the addition of ice 
when required. Following a fixed sonication period, several drops of the suspension
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were immediately added to the SVC until a suitable obscuration level was obtained (15- 
25%). The diffracted light was initially focused onto the photo detector array using a 
100 mm lens (particle size range 0.5 to 120 pm). All solutions were prepared and 
analysed in duplicate.
Once the optimum conditions for deaggregation had been established, a 45 mm lens 
(particle size range 0.1 to 80 pm) was used to more accurately describe the particle size 
distribution of the micronised NST. The large volume circulating cell (LVC) (1 litre) 
was used in conjunction with the 45 mm lens.
Particle Size Distribution o f the Lactose Size Fractions
The particle size distribution of the lactose size fractions was obtained either by 
suspending the particles in the SVC (<45 pm sieve fraction), the LVC (FPL) or by 
feeding the sample across the laser beam through the DPF (63-90 pm sieve fraction). 
The instrumental set-up is described in table 2.5.
Lactose Size 
Fraction
Presentation Optical Lens 
(mm)
Measured Particle Size Range 
(pm)
63-90 pm DPF 300 1.2 to 600
<45 pm SVC 100 0.5 to 120
FPL LVC 45 0.1 to 80
Table 2.5 Instrumental parameters for LALLS studies on the lactose size fractions.
The FPL and <45 pm size fraction were suspended in cyclohexane and 0.1% w/v lecithin
(saturated with the appropriate lactose sample and filtered). Sample preparation and
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size measurements were as described for NST. The samples were examined following 
deaggregation for one minute in the ultrasonic water bath.
The coarse carrier sieve size fraction (63-90 pm) was measured using the DPF. A small 
mass of the lactose sieve fraction (2 to 3 mg) was drawn through the DPF using a 
vacuum cleaner (Electrolux Power System 1500W) at a flow rate of approximately 100 
litres min'1 to aerosolise the powder samples.
Results and Discussion 
Particle Size Distribution o f NST
Tables 2.6 and figure 2.1 detail the particle size distribution of the NST after various 
time periods in the ultrasonic water bath. Table 2.6 and figure Al (Appendix I) detail 
the particle size distribution of NST as measured with the 45 mm optic lens after 
optimum deaggregation (10 minutes) in the ultrasonic water bath. The values of d(0.1), 
d(0.5) and d(0.9) represent equivalent volume diameters with 10%, 50% and 90% of 
particles less than this value respectively.
Pre-sample preparation, in terms of the energy (sonication time) available for 
deaggregation of the drug agglomerates, would appear to be an important factor 
governing the measured particle size distribution of micronised NST. Sonication time 
was investigated over the range 1 to 30 minutes however, the particle size distribution 
appeared to remain constant after approximately 10 minutes (figure 2.1). The 
temperature of the ultrasonic water bath was maintained between 20 and 25°C to 





Dispersant d(O.l)Oim) d(0.5) (jam) D(0.9) (pm)
Run A Run B Run A Run B Run A Run B
1 Non-saturated 0.64 0.61 5.21 1.36 10.15 5.48
3 Non-saturated 0.64 0.62 1.89 1.42 6.87 6.41
5 Non-saturated 0.62 0.62 1.34 1.34 3.86 5.17
10 Non-saturated 0.62 0.62 1.36 1.33 4.45 5.10
15 Non-saturated 0.61 0.62 1.31 1.41 4.70 4.55
30 Non-saturated 0.61 0.62 1.20 1.40 5.82 5.12
1 Saturated 0.67 0.64 2.89 2.50 15.89 12.12
3 Saturated 0.63 0.64 2.15 1.89 6.62 6.87
5 Saturated 0.64 0.62 1.80 1.34 4.76 3.86
10 Saturated 0.63 0.62 1.50 1.33 3.50 3.82
15 Saturated 0.63 0.62 1.57 1.38 4.13 4.62
30 Saturated 0.63 0.61 1.47 1.20 4.32 5.82
a10 Non-saturated 0.20 0.24 0.83 0.89 3.89 4.99
Table 2.6 The effects of sonication time, dispersant solution and focusing optics on 
the particle size distribution of micronised NST.
All investigations utilised a 100 mm lens in conjunction with a SVC except; 
a A 45 mm lens was used in conjunction with a LVC.
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Figure 2.1 Effect of deaggregation time and dispersant solution on the particle size 
distribution of micronised NST.
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Comparison of the particle size data obtained from the saturated and non-saturated 
dispersing solutions following fixed sonication times revealed no apparent differences in 
the particle size distribution. This would suggest that the decreasing particle size of the 
NST was a result of the deaggregation of the agglomerated drug system and not due to 
the drug dissolving in the suspending medium. The particle size distribution of the 
micronised NST after 10 minutes of sonication (LVC) revealed a VMD <0.9 pm with 
90% of the particles having an equivalent volume diameter <5 pm.
Wong et al. (1995b) determined the VMD of micronised NST in liquid suspension 
(LALLS) as 5.01 pm with 67% of the material within the size range 0.5 and 7.0 pm. In 
the present study the particle size distribution of the micronised NST is considerably 
smaller than that determined by Wong et al. (1995b). Reasons for this could include the 
use of different batches of NST or differences in the preparation of the samples prior to 
particle size analysis.
Carrier Lactose Particles
Table 2.7 summarises the parameters that describe the particle size distribution of the 
lactose size fractions. The particle size distributions as determined by LALLS are 
shown in Appendix I (figures A3 to A5).
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Lactose d(0.1) pm d(0.5) pm d(0.9) pm
Size Fraction Mean SD Mean SD Mean SD
63-90 pm AJS 64.9 3.0 96.5 1.7 140.3 5.6
<45 pm 1.3 0.3 23.0 5.1 47.9 6.1
FPL 1.2 0.1 5.8 0.2 19.3 1.0
Table 2.7 Particle size analysis of the size fractions of a-lactose monohydrate (n = 3).
For polydisperse systems analysed by LALLS, the diffraction pattern for each particle 
size overlaps with those of others in the powder system. Therefore, the mathematical 
algorithms and necessary assumptions required for calculation of the distribution are 
complex (Etzler and Sanderson, 1995). The sole use of unknown computer algorithms 
was considered scientifically unwise therefore, the measured particle size distribution 
was measured using alternative methods of particle sizing (TOFABS and SEM 
investigations).
2.3.1.2 Time of Flight Aerosol Beam Spectroscopy
The aerodynamic diameters of micronised NST and the lactose carrier size fractions 
were measured using the technique of TOFABS (Aerosizer® with Aerodisperser®, API, 
Hadley, MA). The Aerodisperser® is a computer controlled variable shear particle 
deaggregator designed to provide aerosolised dry powders to the sizing instrument. The 
Aerosizer® determines the aerodynamic particle size by accelerating particles in a sonic 
expansion flow and measuring their terminal velocity by transit time across two laser 
beams (Mitchell and Nagel, 1996).
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The extent of powder deaggregation was electronically controlled by varying the 
pressure drop across the annular gap between the disperser pin and the pin bowl, which 
in turn produces a resultant shear force (Hindle and Byron, 1995a). Pressure drops in 
the range 0.5 psi to 5.0 psi (3.45 to 34.5 kPa) correspond to low and high shear forces, 
although the shear forces are neither determined nor displayed (Hindle and Byron, 
1995a). The dispersing pin, which creates the pressure drop within the Aerodisperser®, 
was vibrated to reduce deposition of material on the disperser pin. The feed rate of 
powder to the sizing instrument was varied within an effective experimental range of 
5000 to 10000 particles per second. To achieve this feed rate, the disperser 
automatically increases or decreases the strength and duration of the pulsed air supplied 
to the sample chamber (Hindle and Byron, 1995a).
The time of flight data collected by the instrument software is converted to either 
number or volume based frequency distributions and can be displayed as a function of 
the aerodynamic or geometric diameter. True powder densities (required by the sizing 
instrument for data processing) were determined by helium pycnometry (section 2.3.3).
Hindle and Byron (1995a) described their experiences with this instrument specifically 
as it relates to the particle size measurement of several sieve classifications of 
crystalline lactose and also micronised salbutamol sulphate (SS) and terbutaline 
sulphate (TS). Hindle and Byron (1995a) concluded that each compound, because of its 
inherent physical chemistry, required Aerodisperser® method optimisation.
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Materials and Methods
Both the Aerosizer® and the Aerodisperser® were used as supplied. Niven (1993) 
describes the sizing instrument and the deaggregator is described by Hindle and Byron 
(1995a).
Micronised NST
The particle size characterisation of a micronised powder requires that the powder be 
dispersed into its constituent particles. The effects and interactions of the instrument 
variables on the deaggregation and resultant particle size distribution of NST were 
investigated. Operating variables were selected in an attempt to fully deaggregate NST 
(Hindle and Byron, 1995a). High and low shear forces (corresponding to pressure drops 
of 34.5 and 3.45 kPa) at high and low flow rates (5000 to 10000 particles per second) 
were investigated with a sample run time of between 60 and 300 seconds.
Lactose Size Fractions
Hindle and Byron (1995a) concluded that for lactose samples (sieve size fractions 0-63 
pm, 63-120 pm and 120-200 pm), complete deaggregation occurred even at low shear 
forces. The particle size distribution of the lactose size fractions was not significantly 
altered as a function of run time (200-500 seconds). Particle size reduction even under 
high shear conditions did not occur (Hindle and Byron, 1995a).
The particle size distribution of the three size fractions of lactose (63-90 pm, <45 pm 
and FPL) were investigated using a high shear force (34.5 kPa) to deaggregate and 
disperse the powder samples and a high flow rate (10000 particles per second) to feed
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the material into the sizing instrument. Samples were analysed for two minutes and 
three runs were performed for each lactose size fraction.
Results and Discussion
Figure 2.2 summarises the effects of varying the shear force and feed rate on the 
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Figure 2.2 The effects of the deaggregating shear force and flow rate on the measured 
particle size of NST.
A high shear force and a low feed rate appear to produce the greatest degree of 
deaggregation however, even these “optimised” conditions fail to completely 
deaggregate the micronised powder system. Figure 2.2 is just a summary of part of the 
work conducted on trying to optimise the instruments variables (sample run time, shear 
forces, flow rate) in an attempt to fully deaggregate NST. NST failed to deaggregate
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completely for any given set of experimental conditions, a finding also reported by 
Hindle and Byron (1995a) when analysing micronised TS. It would appear that either 
the shear forces generated with the deaggregator instrument are insufficient to 
completely break apart the particles of NST or that the pulsed air supply charges the 
powder particles within the metal sample chamber (tribolelectrification) causing re­
agglomeration of NST particles.
However, Hindle and Byron (1995a) have successfully deaggregated micronised SS. 
Therefore, this technique could be used in future studies to assess the effects of 
physicochemical changes of the NST particles on the cohesive interactions governing 
the deaggregation and dispersion of the powder system (York and Hanna, 1996).
Table 2.8 summarises the parameters describing the particle size distributions of the 
lactose size fractions as measured by TOFABS, data which can be compared to 
information obtained from LALLS and SEM investigations.
Lactose size fraction d(0.1) d(0.5) d(0.9)
63-90 pm (AJS) 55.2 ±3.6 83.6 ±2.9 109.1 ±2.91
<45 pm 20.3 ± 2.4 36.1 ±2.3 45.6 ±1.6
FPL 6.9 ±2.0 14.2 ±1.3 23.4 ± 1.3
Table 2.8 The particle size distribution of the lactose carrier size fractions determined 
using TOFABS. Values are the mean ± SD of 3 determinations.
The data is a summary of a volume based frequency displayed as a function of the 
aerodynamic diameter.
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2.3.2 Surface Area M easurements
Materials and Methods
Surface area determinations for the lactose size fractions (63-90 pm, <45 jam and FPL) 
and micronised NST were performed on the Gemini 2360 instrument (Micromeritics, 
Particle Technology Instruments, Georgia, U.S.A.). Nitrogen was used as the adsorbate 
gas and an empty balance tube of identical dimensions used to measure the pressure 
differential generated.
Fine materials (NST, FPL and the <45 pm lactose sieve fraction) were filled into the 
standard glass bulb (volume: 6.5 cm3). The large glass bulb (volume: 12 cm3) was used 
to characterise the 63-90 pm sieve size fraction of lactose.
Accurately weighed samples were loaded into the appropriate glass bulb and degassed at 
50°C for 24 hours to try and remove pre-adsorbed gases and vapours from the surface of 
the solid (FlowPrep 060 Degasser, Micromeritics, Particle Technology Instruments, 
Georgia, U.S.A.). Increased temperatures were avoided to minimise dehydration of the 
samples. The samples were re-weighed following out-gassing and the values used for 
subsequent surface area determinations.
Results and Discussion
Table 2.9 details the specific surface area of the lactose size fractions and the micronised 
NST. Micromeritics claim that the Gemini 2360 instrument is able to measure specific 
surface areas as low as 0.01 m2 g'1 and total surface areas in the range 0.1 to 300 m2.
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Material Run Adsorption Parameters Specific 
Surface Area 





1 85 0.04 0.9998 1.2
2 93 0.04 0.9999 1.2
3 84 0.04 0.9986 1.2
<45 pm 
Lactose
1 38 0.21 0.9989 0.5
2 36 0.27 0.9989 0.5




1 25 1.63 0.9997 0.1
2 23 1.64 0.9998 0.1




1 61 0.01 0.9999 7.2
2 60 0.01 0.9999 6.9
3 59 0.01 0.9993 7.3
Table 2.9 Surface area determination of the lactose size fractions and NST.
When analysing the surface area data, a number of parameters should be checked to 
ensure the validity of the data. The correlation coefficient should be as close to 1 as 
possible, with a range of 0.999 to 1 being acceptable in most cases (Webb and Orr,
1997). The C constant is a measure of the affinity of the adsorbate for the material. For 
nitrogen, the C value can range from 3 to 1000 depending on the adsorption isotherm of 
the material (Webb and Orr, 1997).
As expected, decreasing the lactose size fraction increased the surface area of the 
material. The far greater specific surface area of the micronised NST when compared to 
the FPL (VMD = 5.8 pm) supported LALLS and LTSEM conclusions that the NST is 
an ultrafine powder. The results were used when: a) calculating the concentration of 
NST required for monolayer particle coverage on the coarse lactose size fraction (63-90 
pm) (Appendix I) and b) comparing the milled and micronised forms of NST (section 
8.3.4).
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2.3.3 True Density M easurements
True density measurements for each sample were determined using a helium-air 
pycnometer (Type 1302 Micromeritics Instruments Corp., Norcross, USA).
Method
NST and the lactose size fractions were stored at 12% RH prior to measurements in an 
attempt to reduce/remove surface moisture. Nedocromil sodium is still stable as the 
trihydrate at this humidity (Khankari et al. 1998). Approximately 0.5 to 1 g of powder 
was accurately weighed into the small sample cell of a helium pycnometer. Each 
powder sample was purged with helium prior to collecting ten sequential density 
measurements and the mean density value determined. The mean value of three 
experimental runs, using different powder samples, was determined.
Results and Discussion
A summary of the density measurements is presented in table 2.10.
The values can be compared with data obtained by Wong et al. (1995a) who estimated 
the true density for micronised NST to be 1.60 g cm’3. The values were used for the 
TOFABS investigations (section 2.3.1.2).
Material True Density (g cm'3)
NST (micronised) 1.63 ± 0.0220
63-90 pm lactose 1.54 ±0.0003
<45 pm lactose 1.54 ± 0
Fine particle lactose 1.54 ± 0
Table 2.10 True density values for the micronised NST and the carrier size fractions 
of lactose. Values are the mean ± SD of 3 determinations.
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2.4 Analytical Techniques
2.4.1 UV Analysis of Nedocromil Sodium.
The British Pharmacopoeia (1998) does not include an official assay for the 
determination of NST therefore, the ultra violet/visible (UV7VIS) absorption spectrum 
was measured. Since NST has a chemical structure similar to DSCG (Suschitzky and 
Sheard, 1984) an assay was developed based on the assay for DSCG (BP, 1998). A 
0.002 % w/v solution of NST was prepared in distilled water and analysed over the range 
230 to 800 nm using a scanning spectrophotometer (Perkin-lambda 3 UV/VIS, 
Spectrophotometer). The absorption spectrum of the 0.002% w/v solution displayed four 
maxima: 245 nm, 280 nm, 340 nm and 375 nm. A wavelength of 375 nm was used for 
all future investigations.
Nedocromil sodium exists as the monohydrate at RH < 6.4%, the trihydrate when 
equilibrated between the humidity range 6.4% < RH < 79.5% and the heptahemihydrate 
between 80% < RH < 90% (Khankari et al. 1998). The specific absorption coefficient
(Eict) was determined for powder samples stored at humidities ranging from 12 to 76% 
RH (section 2.2.2) to investigate whether NST sorbs/desorbs significant amounts of 
moisture over the range of humidities likely to be encountered within the laboratory or 
during experimental investigations. The Ef* for the NSHH was determined by 
performing an assay on a sample of NST which had been stored at 86% RH/22°C for 
four weeks (section 2.2.2).
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Equipment:
Hitachi UV spectrophotometer 
Instrument settings: Detection X: 375nm 
1 cm path length cell 
Solvent: distilled water
Method
Three stock solutions (0.1% w/v) were prepared from samples of NST stored at each of 
the following humidities (12, 22-23, 53-55 and 75-76% RH). Three sets of standard 
dilutions, covering the drug concentration range (0.001 to 0.005% w/v), were prepared 
from each of the three stock solutions. Each solution was assayed three times using the 
UV spectrophotometer and the mean absorbance recorded.
When determining a specific extinction coefficient for NSHH, two stock solutions were 
prepared (0.1% w/v) and two sets of dilutions from each stock solution produced, 
(covering the concentration range 0.001 to 0.005% w/v). Each solution was assayed 
three times using the UV spectrophotometer and the mean absorbance recorded.
Three stock solutions (for comparisons of E\^m for NST) and two stock solutions (for 
the determination of for NSHH) and then two series of dilutions for each stock 
solution, enabled the accuracy of the sample preparation to be confirmed and the effects 
of the storage conditions to be assessed.
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Results and Discussion
Comparison o f the for NST Stored at Different Humidities
Tables 2.11 to 2.14 and figure 2.3 summarise the linear regression data obtained from 
the calibration plots for solutions of NST prepared from powder samples stored at the 
four humidity levels. Linear regression was performed using MicroCal® Origin v2.94 
(Microcal Software Inc., MA, U.S.A.).
%
RH
Stock Dilution Slope ( O Intercept Correlation
Coefficient
Mean SD Mean SD
12 A 1 179.6 0.45 -0.00203 0.00154 0.99999
12 A 2 179.9 0.60 -0.00153 0.00208 0.99998
12 B 1 179.1 0.30 0.00180 0.00101 1.00000
12 B 2 178.7 0.40 0.00220 0.00133 0.99999
12 C 1 179.0 0.37 -0.00021 0.00125 0.99999
12 C 2 179.0 0.45 -0.00041 0.00150 0.99999
Table 2.11 Linear regression data for NST (0.001 to 0.005% w/v) analysed by UV 
spectrophotometry (stored at 12% RH).
%
RH
Stock Dilution Slope ( O Intercept Correlation
Coefficient
Mean SD Mean SD
22-23 A 1 179.3 0.18 0.000046 0.00058 1.00000
22-23 A 2 179.5 0.26 -0.000354 0.00087 1.00000
22-23 B 1 178.8 0.46 -0.00135 0.00153 0.99999
22-23 B 2 179.2 0.16 -0.00255 0.00055 1.00000
22-23 C 1 179.1 0.50 -0.00033 0.00166 0.99999
22-23 C 2 179.1 0.56 -0.00013 0.00184 0.99999
Table 2.12 Linear regression data for NST (0.001 to 0.005% w/v) analysed by UV 




Stock Dilution Slope ( O Intercept Correlation
Coefficient
Mean SD Mean SD
53-55 A 1 178.7 0.50 0.00044 0.00167 0.99999
53-55 A 2 179.3 0.57 -0.00126 0.00190 0.99998
53-55 B 1 179.5 0.60 0.000036 0.00202 0.99998
53-55 B 2 179.7 0.55 -0.00036 0.00186 0.99999
53-55 C 1 179.5 0.53 0.00005 0.00178 0.99999
53-55 C 2 179.3 0.53 0.00105 0.00177 0.99999
Table 2.13 Linear regression data for NST (0.001 to 0.005% w/v) analysed by UV 
spectrophotometry (stored at 53-55% RH).
%
RH
Stock Dilution Slope ( O Intercept Correlation
Coefficient
Mean SD Mean SD
75-76 A 1 179.1 0.29 -0.0012 0.0010 1.00000
75-76 A 2 178.9 0.24 0.0017 0.0008 1.00000
75-76 B 1 178.5 0.25 0.0034 0.0008 1.00000
75-76 B 2 178.7 0.29 0.0028 0.0010 1.00000
75-76 C 1 178.7 0.19 0.0020 0.0007 1.00000
75-76 C 2 178.7 0.12 0.0018 0.0004 1.00000
Table 2.14 Linear regression data for NST (0.001 to 0.005% w/v) analysed by UV 
spectrophotometry (stored at 75-76% RH).
The equality of the E\^m values obtained from each of the six regression plots (Al, A2, 
Bl, B2, Cl and C2) for each humidity level were statistically compared using the 
Bartlett test (Appendix II). The Bartlett test indicated no significant difference between
the values of obtained for powder samples stored within each of the four humidity 
levels: 12% {tf = 4.81, p = 0.439); 23-25% ( f  = 1.91, p = 0.861); 53-55% { f  = 2.12, p 
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Figure 2.3 Calibration for NST (0.001 to 0.005% w/v) analysed by 
UV spectrophotometry.
The Bartlett test was then performed on the 24 calibration curves (six sets of data from
each of the humidity environments) to assess any possible effects of the storage
humidity on the E\fm. The Bartlett test indicated no significant difference between the
Ef* derived from the four humidity levels (%2 = 18.69, p = 0.719). However, the data
acquired for the NST stored at 76% RH appeared to provide E\°̂ m values that are lower
in value than the other three storage humidity. This was confirmed by one way analysis
of variance (Minitab statistical software, Addison-Wesley Inc., MA) which revealed a
statistical difference between the four sets of data (F = 3.96, p = 0.023). Fisher’s
pairwise comparisons revealed that the E values derived for the powders stored at
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75-76% were significantly lower than for powders stored at 12 to 55% RH. This may 
be due to adsorption/absorption of moisture by the NST samples.
Determination o f the E\fm for NSHH
Table 2.15 and figure 2.4 summarise the linear regression data obtained from the 
calibration plots for NSHH.
%
RH
Stock Dilution Slope ( 0 Intercept Correlation
Coefficient
Mean SD Mean SD
85-86 A 1 155.3 1.20 -0.0056 0.0039 0.99999
85-86 A 2 154.1 0.84 0.0000 0.0028 0.99999
85-86 B 1 154.5 0.25 0.0001 0.0008 1.00000
85-86 B 2 154.3 0.15 0.009 0.0005 1.00000
Table 2.15 Linear regression data for NSHH (0.001 to 0.005% w/v) analysed by UV 
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Figure 2.4 Calibration for NSHH (0.001 to 0.005% w/v) analysed by UV 
spectrophotometry.
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The Bartlett test was used to statistically compare the E}* values obtained for the 
powder samples stored at 86% RH (NSHH). No significant difference was observed 
between the values (%2 = 2.36, p = 0.797) therefore, the data was plotted as a single 
graph (figure 2.4) and regression values obtained for the NSHH (table 2.16). The 
conversion of NST to NSHH was confirmed by a stoicheiometric comparison of the 
extinction coefficients for both compounds.
General Discussion
Table 2.16 details the regression values used when calculating drug concentrations for 
future experimental procedures.
Experimental Procedure Section zr1%lcm Intercept
Formulation of NST Chapters 2,4,5,6,8 179.3 0.0003
Humidity Investigations 
NST stored between 12 and 55% RH 
NST stored at 76% RH 










Table 2.16 A summary of the regression values to be used in future experimental 
procedures.
For the general formulatory procedures, all powders/formulations were stored between 
53 and 55% RH prior to all experimental investigations. All experimental procedures 
were carried out in an environment that ranged from 19 to 63% RH (section 2.2.2). 
Therefore, the regression data obtained for the powder sample stored at 53-55% RH was 
used. It has previously been demonstrated that the calibration data obtained is not 
significantly different from samples of NST stored at 12 and 23-25 % RH.
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For the studies characterising the effects of storage humidity on the in-vitro aerosol 
performance of NST and NSHH, powders stored <55% RH were analysed using the 
calibration data obtained from powders sample stored at 53-55% RH. However, 
powders stored at 75-76 and 86% RH were analysed suing the calibration data obtained 
from powders samples stored at the respective humidities.
2.4.2 UV Analysis of Terbutaline Sulphate
Materials and Methods
Following the method outlined in the BP (1998), a 0.007 % w/v solution of TS in 
aqueous hydrochloric acid (0.1 M) was prepared and then analysed over the absorbance 
range 240 to 340 nm. A ?Lmax of 278 nm was obtained and all subsequent measurements 
were made at this wavelength.
A validation was performed to ensure a linear relationship existed between the 
concentration of TS in the sample solution and the absorbance measured. Duplicate 
stock solutions containing approximately 0.1% w/v (1 mg ml'1) TS in 0.1M aqueous 
hydrochloric acid were prepared. Two sets of standard solutions were then prepared 
from each stock solution, covering the concentration range 0.002 to 0.010 % w/v (0.02 to 
0.10 mg ml'1). Each solution was assayed using the UV spectrophotometer at a 
wavelength of 278 nm using a 1 cm cell. The mean of three absorbance readings for 
each standard solution was recorded.
Results and Discussion





Dilution No Slope ( O Intercept Correlation
Coefficient
Mean SD Mean SD
A 1 5 69.3 0.12 -0.0007 0.0008 1.00000
A 2 5 69.2 0.14 0.0024 0.0009 0.99999
B 1 5 69.0 0.35 0.0009 0.0023 0.99996
B 2 5 68.9 0.24 0.0020 0.0016 0.99998
A+B 1+2 20 69.1 0.14 0.0011 0.0009 0.99996
Table 2.17 Linear regression data for terbutaline sulphate (0.002 to 0.010 % w/v) 
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Figure 2.5 Calibration curves for TS analysed by UV spectrophotometry 
(0.002 to 0.010 % w/w).
68
The equality of the Ef* derived from the two sets of dilutions from each of the stock 
solutions (A and B) were statistically compared the Bartlett test (Appendix II).
There was no significant difference between the Ef* values obtained from each set of 
standard solutions (%2 = 0.83, p = 0.842). Data from the four sets of standard solutions 
were combined; the E ™ value being 69.1 within the BP limits 65 to 70 (BP, 1998).
2.4.3 Colorimetric Estimation of Lactose
Lactose reacts with methylamine in hot alkaline solution to form a bright violet 
coloured compound with maximum absorbance at 540 nm (Nickerson et al. 1976). The 
reaction first described by Fearon (1942) is the basis for quantitative procedures 
developed by Narinesingh et al. (1992).
The first stage of the reaction is the opening of the glucose ring in the lactose by the 
action of the alkali, with the exposure of an aldehyde group, which then combines with 
the amine (Fearon, 1942). The pigment is liable to destruction by oxidation however, 
addition of a sulphite stabilises the pigment (Fearon, 1942).
Optimum Conditions for Colour Development
Conditions for development of the colour are critical, requiring careful control for 
consistent results. Heating temperature, heating time, pH of the aqueous lactose 
solution, concentration of reducing agent and time to analysis after cessation of the 
reaction must be optimised and then carefully controlled Nickerson et al. (1976).
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A highly alkaline solution is needed for development of the red colour reaction. A pH 
within the range 12.7-12.8 (stabilised with a glycine-sodium hydroxide buffer) provided 
optimum colour development in studies performed by Nickerson et al. (1976).
Narinesingh et al. (1992) concluded that sodium sulfite should be used as the reducing 
agent and if low lactose concentrations are to be determined, concentrations close to the 
optimum (0.020 M) employed.
From his studies using the flow injection analysis apparatus, Narinsingh et al. (1992) 
concluded that the optimum reagent conditions were; 10 parts glycine-NaOH buffer,
1 part methylamine (5% w/v) and 1 part sodium sulfite (5% w/v).
Materials and Methods
The materials used for the experimental detection of lactose are tabulated in section 
2.1.1, table 2.2.
Buffer Production
The buffer was prepared by adding 150 ml of a glycine solution (containing 0.033 moles 
of glycine (2.477 g) and 0.033 moles of sodium chloride (1.936 g)) to 850 ml of NaOH 
(0.385 M), adjusting the apparent pH to 12.7 with NaOH if necessary ) (Coming pH 
meter 240).
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Production o f Methylamine Solution (5% W/J
Methylamine solution (5% w/v) (100 ml) was produced from a concentrated source (40% 
w/v methylamine in water) using distilled water. The solution was prepared daily and 
stored in the refrigerator.
Production o f Sodium Sulfite Solution (5.0% W/J
Sodium sulfite (5.0 g) was dissolved in distilled water and diluted to 100 mis. The 
solution was prepared daily and stored in the refrigerator.
Temperature /  Time Optimisation
Various investigators have used different temperature treatments to develop the violet 
colour (Nickerson et al. 1976). Pigments produced from aqueous lactose solution at 
higher temperatures (95°C for 5 minutes) were reported to be unstable however, at lower 
temperatures (55°C) an excessive reaction time (90 minutes) was required (Nickerson et 
al. 1976).
Following preliminary investigations assessing the extent and stability of colour 
development after various time periods at fixed temperatures, a reaction time of 40 
minutes at 75°C was selected.
Linearity o f Response
Preliminary studies were conducted to ensure a linear and reproducible response existed 
between the lactose concentration and the extent of the colour development. A 1 cm 
path length cell was initially employed to optimise the temperature and duration of time 
for optimum colour development (intensity and stability).
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One stock solution containing approximately 2 mg ml"1 (0.2% w/v) of lactose (FPL) 
dissolved in the glycine-NaOH buffer was prepared. Three sets of standard dilutions 
were then prepared covering the lactose concentration range 0.2 to 1.6 mg ml'1 (0.02% 
to 0.16% w/v). Precise volumes of the lactose stock solution were added to 10 ml of 
methylamine (5% w/w) and sodium sulfite (5% w/w) solutions (1:1). The solutions were 
then made up to 50 ml using the glycine-NaOH buffer so that the ratio of components 
was; 8 parts glycine-NaOH buffer, 1 part methylamine (5% w/v) and 1 part sodium 
sulfite (5% w/v).
The dilutions were then transferred into 20 ml volumetric flasks and loaded at 1 minute 
intervals into the water bath (Gyratory Water Bath Shaker, model 676, New Brunswick 
Scientific, N.J., U.S.A.), equilibrated at (75°C). After exactly 40 minutes, the samples 
were removed at 1 minute intervals from the water bath and analysed immediately using 
the UV spectrophotometer (Milton Roy Spectronic 601) (detection X of 540 nm).
From figure 2.6, it can be seen that the colour development appears to be linearly related 
to the lactose concentration over the concentration range 0.06% to 0.18% w/v. Linear 
regression was conducted on the region of the plots between these two values and the 
results summarised in table 2.18. The final determination for stock A (dilution 1) 
(corresponding to a lactose concentration of approximately 0.17% w/v) did not appear to 
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Figure 2.6 Calibration plot for the colorimetric determination of lactose 
(1 cm path length cell)
Parameter *Dilution Series 1 Dilution Series 2 Dilution Series 3
Mean SD Mean SD Mean SD
Slope 5.04 0.08 5.10 0.10 5.04 0.09




Table 2.18 Linear regression analysis for calorimetric determination of lactose 
(concentration range 0.06 to 0.18% w/v: 1cm path length cell) except 
*(concentration range 0.06 to 0.15% w/v: 1cm path length cell).
Using a 1 cm path length cell the minimum concentration detectable (i.e. above 0.1 
absorbance units) was approximately 0.6 mg ml'1 (figure 2.6). However, the linear 








Therefore, a 4 cm path length cell was used to increase the sensitivity of the detection 
system. Following the procedures previously described, a series of dilutions were 
prepared covering the lactose concentration range 0.2 to 2.0 mg ml"1 (0.02 to 0.2% w/v). 
A 4 cm path length was chosen to increase the absorbance values at the lower end of the 
concentration range. The calibration curve appears to be linear over a lactose 
concentration range 0.3 to 0.6 mg ml'1 (figure 2.7). Therefore, a calibration plot was 
generated to more thoroughly cover this concentration range (figure 2.8).
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Figure 2.7 Calibration plot for colorimetric determination of lactose
(concentration range 0.02 to 0.2 % w/v: 4cm path length cell).
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Figure 2.8 Calibration plot for colorimetric determination of lactose
(concentration range 0.2 to 0.6 mg ml'1: 4 cm path length cell).










Table 2.19 Linear regression results for colorimetric determination of lactose
(concentration range 0.02 to 0.06 % w/v: 4 cm path length cell).
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General Discussion
The limitations of the described technique are recognised however, the colorimetric 
reaction provides a semi-quantitative means of assessing the in-vitro aerosol deposition 
of FPL (section 5.2).
Alternative methods available for lactose determination include those based on high 
performance liquid chromatography using a refractive index detector (Srichana et al. 
1998) and enzymology using P-galactosidase and glucose oxidase-peroxidase 
(Swindlehurst and Nieman, 1988). However, many of the above procedures are 
reported to be excessively time consuming, relatively insensitive and require either 
expensive equipment or involve complex sample pre-treatment (Narinesingh et al. 
1992).
2.5 In-vitro Aerosol Characterisation
Device Selection
It was considered that the poor deaggregating capabilities of alternative capsule based 
devices (Rotahaler® and Spinhaler®) (Vidgren et al. 1988b) may cause problems when 
comparing the in-vitro aerosol performance of different powder systems. Therefore, a 
single dose capsule based device, the Cyclohaler®, was used to assess the in-vitro 
aerosol performance of the powder systems. Several studies have reported that when 
used optimally, the performance of the Cyclohaler® is comparable to that of other DPI 
devices (Pitcairn et al. 1997; Vidgren et al. 1988b; Zanen et al. 1992).
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The majority of in-vitro aerosol investigations were performed using an airflow rate of 
60 litres min"1. However, it is now recognised that to more accurately relate to patient 
usage, the flow rates used in the in-vitro testing of DPIs should be adapted to the air 
flow resistance of the device. Clark and Hollingworth (1993a) and Olsson and Asking 
(1994) have reported on the air flow resistance of different DPI devices and the effects 
on the maximum inhaled flow rate (equation 2.1)
T ap  = Qd.Rd AP = Pressure drop across the device Equation 2.1 
Qd = Flow rate through the device 
Rd = Device resistance
Available DPIs devices were categorised as being of low, medium or high resistance 
and then assessed at an appropriate flow rate (Hindle and Byron, 1995b). It is now 
generally accepted that the pressure drop across the DPI, achieved by adult patients with 
respiratory disease when inhaling through a DPI at peak inspiratory flow rate is 
typically in the region of 4 kPa. Therefore, international Pharmacopoeia harmonisation 
has concluded that drug delivery from DPIs should be determined at an air flow rate 
equivalent to a 4 kPa pressure drop across the device (Ganderton, 1996; Olsson et al.
1998).
Following methods described by the pharmacopoeias (EP and USP), a flow rate of 96 
litres min"1 (corresponding to a pressure drop of 4 kPa across the device) would be 
necessary to assess the performance of the Cyclohaler®. Materials and methods used in 
the determination of the 4 kPa pressure drop are detailed in Appendix III. However, the 
present study used the two impingers (Apparatus A and MSLI) as a means of assessing
77
the interparticle interactions governing the aerosol performance o f nedocromil sodium. 
It is considered that a reduced flow rate (60 as opposed to 100 litres min'1) may be more 
appropriate for this type of investigation since the increased shear forces generated at 
higher flow rates may mask any beneficial formulatory changes.
2.5.1 Modified Apparatus A
The method used to assess the aerosol performance o f the dry powder systems was 




Figure 2.9 Apparatus A (BP, 1998). Dimensions are in mm.
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Apparatus A has an ECDso% of 6.4 pm at the prescribed flow rate of 
60 ± 5.0 litres min*1 (Hallworth and Westmoreland, 1987). However, in the present 
study an ECD5o% of 5 pm was considered more representative of “potentially respirable” 
size fractions.
Impactor theory (Hinds, 1982) provides a relationship between the linear flow rate at the 
jet orifice, the jet diameter and the ECD5o% (equation 2.2).
ECD50%





rj = viscosity of air 
W = jet diameter
Stk5o=Stokes number for 50% collection efficiency 
C = Cunningham slip factor (-1.0 for particles >1 pm) 
p = density of reference particle (unit density, 1000 m3 kg*1) 
U = linear velocity of air
For the standard jet width (14 mm) and flow rate (60 litres min*1) defined for Apparatus 
A, equation (2.2) reduces to equation (2.3) (Hallworth and Westmoreland, 1987).
E C D ^  =  X
w: 0.5 Equation 2.3
When F, the volumetric flow rate at the jet orifice, is expressed as litres min*1 and W, the 
jet diameter is in mm, the Apparatus A constant X has a value of 0.95.
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Although this has not been verified experimentally, Hallworth and Westmoreland 
(1987) claim this value should remain constant for alternative values of flow rate and jet 
diameter provided the stage-1 liquid vortex shape and jet orifice to liquid spacing are 
kept similar. However, Miller et al. (1992) state the latter is not a important parameter 
with respect to ECDso%.
The internal diameter of the stage-1 jet of Apparatus A was modified (University of 
Bath glass-blowing workshop, Bath, U.K.) to give a calculated ECDso%  of 4.80 pm at 
60 litres min'1. The upper section of the jet (between the throat cone joint and the stage- 
1 flask joint) retained the same standard dimensions and the length of the glass tube 
forming the jet was maintained as that specified for Apparatus A (BP, 1998) (figure 
2.9).
Although no attempt was made to calibrate the modified Apparatus A, the proof of 
principle was confirmed by mono-sized sphere calibration of comparable jets. The 
ECDso% of the modified stage-1 jet (11.6 mm) was measured as 5.3 ± 0.3 pm by AEA 
technology (Aerosol Science Centre, Oxfordshire, U.K.). The modified stage-1 jet 
(11.6 mm) was used throughout the study and the impinger subsequently referred to as 
modified Apparatus A.
When studying the effects of flow rate on the deaggregation properties of the powder 
systems (section 8.4), alternative stage-1 jets were manufactured, maintaining an 
ECD.5o% of approximately 5 pm at the specified flow rate. The internal diameters of the 
stage-1 jets together with the theoretical and calculated ECDso% are described further in 
section 8.4.
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The majority of the studies utilising the modified Apparatus A, (chapters 2, 4, 5, 6 and 
7) were performed at 60 litres m in1 as described in the BP (1998). Unless otherwise 
specified, the modified apparatus A was assembled and charged with 7 mis of solvent in 
stage-1 and 30 mis in stage-2. With the Cyclohaler® loaded with an empty capsule in 
position, the vacuum pump (Gast Manufacturing Inc., Michigan, U.S.A) was operated 
and the flow through the DPI was adjusted to 60 litres min'1 using a mass flow meter 
(Hastings Mass Flow Meter, HFM 201). Flow through the device was achieved by 
accommodating the device within a specially manufactured glass casing, which was 
fitted to the glass throat of the Apparatus A using an elastomeric adapter.
Capsules were removed from the storage environment (53-55% RH) and then filled with 
the powder formulation immediately before in-vitro aerosol assessment. If brittle 
fracture of the capsule occurred upon priming, the run was aborted and the capsule 
discarded.
The vacuum pump was operated at 60 litres min'1 for 4 seconds, sufficient time for 4 
litres of air to pass through the device. The impinger was then dismantled and the 
capsule and Cyclohaler® contents, the throat and stage-1 combined, and stage-2 rinsed 
into appropriate volumetric flasks and adjusted to an appropriate volume with solvent.
2.5.2 (5-Stage) Multistage Liquid Impinger
The MSLI consists of impaction stages 1, 2, 3 and 4 and a final filter (Type A/E glass, 
76 mm diameter, Gelman Sciences, Michigan, U.S.A.). At an airflow of 60 litres min*1 
the ECD50o/# of stages 1 to 4 are 13.0, 6.8, 3.1 and 1.7 pm respectively. The after filter 
effectively retains aerosolised drug in the particle size range 0 to 1.7 pm.
The MSLI was assembled as described in the European Pharmacopoeia (1998) with 
twenty mis of distilled water filled into stages 1 to 4. The induction port used 
throughout the study was the Apparatus A glass throat (BP, 1998). However, it is 
recognised that the USP metal throat is now recommended (European Pharmacopoeia, 
1998). The MSLI was connected to the vacuum pump and the flow through the 
impinger adjusted to 60 litres min'1 as described in section 2.5.1. The capsule was filled 
and then its contents discharged as described in section 2.5.1. Following powder 
discharge, the contents of the capsule and the Cyclohaler® were rinsed with distilled 
water and diluted quantitatively to an appropriate volume. The same procedure was 
adopted for the mouthpiece adapter and the glass induction port. The inside of the inlet 
jet tube (stage-1) was rinsed, allowing the solvent to flow into stage 1. The drug was 
rinsed from the inner walls and the collection plate into the solution in the respective 
stage by tilting and rotating the apparatus while ensuring that no liquid transfer occurred 
between the stages. The MSLI was then placed on a rotating platform (Bellydancer® 
Stovall Life Science Inc., Greensboro, U.S.A.) for 10 minutes to promote further 
rinsing. Each stage was then thoroughly rinsed out and made up to an appropriate 
volume using distilled water.
2.5.3 Parameters Describing the In-vitro Aerosol Performance.
Emitted Dose
The drug emitted from the device was expressed as the total quantity of drug recovered 
from the sampling apparatus (MSLI or modified Apparatus A), as a mass (Emitted Dose 
or ED) and as a percentage of the recovered dose (Emitted Percent).
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Fine Particle Component (Modified Apparatus A)
The fine particle component of the aerosol was expressed as the quantity of drug 
recovered in stage 2, as a mass (Fine Particle Dose or FPD) and as a percentage of the 
ED (Fine Particle Fraction or FPF).
Fine Particle Component (MSLI)
The fine particle component of the aerosol was defined as the quantity of drug recovered 
on stages 3 to 5 (filter) (MMAD: 0-6.8pm at 60 litres min'1), expressed as a mass (FPD) 
or as a percentage of the ED (FPF).
The extra fine particle component of the aerosol was defined as the quantity of drug 
recovered on stages 4 and 5 (filter) (MMAD: 0-3.1 pm at 60 litres min'1), expressed as a 
mass (Extra Fine Particle Dose) or as a percentage of the ED (Extra Fine Particle 
Fraction).
Approximately 8 mg (pure NST) or 20 mg (carrier based systems) were accurately 
weighed into hard gelatin capsules before in-vitro aerosol assessment. In order to 
accurately compare the ED and FPD, the two parameters were normalised with respect 
to either an 8 or 20 mg capsule fill weight. Capsules fill weights were maintained 
within ±10 % of the desired weight. It was considered that the minor differences in fill 
weights would not dramatically influence the aerosol performance of the formulation.
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2.6 In-Vitro Aerosol Characterisation of NST
The in-vitro aerosol performance of the pure drug system was characterised to 
investigate the magnitude of the cohesive interactions; assessed by the degree of 
deaggregation and subsequent stage-2 deposition of NST (modified Apparatus A).
During the preparation of carrier lactose based formulations (chapters 4, 5 and 6), 
various blending procedures (HB, TTM and RBB) were employed to mix the powder 
systems. Screening procedures were introduced either as pre-blending stages or 
incorporated into the mixing protocol to improve the distribution of micronised drug 
particles upon the surface of the coarse lactose particles by increasing the deaggregation 
of the drug agglomerates (Lord, 1993; Peart, 1996; Robertson, 1997). With high dose 
drug systems these processing procedures may have a detrimental effect on drug 
deaggregation and subsequent dispersion upon aerosolisation. Therefore, the effects of 
the screening and blending procedures on the in-vitro aerosol performance of the pure 
drug powder was investigated.
2.6.1 Formulation Procedures
Table 2.20 summarises the experimental procedures performed on the drug powder prior 
to in-vitro aerosol characterisation. The procedures were designed to try and reproduce 
the shear forces the powder system may be subjected to during the formulation studies. 
Approximately 10 grams of micronised NST was used in each study. The three 





Non sieved NST used as received.
355 pm NST passed through a 355 pm aperture sieve mesh using a 
soft powder brush.
250 pm NST passed through a 250 pm aperture sieve mesh using a 
soft powder brush.
Hand Blended NST passed through a 355 pm aperture sieve mesh using a 
soft powder brush. Hand blended for 30 minutes.
Rotary Bladed Blender NST passed through a 355 pm aperture sieve mesh using a 
soft powder brush. Mixed for 2 minutes.
Turbulent Tumbling 
Mixer
NST passed through a 355 pm aperture sieve mesh using a 
soft powder brush. Tumbled for 10 minutes at 42 rev min'1.
Table 2.20 Preparation of “processed” NST for in-vitro aerosol characterisation.
2.6.2 In-vitro Aerosol Characterisation of NST
Materials and Methods
The aerosol performance of micronised NST subjected to the formulation procedures 
outlined in table 2.20 was characterised using the modified Apparatus A. 
Approximately 8 mg of drug was accurately weighed (Mettler AT261 DeltaRange, 
Mettler Toledo, Switzerland) into a hard gelatin capsule and discharged from the 
Cyclohaler® at 60 litres min'1. The 8 mg capsule fill weight was chosen in order to make 
comparisons with the ED and FPD of carrier based systems formulated in 
sections 4 and 5.
Results and Discussion













Hand blended Tumbling Action 
Mixer
Rotary B laded 
Blender
% Capsule 19.2 ±8.4 2.95 ±0.31 2.88 ± 0.40 4.64 ± 0.86 4.02 ± 0.52 5.12 ± 1.1
% Device 20.3 ± 2.6 21.7 ±1.7 22.5 ± 1.4 19.5 ±2.3 19.0 ±0.73 17.5 ±3.3
% Stage One 50.3 ± 10 63.1 ±2.4 .59.9 ±1.4 65.0 ±3.5 66.2 ±1.2 66.5 ±5.1
% Stage Two 10.2 + 0.65 12.3 ± 1.1 14.8 ±0.65 10.9 ±2.1 10.8 ±0.74 10.8 ±0.88
Emitted Dose (mg) 4.82 ± 0.75 6.05 ±0.17 6.00 ±0.10 6.13 ±0.14 6.19 ±0.09 6.27 ± 0.41
Emitted Percent (%) 60.5 ± 9.8 75.4 ± 1.6 74.6 ± 1.2 75.9 ± 1.8 77.0 ± 1.1 77.4 ± 4.4
Fine Particle Dose (mg) 0.811+0.056 0.985 ± 0.083 1.19 ±0.058 0.882 ±0.18 0.869 ± 0.061 0.875 ± 0.062
Fine Particle Fraction (%) 17.3 ±3.8 16.3 ±1.7 19.8 ±0.94 14.4 ±3.0 14.1 ±0.96 14.1 ± 1.9
Drug Recovered (%) 99.8 ± 1.1 100 ± 1.4 100 ±1.1 101 ±1.3 100 ±2.1 101 ± 1.2
Table 2.21 The effects of various formulation procedures on the in-vitro aerosol performance of NST. 
Values are the mean ± SD of 5 determinations.
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Figure 2.10 The effects o f the formulation procedures on the in-vitro aerosol 
performance o f  NST.












Figure 2.11 The effects o f the formulation procedures on the in-vitro aerosol 
performance o f  NST.
Each column shows the mean of 5 determinations (bars represent SDs).
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No Screening Stage
Y/7//A  Screened (355 pm-mesh) 
Screened (250pm-mesh) 
Hand Blended 
Turbulent Tumbling Mixer 
ITTTTTB Rotary Bladed Blender
ED FPD
In-vitro Aerosol Characterisation
Incomplete capsule emptying was observed for the sample of NST which was used as 
received (not screened), e.g. 19.2 ± 8.4% of the nominal dose remained within the 
capsule compared with <5 % for the NST screened through a 355 pm aperture sieve 
mesh. Therefore, the use of a screening stage prior to all future formulation studies was 
considered essential to destroy/reduce agglomerates of pure drug, promoting both 
complete and reproducible capsule emptying.
One way analysis of variance revealed significant differences between the 
deaggregation (FPF) (F = 4.91, p = 0.003) and subsequent stage-2 deposition (FPD) (F 
= 10.58, p < 0.001) of NST samples subjected to the formulation procedures.
The introduction of a screening stage could be envisaged to affect the interparticle 
cohesive interactions in one of two ways. In the first, screening the powder sample 
through decreasing mesh apertures may force the constituent particles closer together, 
increasing the interparticle forces of attraction (Hickey et al. 1994). Alternatively, the 
screening stages may deaggregate the drug self-agglomerates providing an increased 
number of potentially respirable fine particles. Fisher’s pairwise comparisons revealed 
that the introduction of a screening stage (355 pm) significantly increased the 
generation of fine particles (Dae: 0.5 to 5.3 pm) when compared to the non-screened 
material. Fisher’s pairwise comparisons also revealed that the use of the finer mesh 
(250 pm) further improved the generation of fine particles. However, due to 
difficulties/drug losses upon screening the powder samples through a 250 pm aperture 
mesh, all future formulations were prepared from NST pre-screened through a 355 pm 
aperture mesh.
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Following the screening stage (355 pm), the blending procedures (TTM, RBB and HB) 
did not significantly affect the ED (F = 0.73, p = 0.550) the deaggregation (FPF) (F = 
1.40, p = 0.278) nor the fine particle deposition of NST (F = 1.32, p = 0.302).
Based on the in-vitro aerosol characterisation of the pure drug systems following the 
various processing stages, it was hoped that changes affected by the formulatory 
procedures (chapters 4 and 5) could be interpreted more accurately in terms of changes 




MICROSCOPY AND ENERGY 
DISPERSIVE X-RAY ANALYSIS
3.1 General Introduction
The particle size and shape of drugs commonly administered to the lung have previously 
been determined using conventional SEM. Pre-formulation changes to the morphology 
and particle size of these drug particles have also been characterised using conventional 
SEM. These studies include: determining the effects of micronisation and spray drying 
on compounds (Chawla et al. 1994; Vidgren et al. 1989), selection of alternative salts 
forms (Jashnani et al. 1995; Jashnani and Byron, 1996) and surface modification of the 
drug particles (Fults et al. 1997; Hickey et al. 1992). Studies on carrier based inhalation 
systems have provided information relating to the action of binary and ternary 
components within powder blends (Braun et al. 1996; Lucas et al. 1998a).
3.1.1 Conventional SEM
The technique of SEM involves the bombardment of a sample surface with a fine beam 
of electrons. Upon impact, secondary electrons from atoms in the sample surface are 
liberated and are subsequently detected to form an image. The SEM image typically 
contain wide ranges of contrast and depth of field (Jeffree and Read, 1991a). As a 
result, SEM can provide an excellent picture of the sample surface.
Conventional SEM ideally requires samples which are dry, mechanically stable, non­
volatile and electrically conducting (Jeffree and Read, 1991a). Unfortunately, many 
pharmaceutical powders do not possess these characteristics. Due to the high electrical 
resistivity of the majority of pharmaceutical powders, samples must be coated with a 
thin layer of gold prior to imaging to prevent accumulation of beam electrons during 
electron irradiation.
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When imaging hydrated powders such as NST using conventional SEM, the low 
pressures within the SEM chamber (<10'3 Pa) may cause evaporation of adsorbed or 
loosely bound absorbed surface water. This may lead to a break up of the conducting 
gold coat with subsequent sample charging. The loss of water may also lead to 
dimensional changes within the sample (Beckett and Read, 1986).
LTSEM and ESEM were used as alternative techniques to image nedocromil sodium, 
alleviating the problems of sample charging and image distortion associated with 
conventional SEM investigations.
3.1.2 LTSEM
By freezing and thus stabilising the adsorbed and absorbed water, LTSEM enables 
powders and other delicate materials (Babic et al. 1996; Bastacky et al. 1987) to be 
analysed in their fully hydrated state (Jeffree and Read, 1991a). The benefits of 
analysing frozen-hydrated pharmaceutical samples are: (a) they retain most or all of 
their water (absorbed and adsorbed); (b) they display a reduced number of artefacts 
relating to dehydration (shrinkage and structural collapse) and (c) crystalline and surface 
water is rapidly immobilised by cryofixation hence the conducting coat remains intact, 
minimising charging effects.
For high resolution studies, attention must be paid to minimising the artefacts that may 
be associated with LTSEM, e.g. ice crystal formation, water vapour contamination and 
electron beam damage (Jeffree and Read, 1988). However, for most biological 
applications it has been well established that LTSEM can provide improved
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preservation of sample fine structure compared with conventional SEM (Jeffree and 
Read, 1991b).
3.1.3 ESEM
Examination of hydrated compounds at increased pressures within the ESEM is another 
alternative to conventional SEM. The environmental SEM uses a differential pumping 
system to separate the high vacuum region of the electron gun and column from the 
specimen chamber (Danilatos, 1991). Pressures in the range of 0.13-2.7 kPa are 
maintained in the chamber by controlling the admittance of a water vapour (Danilatos, 
1991). The water vapour in the specimen chamber also contributes to the amplification 
of the signal generated by the secondary electrons produced from the sample surface 
(Danilatos, 1991). Ionisation of the gas around the sample also suppresses charge 
accumulation on insulating specimens (Danilatos, 1991). Therefore, ESEM allows the 
sample surface to be imaged in its natural hydrated state without prior sample 
preparation that can include freeze drying and coating (D’Emanuele et al. 1998). 
However, there is an increased tendency for beam damage to occur due to the sample 
interacting with water (Jenkins and Donald, 1997).
The ESEM has been shown to be a useful tool in the examination of pharmaceutical 
formulations where it has been used to evaluate a range of hydrated and other materials 
(D’Emanuele and Gilpin, 1996).
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3.1.4 EDAX
X-ray microanalysis is a technique that allows a chemical analysis to be performed on a 
material within a well defined region (1 jam2) of the specimen (Goldstein et al. 1992). 
The energy of the X-ray released by an atom, excited by electron irradiation, is 
dependent upon the elemental atomic number (Goldstein et al. 1992). Elemental 
analysis can be performed on SEM samples since beam electrons also form X-rays by 
beam deceleration and interaction with the atoms of the solid. The technique known as 
energy dispersive X-ray analysis (EDAX) can give information regarding the location of 
an element within a sample.
3.2 Materials and Methods
3.2.1 Conventional SEM
Conventional SEM was carried out using the JEOL T330 scanning electron microscope 
(Japanese Electron Optics Ltd, Tokyo, Japan). Representative powder samples were 
mounted on aluminium specimen stubs using double-sided carbon coated adhesive tabs. 
Prior to examination and analysis the powders were gold coated for five minutes 
(Sputter Coater, Model S150B, Edwards High Vacuum, Sussex, U.K.). Carrier size 
fractions of lactose (63-90 pm, <45 pm and FPL) were analysed using conventional 
SEM. Initially, this technique was also used to analyse NST.
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3.2.2 LTSEM
The preparation and analysis of frozen hydrated samples for LTSEM examination 
involves three main operational phases: (a) sample preparation and cryofixation, (b) 









Figure 3.1 Flow diagram depicting the operational stages necessary for LTSEM 
sample preparation and analysis.
( a )  Sample Preparation and Cryofixation
Samples for cryofixation were sprinkled onto adhesive carbon disks which were then 
attached to a metal stub using a mixture of a cryo-adhesive (Tissue-Tek O.C.T. 
Compound, Miles Laboratories Inc., Naperville, USA) and a conducting compound, 
colloidal carbon (Leit-C, Gerhard Neubauer, Munster, Germany). The cryo-adhesive 
formed a strong bonding, wax-like solid when frozen. Cryofixation was then achieved 
by immersing (plunge cooling) the powder sample into sub-cooled nitrogen at -210°C 
(nitrogen slush). This process instantly freezes the sample and should stabilise its 
physical structure. The sample was then transferred to a cryogenic unit (CT1500 Cryo- 
Trans system, Oxford Inst., U.K.) in an evacuated transfer device to avoid condensation 
of atmospheric moisture onto the cold sample surface. The sample was subsequently 
loaded into the SEM chamber via the cryo-preparation chamber. Sublimation of
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superficial ice from the powder surface, in the form of contaminating frost, was 
achieved in the SEM chamber by increasing the stage temperature to -80°C for 
approximately 10 minutes. This process, termed partial freeze-drying (Jeffree and Read, 
1991a), can be directly visualised in the SEM.
(b )  Coating
The sample was then transferred from the SEM chamber to the cryogenic preparation 
chamber (-180°C) where it was sputter coated with gold in a low-pressure atmosphere of 
argon. The sample was coated at -180°C for three minutes. During coating a vacuum of 
20 Pa was drawn and a current of 2 mA at 4V applied across the sample.
( c ) Examination and Analysis
Examination of the powder samples was carried out at approximately -170°C using a 
low temperature SEM stage (SEM 6310, JEOL, U.K.). The stage was cooled using 
cooled nitrogen gas. Specimens of drug particles and powder blends were imaged at 
magnifications over the range x 100 to 25000. This provided information on the size 
and shape of individual drug crystals as well as the distribution of the drug particles 
within the powder systems.
3.2.3 ESEM
ESEM studies were performed on an Electroscan E3 (Philips ElectroScan, Wilmington,
Mass., U.S.A.). The powder samples were sprinkled onto aluminium specimen stubs,
mounted onto the peltier stage and allowed to cool to 4°C. The ESEM chamber was
then pumped down to 0.53 kPa with water vapour introduced as the imaging gas. An
accelerating voltage of 10 kV was used. The working distance used of 12 mm
represents a gas path length of 1.5 mm. Manipulating the gas pressure within the ESEM
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chamber controlled the humidity. The technique was used to investigate samples of the 
drug and powder formulations at magnifications up to x 1700.
3.2.4 EDAX
Sample Preparation
Sample preparation for EDAX was similar to that employed for studies using the 
techniques of LTSEM. Cryofixation, transfer to the cryogenic unit and sublimation of 
superficial ice was achieved as previously described in section 3.2.2. However, a thick 
gold coating would reduce the intensity of emitted X-rays therefore, the samples were 
carbon coated. Carbon has a low atomic number and does not interfere with the 
measurements of other elements (Goldstein et al. 1992). The samples were 
evaporatively coated with carbon in the cryogenic preparation chamber (-180°C) in a 
low-pressure atmosphere of argon. During coating a vacuum of 20 Pa was drawn and a 
current of 2 mA at 4 V applied across the sample.
Sample Analysis
EDAX analysis was carried out at approximately -170°C using a low temperature SEM 
stage. Samples were analysed for sodium, present as the salt of the nedocromil powder 
but not present in significant quantities in the other formulation components. The X- 
rays signals were analysed with an X-ray analyser (AN1000, Oxford Instruments, U.K.). 
An accelerating voltage of 15 kV was used and the powder irradiated for 100 to 200 
seconds.
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3.3 Results and Discussion
SEM images of the micronised NST and the lactose carrier size fractions (63-90 pm, 
<45 pm and FPL) are described in sections 3.3.1 to 3.3.3. The remaining electron 
micrographs, including conventional SEM, LTSEM and ESEM images of micronised 
TS (figure 6.10), milled NST (figures 8.2 and 8.3) and formulations containing NST 
blended with various lactose size fractions (chapters 4 and 5) are discussed in the 
relevant section of the study.
3.3.1 Conventional SEM
Table 3.1 details the drug and excipient powders imaged using conventional scanning 
electron microscopy.
Material Figure





Table 3.1 Conventional scanning electron micrographs of the excipient and drug
powders used in the study.
Lactose Size Fractions
Images of the carrier size fractions of a-lactose monohydrate (figures 3.2 to 3.5) support 
the particle size measurements obtained using the techniques of LALLS (section 
2.3.1.1) and TOFABS (section 2.3.1.2). Conventional SEM investigations produced 
clear images with negligible charging effects.
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Micronised NST
Figures 3.6 and 3.7 depict a binary powder blend containing NST (40% w/w) formulated 
with the 63-90 pm lactose size fraction, studied using conventional SEM.
NST is stable as the trihydrate under ambient conditions (55% RH and 20-25°C) 
(Khankari et al. 1998). Thermal analysis of the trihydrate revealed that two thirds of the 
absorbed moisture is loosely bound whilst one third is tightly bound (Khankari et al. 
1995). The research conducted by Khankari and Grant is discussed further in section 
7.2. However, it is considered that damage to the conductive gold coating, likely due to 
evaporation of water from the highly hydrated sample (loosely absorbed and adsorbed 
surface moisture), caused an accumulation of negative charge on the sample surface. 
Subsequent powder charging produced effects of over-brightness and image distortion 
making the resulting electron micrographs impossible to interpret.
In non-hygroscopic powders some of these problems can be overcome if samples for 
SEM are prepared by pre-storing the powders at low humidities or drying the samples 
under vacuum to remove any excess surface moisture. However, storage and/or drying 
of NST may convert the trihydrate to the monohydrate, which is very hygroscopic 
(Khankari et al. 1998). Initial investigations suggested that rapid re-uptake of water by 
the sample during powder transfer and sample mounting negated the effects of this pre­
conditioning.
3.3.2 LTSEM
LTSEM electron micrographs of fully hydrated micronised NST particles are shown in 
figures 3.8 and 3.9. The uncharged nature of the specimen resulting from cryogenic
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preparation can be seen from the resolution and clarity of the images compared with 
those obtained using conventional SEM (figures 3.6 and 3.7). Accelerating voltages of 
15 kV at magnifications up to x 25000 (figure 3.9) were employed without any apparent 
build up of negative charge.
Imaging of the shape and particle size of NST revealed an ultrafine powder consisting of 
irregularly shaped particles (figure 3.8 and 3.9). From the samples analysed, the particle 
size would seem to correlate well with measurements obtained from the LALLS studies: 
VMD <1 (im with 90% of the particles having an equivalent volume diameter of <5 pm 
(section 2.3.1.1). The images also support the conclusions that the decrease in the 
measured particle size following fixed sonication periods was due to the deaggregation 
of larger drug agglomerates and not a result of the powder samples dissolving in the 
suspending medium. These images further support the suggestions that Wong et al. 
(1995b) and Clark and Hollingworth (1993b) may have measured agglomerates of NST 
and not discrete particles. It is concluded that LTSEM has provided important 
supporting evidence that the micronised NST provided is an ultrafine powder.
The technique of LTSEM was also employed to image the distribution of NST particles 
within lactose carrier based systems (chapters 4 and 5). Information derived from these 
images supported theories regarding the effects of formulation procedures on the 
interparticle forces governing the aerosol performance of the powder systems. The 
images are described further in the appropriate sections.
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3.3.3 ESEM
ESEM images of the binary powder systems containing NST are displayed and 
described in detail in the appropriate section of the study (chapters 4 and 5). The 
electron micrographs provided important information as to the effects of various mixing 
procedures on the drug particle’s distribution within powder blends formulated for 
inhalation.
3.3.4 EDAX
Table 3.2 details the drug and excipient powders investigated using EDAX. Spot 
analysis was initially performed on a sample of pure NST (no carrier) to ensure a 
satisfactory sodium peak was obtained (figure 3.10). Fine particle lactose (figure 3.11) 
and the adhesive carbon stubs (figure 3.12) were then analysed to confirm that no 




Carbon adhesive tab 3.12
Table 3.2 Materials analysed using the technique of EDAX
Powder blends containing NST and FPL were studied using EDAX (spot analysis) to 
support a theory relating to the intercalation of fine excipient particles within self­
agglomerated drug systems. Section 5.1.2 summarises the results of this study and 




ESEM analysis of binary powder blends containing 40% w/w NST and a lactose carrier, 
produced lower resolution images (figures 4.7 to 4.9) than were achieved in the LTSEM 
studies (figures 4.5 and 4.6). However, the ESEM images still provided important 
information and confirmed that the preparation stages (cryo-fixation and gold coating) 
and the low pressures necessary for LTSEM investigations, do not appear to affect the 
drug particles’ appearance or distribution within these binary systems.
LTSEM and ESEM are alternative techniques to conventional SEM for imaging 
hygroscopic hydrated pharmaceutical compounds when dehydration of the powder is 
either undesirable or impractical. Consideration must also be given to the effects of the 
low pressures (<10'3 Pa), encountered within the conventional SEM chamber, on the 
distribution of drug particles within blends formulated for inhalation. Loosely adhered 
drug particles may be redistributed or removed from the carrier lactose system when 
subjected to the high vacuum within the conventional SEM sample chamber. This is 
undesirable when trying to image the drug particles’ distribution within high and low 
dose DPI formulations. ESEM and LTSEM procedures may minimise this problem by 
analysing the powder samples at higher pressures (~0.5 kPa) or by freezing and thus 
stabilising the powder system. LTSEM has been used to study highly hydrated fragile 
biological specimens including frozen hydrated mouse lungs (Bastacky et al. 1987). 
The technique also proved essential in the imaging of highly hydrated polysaccharide 
macromolecules (Chenu and Tessier, 1995). However, the use of LTSEM to study 
pharmaceutical powder formulations prior to this study (Clarke et al. 1998) has not been 
reported.
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Figure 3.2 Conventional SEM electron micrograph o f a-lactose monohydrate 
(63-90 pm carrier sieve fraction).
Figure 3.3 Conventional SEM electron micrograph o f a-lactose monohydrate 
(63-90 pm carrier sieve fraction).
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Figure 3.4 Conventional SEM electron micrograph of a-lactose monohydrate 
(<45pm carrier sieve fraction).
Figure 3.5 Conventional SEM electron micrograph of a-lactose monohydrate 
(Fine Particle Lactose).
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Figure 3.6 Conventional SEM electron micrograph of a binary powder blend
containing NST (40% w/w) and a 63-90 pm lactose size fraction (60% w/w).
Figure 3.7 Conventional SEM electron micrograph o f a binary powder blend
containing NST (40% w/w) and a 63-90 pm lactose size fraction (60% w/w).
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Figure 3.8 LTSEM electron micrograph of micronised NST.
Figure 3.9 LTSEM electron micrograph of micronised NST.
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Figure 3.10 Energy dispersive X-ray spot analysis o f NST.
< .0  2 .560  keU
FS= 4K ch 1:
MEMis FINE PARTICLE LACTOSE





Figure 3.12 Energy Dispersive X-ray spot analysis o f carbon adhesive tab.
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CHAPTER 4
THE FORMULATION OF 
NEDOCROMIL SODIUM 
TRIHYDRATE AS A DRY POWDER 
FOR INHALATION
4.1 Introduction
The performance of carrier based and agglomerated dry powder aerosol formulations is 
predominantly influenced by the physicochemical characteristics of the constituent 
particles and the interparticle interactions operating within these systems (Hickey et al. 
1994). The interparticle forces must be sufficient to withstand disruption by general 
processing techniques but should allow efficient regeneration of discrete particles or 
potentially respirable drug agglomerates upon aerosolisation.
To assess the interparticle forces that govern the aerosol performance of the high dose 
NST powder systems, various formulatory procedures were investigated. The effects of 
different lactose size fractions, alternative blending techniques and drug concentration 
on the deaggregation and subsequent fine particle deposition of NST were characterised.
Carrier-based formulations were initially prepared incorporating a high percentage of 
NST (40% w/w) with a 63-90 pm sieve size fraction of a-lactose monohydrate (AJS). 
40% w/w NST was selected based on the provision of an acceptable powder dose in light 
of existing formulations of a high dose anti-allergic compound DSCG, currently 
available in a DPI formulation as Intal®. The recommended adult dose for DSCG is 10 
mg four times a day when administered as a MDI compared to 20 mg four times a day 
when administered as a DPI formulation (BNF, 1999). Despite the differences in drug 
concentration, the DPI and MDI formulations both display a similar therapeutic efficacy 
(Taburet and Schmit, 1994).
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Nedocromil sodium is only available for the treatment of asthma in the U.K. as an MDI 
formulation (Tilade®), with a recommended dose of 4 mg four times a day (BNF, 1999). 
Therefore, 8 mg of NST was initially formulated with a lactose carrier for dry powder 
inhalation, double the MDI dose as for the DSCG. For a 20 mg capsule 1511 this 
corresponded to a concentration of 40% w/w NST and was in the concentration range (10 
to 50% w/w\  of previous studies assessing the in-vitro aerosol performance of NST as a 
high dose inhalation system (Wong et al. 1995a and 1995b).
Unless otherwise stated, the drug content uniformity and in-vitro aerosol performance of 
all blends was investigated as described in section 2.2.4 and 2.5.1.
4.2 Mono-Component Coarse Lactose Carrier Systems
4.2.1 Formulations Prepared Using the Turbulent Tumbling Mixer
The term “mono-component lactose system” is defined as a carrier containing a single 
sieve size fraction of lactose (Lord, 1993).
The component powders were initially blended using a TTM, a mixing technique central 
to recent studies investigating the interparticle forces that influence the performance of 
DPI formulations (Lord, 1993; Lucas et al. 1998a and 1998b).
I l l
4.2.1.1 Mixing Investigations 
Materials and Methods
Mixes were prepared (30 g) containing 40% w/w NST and a carrier lactose sieve size 
fraction (63-90 pm; AJS) using the TTM (42 rev. m in1). The two components were 
mixed in a 250 ml glass container with a plastic screw cap according to one of the 
following three blending procedures;
Mix A - The two components were mixed for 60 minutes.
Mix B - The two components were mixed for 5 minutes, the powder mix screened (355 
pm) and then returned to the glass container for a further 55 minutes of 
mixing.
Mix C - The two components were mixed for 10 minutes, subjecting the powder mix to 
a two stage screening process after 5 minutes of mixing (355 pm and then a 
250 pm aperture sieve mesh). Blends mixed following this procedure were 
prepared and analysed in duplicate.
Powder samples (20 mg) were removed from various parts of the powder bed after fixed 
time intervals for analysis of drug content (section 2.2.4). The distribution of NST 
particles within the coarse carrier based formulations was imaged using the techniques 
of LTSEM (section 3.2.2) and ESEM (3.2.3).
Results and Discussion
The drug content uniformity information and data for the three powder formulations are 
summarised in tables 4.1 (mix A and mix B) and 4.2 (mix Cl and C2) and in figures 4.1 








Mean (mg) CV (%) Mean (mg) CV (%)
1 7.43 7.33 7.45 5.82
2 7.61 6.06 7.42 4.37
3 7.62 8.09 7.79 4.14
4 7.46 5.42 7.64 3.18
5 7.88 4.12 7.51 4.20
no screening stage 355 jim screening stage
6 7.86 4.43 7.57 1.83
8 7.67 4.91 7.46 2.33
10 7.66 4.41 7.51 1.07
12 7.80 4.16 7.74 1.47
14 7.74 2.67 7.61 1.83
16 7.29 4.77 7.55 3.09
18 7.61 3.17 7.58 2.65
20 8.41 5.34 7.71 3.75
24 7.77 5.22 No data acquired
28 7.50 4.04 No data acquired
30 7.55 5.52 7.46 1.28
40 7.96 6.64 7.31 2.06
50 7.41 5.87 7.45 1.91
60 7.28 4.30 7.85 2.61
Table 4.1 Effects of the mixing time and the introduction of a screening stage on the 




Mix Cl Mix C2
Mean (mg) CV (%) Mean (mg) CV (%)
1 7.78 6.46 7.95 4.13
2 7.79 3.83 8.31 5.31
3 7.84 2.00 7.83 1.47
4 7.95 2.71 8.05 1.33
5 8.07 6.31 7.90 2.27
355 jim and 250 jim screening stage
6 7.79 1.37 7.99 1.66
8 7.82 1.07 8.06 1.40
10 7.85 1.86 7.98 1.48
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Figure 4.3 The effect of mixing time on the drug content uniformity data 
of mix Cl and C2.
A consideration of the mixing and segregation processes assumed to be operating within 
the powder mixture helps in the interpretation of the results (figure 4.4). Total mixing 
theory (Staniforth, 1981), asserts that particles may be mixed randomly, non-randomly, 
by ordering, by partial ordered randomisation or by any combination of these 
mechanisms occurring in dynamic equilibrium.
The situation would appear to be even more complex when considering a high dose 
micronised drug system (NST) and a coarse carrier component (63-90 pm lactose) 
(figure 4.4).
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Ordered (cohesive and adhesive) interactions will exist between the drug/drug and 
drug/carrier particles (Hersey, 1975). During the process of mixing, a dynamic 
equilibrium will exist since some adhered drug particles may detach from the carrier 
surface whilst other unattached drug particles may subsequently adhere. These 
interactions are presumed to govern the mixing performance of low dose drug systems 
where the drug to carrier ratio is typically between 1:50 and 1:500 (Wong et al. 1995a).
Coarse lactose carrier
















Ordered Mixing Random Mixing
Total Mixing
Figure 4.4 Diagrammatic representation of the interactions operating within 
the high dose powder system.
However, in high dose drug formulations, additional mechanisms are thought to be 
operational. It has previously been suggested that in high dose drug systems, drug
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particles may adhere onto the carrier surface as multi-layers or exist as cohesive 
aggregates independent of the carrier component (French et al. 1996, Wong et al. 
1995b). A percentage of the carrier particles may also exist practically devoid of 
adhered drug (Wong et al. 1995b).
Due to the high percentage of drug present within the system, it is considered that the 
quality of the mix will be governed by the interactions operating between the 
agglomerates of pure drug and the ordered units of NST and carrier (lactose particles 
with either minimal, mono- or multi-particle layer drug coverage).
Segregation of a powder is caused by differences in the physical and mechanical 
properties of the constituent particles and can be enhanced by the mode of mixing 
(Staniforth, 1982). The mechanisms of size segregation include percolation of fines 
through the gaps between larger particles and segregation due to vibration, causing large 
particles to move upwards through a mass of finer material (Williams and Shields, 
1967).
Yip and Hersey (1977a) defined two distinct types of segregation occurring in ordered 
mixes, ordered-unit segregation and constituent segregation. Ordered unit segregation 
occurs when carrier particles of various sizes with different number of adherent particles 
move to different areas of the powder bed. Segregation occurs even though there is no 
change in the distribution of adherent particles on individual carrier particles. Ordered 
unit segregation can be minimised by using monosized carrier particles (Samyn and 
Murphy, 1974).
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Therefore, it is suggested that when considering high dose formulations of NST, 
constituent segregation is mainly responsible for the increase in the % CV with an 
increase in mixing time. Constituent segregation occurs when the finer particles are 
dissociated from the coarse particles either by fine particles becoming dislodged as a 
result of weak interparticle forces or when a true ordered mix is not formed. The later 
system may occur when there are more fine particles in a mix than the carrier is able to 
carry (Bryan et al. 1979). Free particles within a mix have been shown to produce 
aggregates which exacerbate the segregation tendency (Yip and Hersey, 1977a).
Mixing Performance o f Blend A
Visual inspection of mix A after the extended mixing time (60 minutes) revealed that 
agglomerates of pure NST appeared to be existing separately from the coarse lactose 
carrier. However, at some point during the mixing process, the pure drug agglomerates 
may be uniformly distributed throughout the powder system as suggested by the CV for 
mix A being less than 5% between the mixing times of 5 and 20 minutes.
The physical properties of the interacting particles may change throughout the mixing 
process. Electrical forces generated during the mixing process (triboelectrification) may 
contribute to the self-agglomeration of the micronised particles (Williams and Shields, 
1967). Therefore, with an increased mixing time, the size and density of the pure drug 
agglomerates and/or drug coated lactose carrier may change, possibly promoting an 
increase in the segregation of the blends. Rippe et al. (1964) found that density 
differences alone had negligible effects on segregation but when combined with a 
particle size difference, a marked increase in segregation tendency occurred. This may
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explain the decrease in drug homogeneity observed for mix A after 20 minutes (CV > 
5%).
Alternatively, the aggregated drug particles (adsorbed multiparticle layers or self­
agglomerates) may reach an optimum size after which, the gravitational forces acting on 
the aggregated drug system exceeds the van der Waals forces of attraction. Further 
mixing may cause the agglomerates to fracture, resulting in a proportion of the drug 
system existing within the powder system as smaller fragments and therefore more 
prone to segregation (Williams and Shields , 1967).
The material properties of the mixing vessel may also influence electrostatic charge and 
possibly the distribution of micronised drug particles within the carrier based system 
(Lord, 1993; Peart, 1996).
Further evidence of drug self-agglomerates existing within the powder systems was 
provided by the sieve size fractionation of mix A, to separate the agglomerated drug 
from the coarse carrier. Three sieve size fractions were collected (>212pm, 125-212 pm 
and <125 pm) by gently tapping the sieve stack for one minute. Vibration of the sieve 
stack and/or rolling of the powder across the metal mesh were avoided to reduce the 
possibility of promoting further agglomeration of the drug powder.
Table 4.3 summarises the drug content uniformity data for the three sieve size fractions 







Mean (mg) CV (%)
60 >212 19.59 1.18
60 125-212 5.32 2.28
60 <125 2.10 3.69
Table 4.3 Effect of sieve size classification on the drug content uniformity 
of mix A (n = 10 x 20 mg).
The finer aperture mesh (<125 pm) was selected to allow the majority of the lactose 
particles (63-90 pm) to pass through but prevent the passage of the larger agglomerates 
of pure drug. The <125 pm sieve fraction contained approximately 10 % W/WNST whilst 
the >212 pm sieve fraction contained approximately 98% w/w NST. Visual inspection of 
the >212 pm confirmed that excessive mixing within a TTM can lead to the formation 
of drug self-agglomerates which exist separately from the coarse carrier within the 
blend.
Mixing Performance o f Blends B and C
The incorporation of screening stages in mixing procedures has been shown to 
significantly improve the drug particles distribution within carrier based formulations 
(Lord, 1993; Wong et al. 1995a). Therefore, the formulation procedure for blends B and 
C included a screening stage (250 pm mesh and/or 355 pm), introduced after 5 minutes 
in an attempt to destroy drug self-agglomerates and promote the redistribution of drug 
particles onto the surface of the lactose carrier (Lucas et al. 1998a). Screening the 
powder through a 355 pm aperture mesh was initially investigated (mix B) since the 
drug adhered to sieves with a smaller aperture size, making screening without drug 
losses difficult.
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The screening procedure (mix B) reduced the % CV of the blend as shown in figure 4.2. 
However, the % CV again appeared to increase after approximately 10 minutes, 
presumably due to drug self-agglomeration and subsequent segregation. The blending 
procedure adopted for mix C incorporated a more stringent screening process in an 
attempt to more completely destroy the drug self agglomerates. The initial 355 pm 
screening stage enabled the second screening stage (250 pm) to be performed with 
greater ease. Following 10 minutes of mixing, the CV was < 2 % for both Cl and C2. 
The mixing procedure employed for the preparation of blends Cl and C2 was 
considered optimised for the TTM.
The effects of increased mixing times (TTM) on the physical properties and in-vitro 
aerosol performance of pure NST agglomerates are described in chapter 6.1.
L TSEM Investigations
LTSEM and ESEM analysis provided important information regarding the degree of 
mixing and the interparticle forces likely to influence the performance of the carrier 
based drug systems.
The existence of multi-layer particle adhesion was further supported by LTSEM (figures 
4.5 and 4.6) and ESEM investigations (figures 4.7 to 4.9) of mix C. A large proportion 
of the NST appeared to be adhered onto the surface of the lactose carrier as multi­
particle layers (figures 4.6 to 4.9).
The CV for the drug distribution within mix C was <2 %, again suggesting that the pure 
drug agglomerates may be evenly distributed throughout the powder mixture.
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Figure 4.5 LTSEM electron micrograph of 40% 7 W NST blended (TTM) 
with 63-90 pm lactose (Mix C).
Figure 4.6 LTSEM electron micrograph of 40% 7 W NST blended (TTM) 
with 63-90 pm lactose (Mix C).
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Figure 4.7 ESEM electron micrograph o f 40% 7 W NST blended (TTM)
with 63-90 pm lactose (Mix C).
cr*m
Figure 4.8 ESEM electron micrograph o f 40% 7 W NST blended (TTM) 
with 63-90 pm lactose (Mix C).
123
1 Q'ytrn
1 0 k V  E S D  X 1 7 0 0  D =  1 2  m m  P  =  4 . 0 T
ElectraScan 9 8 . 0 3 . 1 6  R 3 6 0
Figure 4.9 ESEM electron micrograph of 40% 7 W NST blended (TTM) 
with 63-90 pm lactose (Mix C).
Figure 4.8 also suggests the presence o f self-agglomerates o f drug existing within the 
mix even after a stringent screening stage and minimal mixing (Mix C).
The optimised mixing process detailed for the TTM is similar to the mixing technique 
described by Wong et al. (1995a). Wong et al. (1995a) concluded that provided the raw 
materials (carrier lactose and micronised NST) were pre-screened, a single 5 minute 
mixing stage (Turbula Mixer, 42 rev. m in ') produced a satisfactory blend with the large 
drug agglomerates being removed/destroyed by the pre-screening technique. However, 
in the present study, inclusion of a screening stage both prior to and midway through the 
blending procedure although producing satisfactory drug content uniformity data failed 
to completely remove/destroy drug self-agglomerates within the system. A simple 
evaluation o f drug content uniformity may disguise the presence of drug self
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agglomerates in a high drug dose system since the drug aggregates themselves may be 
uniformly distributed throughout the powder sample.
4.2.1.2 In-vitro Aerosol Characterisation 
Materials and Methods
Preliminary studies characterised the in-vitro aerosol performance of the formulations 
prepared using the optimised mixing procedure (blends Cl and C2). Optimisation of 
the binary system refers solely to the drug content uniformity of the powder mixture.
The aerosol performance of the formulation tumbled for 60 minutes (mix A), was 
subsequently characterised using the modified Apparatus A. Following 60 minutes of 
mixing, the NST had self-agglomerated with a large proportion of the drug existing 
separately from the lactose carrier system (4.2.1.1). Therefore, the mix was sieve 
classified and the in-vitro aerosol performance of the size fractions again characterised 
using the modified Apparatus A.
Results and Discussion
Data describing the in-vitro aerosol performance of the optimised formulations (mix Cl 
and C2) is summarised in table 4.4.
The in-vitro aerosol performance of mix A after 10, 30 and 60 minutes of mixing and 




Mix Cl Mix C2
% Capsule & Device 
% Stage 1 
% Stage 2 
Emitted Percent (%) 
Emitted Dose (mg) 
Fine Particle Fraction (%) 
Fine Particle Dose (mg)
6.08 ±1.6 
86.6 ±1.5 
7.35 ± 0.72 
93.9 ±1.6 
7.20 ±0.18 
7.83 ± 0.73 
0.59 ± 0.062
5.69 ± 1.8 
87.6 ±2.1 
6.72 ± 0.60 




Drug Recovery (%) 97.8 ±1.0 99.1 ±2,3
Table 4.4 The in in-vitro aerosol performance of mix Cl and C2.
Results are the mean ± SD of 5 determinations.
ED and FPD were normalised with respect to a 20 mg capsule fill weight.
The formulation of NST with the 63-90 pm lactose carrier size fraction of improved the 
percentage of drug emitted from the device/capsule system (>93%) when compared 
with the pure drug systems {<11%) (section 2.6.2). However, comparisons with the 
pure drug aerosol performance (section 2.6.2) suggest that the addition of the 63-90 pm 
coarse carrier or the selected blending procedure does not improve the deaggregation of 
the drug system upon aerosolisation.
A comparison of the aerosol performance of blends Cl and C2 with that of blend A 
(following 10 minute of mixing), suggest that the inclusion of a two stage screening 
process, in an attempt to more fully deaggregate the drug self-agglomerates, had no 
effect on the aerosol performance.
One way analysis of variance revealed no significant difference in the ED (F = 0.10; p = 
0.902) following extended mixing times for blend A. However, there was a significant 
decrease in the deaggregation (FPF) (F = 14.73, p < 0.001) and subsequent stage-2 drug 
deposition (FPD) (F = 4.87, p = 0.028) of the powder systems following 60 minutes of
mixing (Fisher’s pairwise comparisons). The extended mixing time has had a 
detrimental effect on the aerosol performance, presumably due to an increase in 
interactions between carrier/drug or drug/drug particles. Statistical analysis was 
performed on the aerosol performance of the powder system mixed for 60 minutes 
(TTM) before and after sieve size fractionation. One way analysis of variance indicated 
a significant difference in the deaggregation of the powder system (FPF) (F = 14.73; p < 
0.001). Fisher’s pairwise comparisons revealed that the lower dose sieve fraction (<125 
pm) showed an improved deaggregation (FPF) compared with the higher dose powder 
sieve fractions (125-212 pm and >212 pm). However, the FPF is still > 10% w/w for all 
systems.
TTM are recommended for producing ordered mixes when one coarse particle 
component is present (Yip and Hersey 1977b) and have been successfully employed 
when investigating coarse carrier systems containing a lower dose of drug (Lord, 1993; 
Lucas et al. 1998a). The TTM has also been used to formulate powder systems 
containing a high percentage (25 to 80% w/w) of drug, e.g. DSCG (Braun et al. 1996; 
Vidgren et al. 1987b, 1988a, 1988b, 1989, 1990) and NST (Wong et al. 1995a and 
1995b). However, the shear forces generated in the TTM do not appear to be sufficient 
to promote the effective deaggregation and subsequent redistribution of the NST 
particles when formulated as a coarse carrier system. In-vitro aerosol characterisation of 
the formulations in conjunction with LTSEM and ESEM investigations, suggest that the 
drug particles exist mainly as self-agglomerates or as multi-particle layers adhered onto 
the lactose carrier surface. The TTM may even promote the self-agglomeration of the 
drug particles, which may have a detrimental effect on the mixing behaviour and aerosol 
performance of the system.
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In-vitro Aerosol Characterisation
Mixing Time in the TTM (Minutes)
10 30 60 60 60 60
>212pm 212-125 pm A<125pm
% Capsule 1.97 ±0.97 2.69 ± 0.57 2.76 ± 0.32 2.27 ± 0.65 3.0 ±0.39 5.06 ±0.39
% Device 5.02 + 2.0 8.12 ±2.4 5.62 ±1.3 6.58 ± 1.2 5.1 ±0.98 6.24 ± 0.34
% Stage One 86.3 ± 3.5 82.6 ±4.0 86.4 ± 2.0 86.6 ± 1.7 87.0 ± 1.6 81.8 ±0.70
% Stage Two 6.76 ± 0.72 6.64 ± 1.2 5.26 ± 0.82 4.59 ± 0.56 4.9 ± 0.68 6.91 ±0.58
Emitted Dose (mg) 7.24 ± 0.23 7.35 ±0.30 7.27 ± 0.50 17.8 ±0.60 5.1 ±0.19 1.84 ±0.06
Emitted Fraction (%) 93.0 + 2.8 89.2 ± 2.9 91.6 ±1.3 91.2 ± 1.6 91.9 ± 1.3 88.7 ±0.30
Fine Particle Dose (mg) 0.55 + 0.051 0.60 ±0.11 0.42 ± 0.062 0.90 ±0.11 0.30 ± 0.047 0.14 ±0.013
Fine Particle Fraction (%) 7.29 ± 0.97 7.48 ±1.5 5.75 ± 0.97 5.04 ± 0.63 5.3 ± 0.76 7.79 ± 0.66
Drug Recovered (%) 102 ±1.6 99.4 ±2.1 99.4 ± 6.7 99.9 ±1.8 103 ±2.8 98.7 ±2.8
Table 4.5 The in-vitro aerosol performance of mix A after extended mixing times (TTM) and following sieve fractionation. 
Results are the mean ± SD of 5 determinations.
A Three 20 mg capsules were discharged into the modified Apparatus A for each determination.
ED and FPD were normalised with respect to a 20 mg capsule fill weight.
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Device Stage 1 Stage 2
Modified Apparatus A
l"."'"'-'si 10 minutes - TTM 
V ////A  30 minutes - TTM 
E35S5) 60 minutes - TTM 
888883 60 minutes - TTM (>212 |jm)
i m 60 minutes - TTM (212-125 pm)
frnrm 60 minutes - TTM (<125 pm)
Figure 4.10 Effect o f mixing time and size classification on the in-vitro aerosol 
performance of the binary powder system.
Each column shows the mean o f 5 determinations (bars represent SDs).
Yip and Hersey (1977b) suggest that when an ordered mix o f two fine particles is 
required, a mixer producing high shear forces is desirable. This suggestion may also be 
applicable to the formulation o f high dose powder systems for inhalation.
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4.2.2 Form ulations Prepared Using Alternative Blending Techniques
Alternative blending techniques were employed in an attempt to improve the 
deaggregation of the NST self-agglomerates and promote the more complete 
redistribution of drug particles onto the lactose carrier surface.
4.2.2.1 Materials and Methods
The general mixing procedures are described in detail in section 2.2.3 with a brief 
description of the exact methods summarised below. All powder formulations were 
prepared and analysed in duplicate.
Turbulent Tumbling Mixer: Data obtained from the optimised blending procedure (mix 
Cl and C2) was selected. The blending procedure was discussed in detail in section 
4.2.1.1.
Hand Blending: The blends (10 g) were hand mixed for 15 minutes as described in 
section 2.2.3.
Rotary Bladed Blender. The blends (10 g) were mixed for 4 minutes as described in 
section 2.2.3.
The drug content uniformity (section 2.2.4) and the aerosol performance (2.5.1) of the 
powder systems were assessed as previously described.
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4.2.2.2 Results and Discussion
Table 4.6 summarises the drug content uniformity data for the formulations prepared 
using the different blending techniques.
Mixing Process Content Uniformity
Run 1 Run 2
Mean (mg) CV (%) Mean (mg) CV (%)
Turbulent Tumbling Mixer 7.85 1.86 7.98 1.48
Hand Blended 7.97 1.39 8.01 1.37
Rotary Bladed Blender 7.81 1.22 7.89 0.80
Table 4.6 Effect of the blending technique on the content uniformity of NST 
(40% w/w) formulated with a coarse carrier lactose (63-90 pm : AJS). 
n =  10x20 mg.
The results for all three mixing techniques indicate a similar degree of mixing in terms 
of drug content uniformity as indicated by CV < 2% for all blends. One way analysis of 
variance indicated a significant difference in the mean drug content for the formulation 
prepared using the three blending techniques (F = 2.93, p = 0.026) but Fisher’s pairwise 
comparisons revealed no obvious trends. This would suggest that no significant drug 
losses have occurred when blending the powders using procedures capable of producing 
increased shear forces.
Table 4.7 and figures 4.11 and 4.12 summarise the in-vitro aerosol performance of the 
powder systems formulated using the three blending techniques.
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In-vitro Aerosol characterisation Turbulent Tumbling Mixer Hand Blended Rotary Bladed Blender
Run 1 Run 2 Run 1 Run 2 Run 1 Run 2
% Capsule & Device 6.08 ±1.5 5.69 ±1.8 14.9 ±0.81 10.2 ±1.7 18.8 ± 1.1 19.2 ±4.7
% Stage 1 86.6+1.5 87.6 ±2.1 77.4 ±1.2 83.1 ± 1.8 72.9 ± 0.82 72.1 ±4.4
% Stage 2 7.35 ± 0.72 6.72 ± 0.60 7.70 ± 0.66 6.77 ±0.14 8.25 ± 0.34 8.78 ±4.4
Emitted Dose (%) 93.9 ±1.5 94.3 ± 1.8 85.1 ±0.81 89.8 ± 1.7 81.2 ±1.0 80.9 ± 4.7
Emitted Dose (mg) 7.20 ±0.18 7.37 ±0.17 6.47 ± 0.20 7.01 ±0.21 6.39 ± 0.079 6.37 ± 0.36
Fine Particle Fraction (%) 7.83 ± 0.73 7.13 ±0.68 9.05 ± 0.79 7.54 ± 0.26 10.2 ±0.33 10.9 ±0.64
Fine Particle Dose (mg) 0.564 ± 0.056 0.525 ± 0.046 0.585 ± 0.053 0.529 ± 0.020 0.649 ± 0.024 0.692 ± 0.046
% Drug Recovery 97.8 ±1.0 99.5 ±2.3 96.8 ± 2.2 99.4 ± 2.0 100 ±0.96 100 ±1.7
Table 4.7 The in-vitro aerosol performance of NST (40% w/w) formulated with lactose (63-90 pm, AJS) using different 
blending techniques.
Results are the mean ± SD of 5 determinations.













Device Stage 1 Stage 2
M odified A p p a ra tu s  A
Figure 4.11 The in-vitro aerosol performance o f NST (40% w/w) formulated with lactose 
(63-90 pm) using the three different blending techniques.
Each column shows the mean of 5 determinations (bars represent SDs).
Modified Apparatus A
Figure 4.12 The in-vitro aerosol performance of NST (40% w/w) formulated with 
lactose (63-90 pm) using the three different blending techniques.





One way analysis of variance in conjunction with Fisher’s pairwise comparisons 
revealed a significant decrease in the ED (F = 21.11,p< 0.001) for the powder systems 
prepared using the RBB compared with the formulations mixed in the TMM. However, 
the formulations prepared using the RBB deaggregated more completely (FPF) (F = 
31.24, p < 0.001) and generated a greater fine particle dose (F = 12.13, p < 0.001) 
compared with the formulations prepared by HB or using the TTM.
It is presumed that the slight increase in the deaggregation of the systems is caused by a 
greater disruption of the drug self-agglomerates with a subsequent redistribution of the 
drug particles onto the carrier surface. However, the aerosol performance of the systems 
is still considered poor and the adoption of mixing techniques capable of producing 
greater shear forces has not improved the aerosol performance compared with the pure 
drug systems (section 2.6.2).
4.2.2.3 Effect o f the Blending Procedures on the Physical Properties o f the Coarse 
Carrier Lactose
The particle size distribution of the coarse lactose sieve size fraction was investigated 
after subjecting the powder to shear conditions similar to those encountered in the HB 
and RBB mixing procedures.
Materials and Methods
The 63-90 pm (AJS) sieve size fraction of lactose (10 g) was HB for 30 minutes or 
mixed in the RBB for 10 minutes. The particle size distribution before and after the
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blending procedures was characterised using the Malvem Mastersizer X in conjunction 
with the dry powder feeder (section 2.3.1.1).
SEM investigations were conducted to further characterise the particle size of the 
“processed” lactose. The methods used to prepare and analysis samples using 
conventional SEM were previously described (section 3.2.1).
Results and Discussion
Table 4.8 summarises the particle size distribution of the 63-90 pm carrier size fraction 
before and after processing. SEM electron micrographs of the carrier lactose before and 
after processing are shown in figures 4.13 and 4.14.
Material Processing d(0.1) pm d(0.5) pm D(0.9) pm
63-90 pm (AJS) None 68.5 ± 0.68 94.3 ± 1.3 133.2 ±3.5
63-90 pm (AJS) HB 66.1 ±1.6 94.1 ± 1.3 136.2 ±5.7
63-90 pm (AJS) RBB 67.9 ±1.7 94.0 ± 0.91 130 ±2.8
Table 4.8 Characterisation of the particle size distribution of the carrier lactose sieve 
size fraction (63-90 pm) before and after “processing”.
Values are the mean ±10 determinations.
LALLS in conjunction with conventional SEM investigations revealed that the particle 
size distribution of the lactose carrier fraction does not appear to change following 
processing (HB or RBB). Therefore, the slightly improved aerosol performance of the 
formulations prepared in the RBB is presumably due to the increased shear forces 
improving the re-distribution of NST onto the carrier surface.
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Figure 4.13 SEM electron micrograph of 63-90 pm (AJS) lactose hand blended 
for 30 minutes.
Figure 4.14 SEM electron micrograph of 63-90 pm (AJS) lactose blended (RBB) 
for 10 minutes.
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4.2.3 Form ulations Containing Different Concentrations o f NST
The in-vitro aerosol performance of lower dose formulations containing NST and a 
carrier sieve size fraction of lactose (63-90 pm: AJS) were investigated. Assuming the 
formation of an ordered mix (Hersey, 1975) the theoretical estimation of the maximum 
NST concentration that could be adsorbed onto the coarse carrier surface was 
determined. Using true density and surface area measurements, calculated drug 
concentrations of 3.5 and 6.0 % were required for monolayer coverage (Appendix IV). 
To gain an increased understanding of the forces governing the aerosol performance of 
coarse carrier blends containing NST, formulations containing drug concentrations 
above and below this value were prepared and characterised.
4.2.3.1 Materials and Methods
Powder formulations (10 g) containing concentrations of NST ranging from 0.5 to 40 % 
w/w were prepared by hand mixing the two components as previously described in 
section 2.2.3. HB was adopted to try and promote the redistribution of drug particles 
onto the carrier surface without encouraging drug aggregation, a problem that may arise 
with the use of the TTM (section 4.2.1).
Drug content uniformity was assessed by removing ten powder samples (of appropriate 
weight for quantitative drug analysis: 20 or 40 mg) from various parts of the powder bed 
(section 2.2.4). The in-vitro aerosol performance of the formulations was characterised 
using the modified Apparatus A (section 2.5.1). For accurate quantitative drug analysis, 
assessment of the in-vitro aerosol performance required the delivery of either ten 
capsules of 40 mg powder fill (NST = 0.5% 7 W) or ten capsules of 20 mg powder fill 
(NST = 2.0% w/w) for each determination. For the formulations containing 10 to 40%
137
w/w NST, one capsule (powder fill weight 20 mg) was fired for each determination. One 
powder formulation for each drug concentration was prepared and analysed.
4.2.3.2 Results and Discussion




Mean (mg) CV (%)
a 0.5 0.22 4.16
b 2.0 0.41 0.80
b 10 1.96 1.18
b 20 3.99 2.13
b 30 6.06 0.54
b 40 7.97 1.39
Table 4.9 Drug content uniformity of the powder formulations containing various 
concentrations of NST blended with carrier lactose (63-90 pm: AJS).
(an = 10 x 40 mg; bn = 10 x 20 mg).
The drug content uniformity (CV) for all the powder systems was < 5%.
In-vitro Aerosol Characterisation
Table 4.10 and figures 4.15 and 4.16 summarise the in-vitro aerosol performance of the 
coarse carrier lactose formulations containing between 0.5 and 40% w/w NST.
Data derived from the studies employing alternative blending techniques (run 1) 




NST Concentration (% w/w)
0.5“ 2.0b 10c 20c 30c 40c
% Capsule & Device 6.02 ± 1.5 10.0 ±1.1 12.2 ±1.7 10.9 ±0.95 12.9 ±2.0 14.9 ±0.81
% Stage 1 83.1 ±1.9 79.3 ±1.4 77.1 ±2.4 82.2 ± 0.91 78.4 ±2.1 77.4 ±1.2
% Stage 2 10.9 ± 1.4 10.7 ±0.81 10.7 ± 1.3 6.95 ±0.15 8.75 ± 0.46 7.70 ±0.66
Emitted Percent (%) 93.9 ±1.5 90.0 ±1.1 87.8 ±1.7 89.1 ±0.95 87.1 ±2.0 85.1 ±0.81
Emitted Dose (mg) 0.20 ± 0.004 0.37 ± 0.05 1.66 ±0.05 3.55 ±0.08 5.19 ± 0.19 6.47 ± 0.20
Fine Particle Fraction (%) 11.6 ± 1.5 11.9 ±0.92 12.2 ± 1.6 7.79 ±0.17 10.1 ±0.62 9.05 ± 0.79
Fine Particle Dose (mg) 0.02 ± 0.003 0.04 ± 0.01 0.20 ± 0.02 0.28 ± 0.01 0.52 ± 0.04 0.59 ± 0.05
Drug Recovered (%) 96.3 ±2.1 101 ± 1.1 100 ±1.8 100 ±1.3 102 ±2.78 96.8 ± 2.2
Table 4.10 The effect of NST concentration on the in-vitro aerosol performance of the coarse carrier system.
“Capsule fill = 40 mg: in-vitro aerosol performance determined by firing ten capsules (40 mg) into the modified Apparatus A. 
ED and FPD were normalised with respect to a 40 mg capsule fill weight.
bCapsule fill = 20 mg: in-vitro aerosol performances determined by firing ten capsules (20 mg) into the modified Apparatus A. 
ED and FPD were normalised with respect to a 20 mg capsule fill weight.
cCapsule fill = 20 mg: in-vitro aerosol performance determined by firing one capsule (20 mg) into the modified Apparatus A. 





















Figure 4.15 The effect o f drug concentration on the in-vitro aerosol performance of 
coarse carrier system.














0Z53 2.0% NST 
ESS53 10% NST 
ESSES 20% NST 
30% NST 
m rm 40% n s t
Emitted Dose FPF
In-vitro Aerosol Characterisation
Figure 4.16 The effect o f drug concentration on the in-vitro aerosol performance of 
coarse carrier system.
Each column shows the mean of 5 determinations (bars represent SDs).
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Several studies have investigated the effects of drug concentration on the aerosolisation 
of carrier based powder systems by assessing the in-vitro (Braun et al. 1996; Kassem, 
1990; Steckel and Muller, 1997b; Wong et al. 1995b) and in-vivo aerosol performance 
(Pitcairn et al. 1997) of blends for inhalation.
Kassem (1990) studied the aerosol behaviour of micronised SS blended with a coarse 
lactose earner (63-90 pm) in the ratios of 1:135 to 1:1. The use of micronised drug 
without any carrier was also investigated. Kassem (1990) found that the addition of 
lactose to the formulation improved emptying of the inhaler therefore, more drug was 
made available for “inhalation”. The work of Bell et al. (1971) demonstrated extensive 
coating of the Spinhaler® with DSCG in the absence of a coarse carrier supported the 
findings.
In the present study, one way analysis of variance also revealed a significant difference 
in the percentage of drug emitted for the formulations containing increasing 
concentrations (% w/w) of NST (F = 23.15, p < 0.001). However, Fisher’s pairwise 
comparisons revealed that only the 0.5% w/w NST formulation emitted a significantly 
greater percentage of drug compared with the other systems. Therefore, it would appear 
that for the higher dose formulations, the addition of a coarse carrier does not 
dramatically affect the mass of drug leaving the device.
Kassem (1990) also reported an increase in drug deposition on the lower stages of a 
MSLI as the proportion of lactose in the mixtures was decreased. It was therefore 
suggested that the FPF of a DPI formulation could be improved by increasing the 
concentration of drug in the system (Kassem, 1990). However, this suggestion assumes
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that the interparticle forces dictating the aerosol performance of the powder system are 
the adhesive interactions acting between the drug and carrier particles.
The results of the present investigations suggest that this is not the case for micronised 
NST. One way analysis of variance on the FPF (F = 14.35, p < 0.001) and the 
subsequent stage-2 deposition (%) (F = 18.06, p < 0.001) indicated a significant 
decrease in both parameters when the concentration of NST increased. Fisher’s 
pairwise comparisons revealed that the lower dose formulations (0.5 to 10 % w/w NST) 
deaggregated more completely upon aerosolisation leading to a greater percentage of 
drug depositing in stage-2 of the modified Apparatus A. The formulations containing 
20 to 40 % w/w NST, showed a significant decrease in both parameters indicating that in 
this system, an increased concentration of NST does not improve the efficiency of the 
high dose formulations.
These findings were supported by Steckel and Muller (1997b) who found that 
increasing the concentration of micronised budesonide in a lactose carrier based system 
led to a continuous decrease in the FPF, agglomerates of pure drug building up which 
could not be re-dispersed. Wong et al. (1995a) studied the in-vitro aerosol performance 
of NST (10 to 50 % 7 W) blended with a 45-63 |um sieve size fraction of lactose. The 
FPF (Dae <6.5 pm) as determined by discharging the formulations from the Spinhaler® 
at 60 litres m in1 was approximately 15% and did not show any dramatic changes over 
the drug concentration range. This is presumably due to the choice of mixer (TTM) in 
combination with the coarser carrier system, not effectively deaggregating the drug 
systems. Even for the lower drug concentration formulations, the aerosol performance 
may be limited by the cohesive drug interactions.
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The effects o f powder concentration on the adhesion tendency and mechanical stability 
of interactive mixtures have been investigated by a sieving method (Malmqvist and 
Nystrom, 1982) and segregation tendency tests (Bryan et al. 1979; Staniforth et al. 
1981; Staniforth and Rees, 1983). Centrifuge methods have also attempted to study the 
characteristics of drug adhesion in a model interactive system (Kulvanich and Stewart, 
1987c).
These studies indicated a decrease in the adhesive properties o f drug powder at 
increased concentrations. The reduction in adhesion tendency was explained by the 
limitation o f active sites on the carrier capable o f forming strong bonds with drug 
particles (Hersey, 1975; Staniforth et al. 1981). Excess drug particles formed weaker 
associations with the carrier or remained free in the bulk o f the mixture. Multi-particle 
















Figure 4.17 Diagrammatic representation o f the interparticle forces presumed to be 
influencing the aerosol performance o f the coarse carrier based systems
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However, for an improved FPF and FPD, the dislodged drug particles need to 
deaggregate into potentially respirable aggregates/discrete particles (figure 4.17). This 
would appear to be the case for SS (Kassem, 1990) but not for micronised budesonide 
and NST (Steckel and Muller 1997b; Wong et al. 1995a).
Microscopic Investigations o f  the Coarse Carrier Based Systems 
LTSEM images (figures 4.18 to 4.20) depict a hand blended carrier based formulation 
containing 10% w/w NST. Multi-layers o f drug particles are adhered onto the lactose 
carrier surface (figure 4.19). The drug particle’s affinity for surface crevices and 
discontinuities on the carrier crystal’s surface is also clearly visible (figure 4.20). It can 
be seen that fine powder is likely to fill up the carrier surface irregularities in 
agglomerates rather than cover the surface in a particulate manner.
Figure 4.18 LTSEM electron micrograph of 10% w/w NST blended (HB) with a 
coarse carrier (63-90) sieve fraction of lactose.
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Figure 4.19 LTSEM electron micrograph o f 10% w/w NST blended (HB) with 
a coarse carrier (63-90) sieve fraction of lactose.
Figure 4.20 LTSEM electron micrograph of 10% w/w NST blended (HB) with 
coarse carrier (63-90) sieve fraction of lactose.
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4.2 Bi-Component Coarse Carrier Systems
4.3.1 The Addition of FPL to the Coarse Carrier System
Subsequent sections detail the use of “bi-component” lactose systems which are defined 
as carrier blends containing two size fractions of lactose (Lord, 1993). The effects of 
the addition of FPL on the drug content uniformity (as described in section 2.2.4) and 
the in-vitro aerosol performance of high dose (40% w/w NST) carrier based systems (as 
described in section 2.5.1) were investigated.
43.1.1 Materials and Methods
40% w/w NST was blended with a bi-component carrier system consisting of 63-90 pm 
(AJS) lactose and 5% w/w FPL (% w/w of carrier system). Three 10 g blends, containing 
NST (4 g), 63-90 pm lactose (5.7 g) and FPL (0.3 g) were prepared according to the 
following protocols.
Blend A - Ad-hoc: The three components were HB in one mixing stage for 15 minutes. 
Blend B - FPL pre-mixed with the coarse carrier lactose: The lactose size fractions were 
initially HB for 15 minutes. After 15 minutes the carrier powder was 
screened (355 pm) and then mixed for a further 15 minutes. NST was then 
added to the binary carrier system and HB for 15 minutes.
Blend C - FPL pre-mixed with NST: NST and the FPL were HB for 15 minutes, 
introducing a 355 pm screening stage after 5 minutes. The coarse lactose 
carrier was then added to the NST/FPL binary system and the powder system 
mixed for a further 5 minutes.
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Blend D - No FPL: The binary powder formulation prepared in section (4.2.2) 
containing 60 % w/w carrier lactose and 40 % w/w NST was defined as blend D. 
This blend was a control formulation, i.e. the formulation was prepared using 
a similar mixing procedure as for blends A to C however FPL was not 
incorporated into the system.
The blends were prepared and characterised in duplicate.
4.3.1.2 Results and Discussion




Blend A Blend B Blend C Blend D
Run 1 Run 2
Mean (mg) 7.74 7.71 7.88 7.97 8.01
CV (%) 1.43 1.36 1.97 1.39 1.37
Table 4.11 Influence of mixing order on drug content uniformity, (n = 10 x 20 mg)
The CV for all formulations is <2 %, indicating a satisfactory distribution of NST 
within the powder systems. The addition of 5% w/w FPL to the coarse carrier lactose 
system does not appear to have a detrimental effect on the drug content uniformity 
within the mixtures.












Run 1 Run 2
% Capsule & Device 12.8 ± 1.4 12.4 ±1.4 12.1 ±2.5 14.9 ±0.81 10.2 ± 1.7
% Stage 1 79.6 ± 1.8 80.8 ± 1.7 80.9 ± 3.4 77,4 ±1.2 83.1 ±1.8
% Stage 2 7.57 + 0.51 6.83 ± 0.41 6.88 ± 1.0 7.70 ± 0.66 6.77 ±0.14
Emitted Dose (%) 87.2 ± 1.3 87.6 ±1.4 87.8 ±2.5 85.1 ±0.81 89.8 ± 1.7
Emitted Dose (mg) 6.66 ±0.16 6.60 ±0.17 6.93 ± 0.24 6.47 ± 0.20 7.01 ±0.21
Fine Particle Fraction (%) 8.69 ± 0.68 7.69 ±0.55 7.87 ± 1.3 9.05 ± 0.79 7.54 ± 0.26
Fine Particle Dose (mg) 0.58 ± 0.03 0.51 ±0.03 0.54 ± 0.08 0.59 ± 0.05 0.53 ± 0.02
% Drug Recovery 97.2 ± 1.5 98.2 ± 1.5 101 ±3.0 96.8 ± 2.2 99.4 ± 2.0
Table 4.12 Influence of mixing order on the in-vitro aerosol performance of a NST blended with a binary lactose carrier system.
Values are the mean ± SD of 5 determinations.
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Figure 4.21 The effects o f FPL and mixing order on the aerosol performance o f NST.
Each column shows the mean o f 5 determinations (bars represent SDs).
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Figure 4.22 The effects of FPL and mixing order on the aerosol performance o f NST.
Each column shows the mean o f 5 determinations (bars represent SDs). 
ED = Emitted Dose; FPD = Fine Particle Dose.
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One way analysis of variance revealed that the addition of FPL had no significant effect 
on the ED (F = 2.41, p = 0.083). Similarly, no significant differences were observed in 
the deaggregation (FPF) (F = 0.37, p = 0.70) and subsequent stage-2 deposition (FPD) 
(F = 2.32, p = 0.14) on addition of 5 %w/w FPL, irrespective of the mixing sequence.
Zeng et al. (1996) reported that mixing order was important when considering the 
aerosol performance of formulations containing SS mixed with a coarse carrier lactose 
size fraction (63-90 pm) and FPL (0 to 9% w/w). Powder formulations, prepared by 
adding the drug to a pre-blend of the FPL and the coarse carrier component produced a 
significantly greater FPF of SS (p < 0.05) than formulations prepared using different 
orders of mixing. These findings supported the theories of Staniforth (1996) and Hersey 
(1975) regarding the saturation of the more active binding sites by the FPL.
However, the effects of mixing order were not shown to be significant when considering 
the aerosol performance of formulations containing SS and protein particles (Lucas et 
al. 1998a and 1998b).
Lucas et al. (1998a and 1998b) suggested that the incorporation of FPL into the powder 
system would cause a redistribution of drug/protein particles as previously demonstrated 
by Soebagyo and Stewart (1985), resulting in a hybrid ordered system containing 
drug/coarse lactose ordered units and drug/FPL multiplets. Improvements in the FPF of 
the active component were attributed to the improved liberation of drug/protein particles 
from the FPL. The aerosolised fraction depositing into the lower stage of Apparatus A 
(BP, 1998), may also have contained active/FPL multiplets, i.e. the drug particles are 
deposited without being redispersed (Lucas et al. 1998a and 1998b).
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Reasons for these conflicting conclusions may include the use of different DPI devices, 
differing particle size distributions of SS and/or the influence of mixing procedures 
within each mixing stage. The findings reported by Zeng et al. (1996) were based on 
the deaggregation of SS (VMD = 6.6 pm) from the Rotahaler®. At both the 
experimentally employed flow rates (60 and 90 litres min'1) a large percentage of the 
drug particles even if liberated from the carrier surface would not be able to penetrate to 
the lower stage of the Apparatus A (BP, 1998). Coupled with the poor deaggregating 
capabilities of the Rotahaler® (Vidgren, 1988b), Zeng’s (1996) conclusions regarding 
the importance of mixing order are questionable.
Lucas et al. (1998b) used a sample of SS with a different particle size distribution 
(VMD 2.2 pm), assessed the in-vitro aerosol performance by discharging the 
formulations from the Diskhaler®.
The performance modifying effects of FPL are most likely due to a combination of the 
two mechanisms previously discussed.
Based on the theory proposed by Staniforth and Lord (1996), the liberation of drug 
particles from the carrier surface would be expected to be maximised for blend B. 
However, in the present study, the incorporation of FPL (5% w/w of the coarse carrier 
system) irrespective of the mixing order had no significant effect on the aerosol 
performance of the powder systems. This again supports the theory that the interparticle 
forces dictating the aerosol performance of NST are the cohesive interactions binding 
the drug aggregates (existing independently from the carrier or as multi-particle layers) 
and not the adhesive interactions operating between the drug and carrier.
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Blend D would in theory present the greatest opportunity to physically disrupt the 
drug/drug cohesive interactions. No significant differences were observed, presumably 
because the mixing procedure failed to efficiently deaggregate the drug agglomerates 
and/or the concentration of FPL was insufficient to produce a functional effect.
Therefore, based on the proposed requirement to physically disrupt the drug aggregates, 
alternative carrier systems were investigated in conjunction with mixing procedures 
considered to produce varying degrees of shear.
152
4.4 Alternative Lactose Carrier Systems
4.4.1 Materials and Methods
Mixtures were prepared by initially hand blending 40% w/w NST with a 60% w/w carrier 
system comprising different ratios of a coarse (63-90 pm) and a finer sieve size fraction 
(<45 pm) of lactose. All components were HB in one stage for 15 minutes according to 
the procedures described in section 2.2.3. Four blends (10 g) were prepared containing 
increasing concentrations of the <45 pm sieve size fraction of lactose (table 4.13). The 
first and final mixes in the series were binary blends containing 40% w/w NST blended 
with either coarse carrier (63-90 pm) or fine carrier (<45 pm) lactose respectively.
A binary blend containing 60% 7 W FPL as the carrier system was then prepared using 
the same blending procedure.
The RBB and TTM were then used to prepare the binary blends (10 g) containing the 60 
% 7 W FPL carrier system following the procedures described in section 2.2.3. The 
blends were mixed in the RBB for 2 minutes or the TTM for 10 minutes.
All blends were prepared and analysed in duplicate except the formulations containing 
20 and 40 % 7 W of the <45 pm lactose sieve size fraction. Since the data appeared to be 
following a predictable trend, these formulations were prepared and analysed just the 
once.
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4.4.2 Results and Discussion
Table 4.13 summarises the drug content uniformity data for the different lactose carrier 
systems blended as described in the previous section.
The drug homogeneity throughout the powder systems was satisfactory for all the 
formulation and blending procedures (CV <4.1%). The drug content uniformity data 
also suggests that the HB and RBB mixing procedures produce an improved distribution 
of NST within the powder systems (CV <2 %) compared with the TTM (CV >3%).
The Effects o f Carrier Particle Size on the In-vitro Aerosol Performance o f NST 
Table 4.14 details the in-vitro aerosol performance of the 40% w/w NST formulations 
blended with different carrier systems of 63-90 pm and <45 pm sieve fractions.
One way analysis of variance in conjunction with Fisher’s pairwise comparisons 
revealed that the hand blended formulations containing different lactose carrier sieve 
fractions (63-90 pm and <45 pm) showed a significant difference in their aerosol 
performance. There was a significant difference in the ED for the hand blended 
formulations (F = 22.60, p < 0.001). Fisher’s pairwise comparisons revealed that 
increasing the concentration of the <45 pm sieve size fraction tended to reduce the mass 
of NST leaving the device/capsule system. These results are in agreement with Byron 
(1990) who concluded that a compromise must be made between coarse carriers that 
flow and empty efficiently and finer carriers that deliver an increased fraction of 
potentially respirable particles.
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Lactose Carrier System 




Run 1 Run 2
63-90 qm <45 fim FPL Mean (mg) CV (%) Mean (mg) CV (%)
60 0 0 HB 7.76 1.22 7.90 1.34
40 20 0 HB 7.87 1.04 Not Determined
20 40 0 HB 7.63 1.13 Not Determined
0 60 0 HB 7.69 1.12 7.92 1.28
0 0 60 HB 7.99 1.35 8.12 1.05
0 0 60 TTM 8.35 3.10 8.22 4.12
0 0 60 RBB 7.96 1.35 8.10 1.90
Table 4.13 Content uniformity data for NST (40% w/w) blended with different lactose carrier systems using various mixing techniques





<45 pm (0%) 
63-90 pm (60%)
<45 pm (20%) 
63-90 pm (40%)
<45 pm (40%) 
63-90 pm (20%)
<45 pm (60%) 
63-90 pm (0%)
Formulation 1 Formulation 2 Formulation 1 Formulation 1 Formulation 1 Formulation 2
% Capsule & Device 14.9 ±0.81 10.2 ±1.7 16.8 ± 1.7 15.2 ±1.5 21.0 ±2.5 21.2 ± 1.6
% Stage 1 77.4 ± 1.2 83.1 ±1.8 74,8 ± 2.4 69.2 ± 2.0 61.4 ±2.6 62.8 ± 2.7
% Stage 2 7.70 ± 0.66 6.77 ±0.14 8.38 ± 1.0 15.6 ± 1.6 17.6 ±0.76 16.0 ±1.8
Emitted Dose (%) 85.1 ±0.81 89.8 ±1.7 83.2 ± 1.7 84.8 ±1.5 79.0 ±2.5 78.8 ±1.6
Emitted Dose (mg) 6.47 ± 0.20 7.01 ±0.21 6.40 ± 0.08 6.31 ±0.14 5.97 ± 0.22 6.05 ± 0.099
FPF (%) 9.05 ± 0.79 7.54 ± 0.26 10.1 ±1.3 18.4 ±1.9 22.3 ±1.2 20.3 ± 2.4
Fine Particle Dose (mg) 0.585 ± 0.053 0.529 ± 0.020 0.645 ± 0.082 1.16 ± 0.11 1.38 ±0.065 1.23 ±0.13
% Drug Recovery 96.8 ± 2.2 99.4 ± 2.0 97.8 ± 0.95 97.5 ± 0.91 98.2 ±0.88 97.0 ±0.71
Table 4.14 In-vitro aerosol characterisation of NST (40% w/w) hand blended with different lactose carrier systems. 
Values are the mean ± SD of 5 determinations.
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Modified Apparatus A
Figure 4.23 The effects o f the carrier system on the in-vitro aerosol performance 
o f NST (40% w/w).
Each column shows the mean o f 5 determinations (bars represent SDs).
In-vitro Aerosol Characterisation
Figure 4.24 The effects o f the carrier system on the in-vitro aerosol performance 
o f NST (40% 7 J .
Each column shows the mean of 5 determinations (bars represent SDs).
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One way analysis of variance followed by Fisher’s pairwise comparisons revealed that 
increasing the concentration (% w/w) of the <45 pm fraction significantly improved the 
deaggregation (FPF) (F = 108.13, p < 0.001) and subsequent stage-2 deposition of NST 
(FPD) (F = 88.3, P < 0.001). On addition of 40% w/w of the <45 pm size fraction, there 
was a dramatic improvement in both the deaggregation and subsequent stage-2 drug 
deposition. The FPF of the systems containing the FPL displayed the greatest 
improvement in the deaggregation of emitted drug: >30% compared with <10% for the 
63-90 pm carrier systems. This improved deaggregation for the FPL system, despite 
greater device retention, translated into an improved FPD: >1.89 mg compared with < 
0.6 mg for the 63-90 pm carrier system.
The Effects o f Blending Procedures on the In-vitro Aerosol Performance o f NST 
Table 4.15 and figures 4.25 and 4.26 summarise the in-vitro aerosol performance of the 
40% w/w NST / 60% w/w FPL formulations prepared using the three different blending 
techniques.
One way analysis of variance revealed a significant difference in the ED for the powder 
systems prepared using the three different mixing procedures (F = 56.73, p < 0.001). 
Fisher’s pairwise comparisons revealed that the powder systems prepared using the 
TTM displayed a greater ED compared with the blends prepared by HB or using the 
RBB. This may be due to: a) aggregation of the system or b) a decrease in the 
deaggregation of the formulation, with a subsequent decrease in the generation of 
discrete particles.
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One way analysis of variance revealed a significant difference in the deaggregation 
(FPF) (F = 43.69, p < 0.001) and subsequent stage-2 deposition of NST (FPD) F = 
12.55, p < 0.001). Fisher’s pairwise comparisons revealed that there was a significant 
increase in the FPF following the order, RBB>HB>TTM. The mixing techniques were 
arbitrarily assigned as producing low, medium and high shear forces. Based on these 
assignments, it would appear that increasing the shear forces generated in the mixing 
process significantly improves drug particle deaggregation. However, the improved 
deaggregation of the NST only transfers into a significant improvement in the FPD for 
the systems prepared using the RBB since the more complete regeneration of fine 
particles of NST also increased the percentage of NST retained on the device walls, i.e. 
the formulations prepared by HB showed a decreased ED.
Lord (1993) investigated the performance modifying effects of multi-component lactose 
carrier systems with regards to the aerosol performance of SS. Although in the high 
dose NST investigations, the greatest improvement in the deaggregation of the drug 
system was achieved by reducing the particle size of the carrier material, further 
formulatory investigations could study the interactions/deaggregation mechanisms 
operating within alternative bi-component carrier systems. It is suggested that the 
addition of a far coarser carrier component (e.g. sieve size fraction > 355 pm) to the 
FPL/NST powder system may improve both the emptying and deaggregation of the 
powder system. The coarser carrier component may aid powder flow and fluidisation 
(Lord, 1993) and may even improve the deaggregation of the drug system by colliding 




Turbulent Tumbling Mixer Hand Blended Rotary Bladed Blender
Formulation 1 Formulation 2 Formulation 1 Formulation 2 Formulation 1 Formulation 2
% Capsule & Device 16.2 ±1.1 17.9 ±2.8 25.0 ± 0.76 19.7 ±1.5 30.2 ±2.5 24.9 ±. 1.3
% Stage 1 62.3 ±3.1 61.5 ±3.3 50.6 ± 1.7 55.7 ±1.7 43.3 ±1.9 45.7 ± 0.43
% Stage 2 21.6 ±2.0 20.6 ±1.1 24.3 ± 1.6 24.6 ± 1.5 26.6 ± 1.9 29.4 ± 1.4
Emitted Dose (%) 83.8 ±1.1 82.1 ±2.8 75.0 ±0.76 80.3 ±1.5 69.8 ± 2.5 75.1 ±1.3
Emitted Dose (mg) 7.12 ±0.068 6.92 ± 0.26 5.80 ±0.067 6.35 ±0.15 5.69 ±0.30 5.87 ±0.088
Fine Particle Fraction (%) 25.8 ±2.7 25.1 ±1.8 32.5 ±2.1 30.6 ± 1.7 38.0 ±2.1 39.1 ± 1.3
Fine Particle Dose (mg) 1.83 ±0.19 1.73 ±0.081 1.89 ±0.12 1.95 ±0.13 2.16 ± 0.16 2.30 ±0.10
% Drug Recovery 102 ±1.5 103 ±1.13 97.3 ± 1.0 97.4 ± 1.5 97.5 ±1.46 98.2 ± 1,7
Table 4.15 The in-vitro aerosol characterisation of NST (40% w/w) blended with a FPL carrier system using different blending techniques. 
Values are the mean ± SD of 5 determinations.
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Figure 4.25 The effects o f mixing technique on the in-vitro aerosol performance of a 
40% w/w / 60% w/w FPL binary system.
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Figure 4.26 The effects o f mixing technique on the in-vitro aerosol performance of a 
40% 7 W NST / 60% w/w FPL binary system.
Each column shows the mean of 5 determinations (bars represent SDs).
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4.5 General Discussion
Unlike other systems (Kassem, 1990), it would appear that the interparticle forces 
governing the aerosol performance of high dose NST powder formulations are the 
cohesive interactions acting between the drug particles, a situation also reported for 
budesonide (Steckel and Muller, 1997b).
The dispersion of NST in high dose formulations is highly dependent on the particle 
size of the carrier material, a conclusion also reported by Braun et al. (1996) when 
investigating the aerosol performance of DSCG containing formulations discharged 
from the Microhaler®.
A reduction in the carrier particle size has also been reported to improve the in-vitro 
FPF of several low dose drug formulations including, SS from the Rotahaler® 
(Ganderton and Kassem, 1992; Lord 1993), budesonide from the Spinhaler®, (Steckel 
and Muller, 1997b). Kassem (1990) studied the in-vitro deposition of SS formulated 
with one of five sieve size fractions of lactose (<10 to 125-180 jim) at flow rates up to 
200 litres m in1. It was suggested that the improved FPF of SS was due to the smaller 
carrier particles being subjected to more intense perturbations in the turbulent airstream, 
dislodging drug particles more completely (Kassem and Ganderton, 1989). Another 
possible explanation is that the surface roughness is more pronounced in coarser carrier 
particles (Kassem and Ganderton, 1989).
The work of Lord (1993) also attributed the improved fine particle deposition of SS to
the number of binding sites present on the lactose carrier surface. As the particle size
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increases, the degree o f surface roughness increases due to the greater number of crystal 
imperfections and inter-crystal porosity therefore, an increased number of strong 
binding sites (Lord, 1993).
However, with high dose NST systems, the interparticle interactions governing the 
aerosol performance of the powder formulation would appear to be the cohesive forces 
binding the drug particles. Therefore, it is suggested that the carrier particles are 
behaving as “spacers”, exacting their performance modifying effects by physically 
disrupting the drug/drug interparticle interactions, reducing the number and strength of  
cohesive interactions.
By decreasing the excipient particle size and/or subjecting the powder systems to greater 
shear forces, the performance o f NST as an aerosol system, in terms of more efficient 
regeneration o f discrete drug particles can be improved. Both these formulatory 
strategies would be expected to increase the intercalation o f FPL within the drug 





Figure 4.27 Intercalation of FPL within the self-agglomerated drug system.
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CHAPTER 5
FINE PARTICLE LACTOSE 
CARRIER SYSTEMS
5.1 NST/FPL Powder Systems
The effect of an increased mixing time (RBB) on the in-vitro aerosol performance of the 
binary systems was initially investigated to provide further information on the 
performance modifying effects of FPL in high dose NST systems.
5.1.1 The Effects of an Increased Mixing Time (RBB) on the 
Aerosol Performance of the NST/FPL Powder Systems
Materials and Methods
The binary powder systems (40% w/w NST / 60% w/w FPL) (10 g) were mixed for fixed 
time periods as described in section 2.2.3, assessing the drug content uniformity (section 
2.2.4) and in-vitro aerosol performance (section 2.5.1) of the formulations throughout 
the mixing process. The powder blends were prepared and analysed in duplicate.
Results and Discussion
Table 5.1 summarises the drug content uniformity information and data for the binary 
blends after fixed mixing times in the RBB.
After only 2 minutes of mixing, the mean drug content and uniformity of drug within 
the blend suggest that an acceptable mix has formed (CV <2 %). Increasing the mixing 
time does not appear to have any dramatic effect on the mean drug content nor the 
content uniformity.
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Mixing Time in the 
RBB (minutes)
Drug Content Uniformity
Run 1 Run 2
Mean (mg) CV (%) Mean (mg) CV(%)
2 7.81 0.47 7.96 1.33
4 8.04 0.62 7.89 0.40
8 7.97 0.49 7.90 1.33
16 8.05 1.00 8.14 0.58
24 8.14 2.22 8.07 2.98
32 7.95 0.52 7.88 1.73
Table 5.1 Effects of mixing time (RBB) on the drug content uniformity of the 
40% w/w NST and 60% w/w FPL powder system (n = 10 x 20 mg).
Tables 5.2 and 5.3 and figures 5.1 and 5.2 summarise the in-vitro aerosol performance 
of the powder systems after fixed mixing times (RBB).
One way analysis of variance indicated a significant difference in the deaggregation 
(FPF) (F = 34.56, p < 0.001) and subsequent stage-2 drug deposition (FPD) (F = 29.90, 
p < 0.001) for the formulations blended (RBB) for increased time periods. Fisher’s 
pairwise comparisons revealed that both the FPD and FPF increased significantly after 
each mixing stage up to 8 minutes mixing time. A further significant increase occurred 
following 24 minutes of mixing. However, after 32 minutes the powder formulations 





2 minutes 4 minutes 8 minutes
Formulation 1 Formulation 2 Formulation 1 Formulation 2 Formulation 1 Formulation 2
% Capsule & Device 24.5 + 1.4 26.2 ±1.8 24.9 ± 2.0 28.0 ±2.9 20.2 ± 3.0 21.7 ±2.0
% Stage 1 46.7 ± 2.0 46.7 ± 1.9 40.3 ± 2.8 40.6 ± 2.9 39.5 ±2.7 38.7 ± 1.9
% Stage 2 28.8 ±1.9 27.1 ±1.5 34.8 ±2.0 31.4 ±3.2 40.3 ± 1.3 39.7 ± 1.8
Emitted Dose (%) 75.5 + 1.4 73.8 ±1.8 75.1 ±2.0 72.0 ± 2.9 79.8 ± 3.0 78.4 ± 2.0
Emitted Dose (mg) 5.83 ±0.063 5.64 ±0.12 5.86 ± 0.22 5.63 ± 0.20 6.16 ± 0.18 6.01 ± 0.093
Fine Particle Fraction (%) 38.2 ±2.3 36.7 ±2.0 46.4 ± 2.9 43.6 ±3.8 50.5 ± 1.8 50.7 ± 2.0
Fine particle Dose (mg) 2.23 ±0.16 2.07 ±0.12 2.71 ±0.17 2.45 ±0.24 3.11 ±0.080 3.04 ±0.14
% Drug Recovery 98.9 ± 1.4 97.8 ± 0.89 98.7 ±1.8 97.3 ± 0.67 96.9 ± 0.84 97.1 ±2.2
Table 5.2 Effect of mixing time on the in-vitro aerosol characterisation of NST (40% w/w) blended with FPL. 
Values are mean ± SD of 5 determinations.
ED and FPD were normalised with respect to a 20 mg powder fill weight.
In-vitro Aerosol 
Characterisation
16 minutes 24 minutes 32 minutes
Formulation 1 Formulation 2 Formulation 1 Formulation 2 Formulation 1 Formulation 2
% Capsule & Device 18.8 ±2.5 21.3 ±1.5 20.5 ± 0.54 25.0 ±2.6 27.1 ±2.3 26.8 ±3.5
% Stage 1 40.4 ± 2.7 36.4 ±2.3 36.6 ±2.5 33.3 ±2.2 33.3 ±0.79 34.2 ± 1.5
% Stage 2 40.8 ± 3.4 42.4 ±3.1 42.9 ±2.1 41.7 ±2.0 39.7 ±2.9 39.0 ±3.8
Emitted Dose (%) 81.2 ±2.5 78.8 ± 1.5 79.5 ± 0.54 75.0 ±2.6 72.9 ±2.3 73.2 ±3.5
Emitted Dose (mg) 6.33 ±0.13 6.15 ±0.20 6.26 ±0.13 5.86 ±0.18 5.73 ±0.24 5.60 ± 0.24
Fine Particle Fraction (%) 50.3 ±3.6 53.7 ±3.3 54.0 ±2.9 55.6 ±2.2 54.4 ± 2.3 53.2 ±3.2
Fine Particle Dose (mg) 3.18 ±0.25 3.31 ±0.29 3.38 ±0.12 3.26 ±0.14 3.12 ±0.26 2.98 ± 0.28
% Drug Recovery 96.7 ± 0.35 97.5 ± 0.90 97.4± 1.1 96.9 ± 1.7 98.8 ± 1.0 97.1 ± 1.1
Table 5.3 Effect of mixing time on the in-vitro aerosol characterisation of NST (40% 7 W) blended with FPL. 
Values are mean ± SD of 5 determinations.
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5.1 Effects o f mixing time (RBB) on the emitted dose. 
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Figure 5.2 Effects o f mixing time (RBB) on the fine particle dose. 
Bars represent the mean +SD o f 5 determinations.
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Increasing the mixing time presumably increases the opportunity for intercalation of 
FPL within the drug self-agglomerates. The increased intercalation improves the 
deaggregation and subsequent in-vitro deposition of discrete or potentially respirable 
drug agglomerates as indicated by the increase in the FPF and FPD.
It is recognised that the assignment of shear forces to the three blending procedures was 
purely arbitrary. However, future experimental work may make use of the single vessel 
processor (SVP) developed by Kay et al. (1999) at the University of Bath. Comparable 
results have been obtained with the SVP under controlled operating conditions with 
respect to the drug homogeneity and aerosol performance of an optimised NST/FPL 
powder system (Kay et al. 1998). The FPF of NST (assessed as described in section
2.5.1) reached a maximum after a process time of 5 minutes. However, following 
extended mixing times, the FPF was again found to decrease. This may be due to 
particles of NST adhering to higher energy binding sites on the FPL.
The SVP was operated under controlled processing conditions however, by varying the 
pressure of the fluidising air, the SVP has the capability of controlling and quantifying 
the shear forces used to mix the binary powder systems (Kay et al. 1999).
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5.1.2 LTSEM  and ED AX Investigations
Materials and Methods
Representative samples of the FPL/NST powder system, mixed using the RBB for 8 
minutes, were analysed using the technique of LTSEM (section 3.2.2). To distinguish 
between the two fine particle components, EDAX in conjunction with LTSEM was 
employed (section 3.2.4). Spot analysis of pure NST and FPL powder samples 
confirmed that the particles could be differentiated by the presence (NST) or absence 
(FPL) of a sodium signal (section 3.3.4).
Results and Discussion
LTSEM electron micrographs of the NST/FPL powder systems are depicted in figures 
5.3 and 5.4. Figure 5.3 depicts a fine lactose particle (particle size ~5 pm) disrupting 
the NST self-agglomerates. The cracks and fissures present on the surface of the FPL 
particle are due to electron beam damage. Identification of the two component particles 
on a purely visual basis is scientifically unwise due to an overlap in their particle size 
distributions (section 2.3.1). Therefore, EDAX was employed in conjunction with 
LTSEM to chemically differentiate the particles. Spot analysis was used to focus on 
specific locations within the powder sample and ascertain whether or not a sodium 
signal was generated.
Figure 5.5 is an example of LTSEM characterisation with EDAX spot analysis of the 
binary powder system. The intercalation of FPL within the agglomerated drug system is 
supported by LTSEM and EDAX analysis.
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Figure 5.3 LTSEM electron micrograph of 40% 7 W NST blended with FPL 
in the RBB for 8 minutes.
Figure 5.4 LTSEM electron micrograph of 40% 7 W NST blended with FPL 
in the RBB for 8 minutes.
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Figure 5.5 LTSEM and EDAX spot analysis o f the 40% NST / 60% FPL binary powder system.
5.2 The In-vitro Aerosol Performance of FPL
Materials and Methods
The preparation and storage of the glycine-NaOH buffer, methylamine and sodium 
sulphite solutions were described in section 2.4.3.
Stage-1 of the modified Apparatus A was charged with 7 ml of glycine-NaOH buffer.
Stage-2 was charged with 5 ml of both methylamine (5% w/v) and sodium sulphite 
(5% 7 V) and 15 mis of glycine-NaOH buffer.
Hard gelatin capsules (size 3) were filled with 20 mg of FPL immediately prior to 
aerosol characterisation and ten capsules subsequently fired into the modified Apparatus 
A (60 litres min'1) for each determination.
The capsules and devices were rinsed with 40 ml of the glycine-NaOH buffer and then 
made up to volume (50 ml) with 5 ml of both methylamine (5% 7 V) and sodium 
sulphite (5% 7 V) solution.
The elastomeric throat-piece adapter, the throat and stage-1 were rinsed using the 
glycine-NaOH buffer into a 200 ml volumetric flask, and made up to volume (200ml) 
with the buffer. 100 ml of this solution was then added to 20 mis of both methylamine 
(5% 7 W) and sodium sulphite (5% 7 W) and then made up to volume (200 ml) with 
glycine-NaOH buffer. This procedure produced a 1 in 2 dilution of the stage-1 washing 
but maintained a buffer : methylamine : sodium sulphite ratio of 8:1:1.
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The stage-2 contents were rinsed into a 50 ml volumetric flask using the buffer solution, 
and made up to volume (50ml). All solutions were then transferred to 25 ml volumetric 
flasks allowing analysis of FPL to be performed in duplicate for each set of washings.
The water bath was loaded with washings from two experimental runs and a series of 
standard solutions. Conditions and experimental procedures for colour development 
and FPL determination were as described in section 2.4.3. Six experimental runs were 
performed.
Results and Discussion
Table 5.4 and figure 5.6 summarise the in-vitro aerosol characterisation of FPL. It 
would appear that within the FPL carrier based system, approximately 12% of the 
carrier material would be potentially respirable. When considering the optimised 40% 
NST / 60% FPL system previously described this equates to approximately 1.4 mg of 
FPL for a 20 mg capsule fill weight.
Investigations studying the deposition of FPL when formulated with NST were 
unsuccessful due to the NST interfering with the colour development of the 
lactose/methylamine reaction.
Due to the extremely low specific absorption coefficient and the poor calibration results 
(section 2.4.3), the technique was considered only semi-quantitative. It is also 
recognised that the aerosol performance of FPL in NST/FPL formulations may be 
influenced either by: a) the NST particles binding to the FPL particles increasing the Dae 
or b) the NST improving the deaggregation of the FPL.
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In-vitro Aerosol Characterisation Mean ± SD
Capsule + Device (%) 5.75 ±0 .45
Stage 1 (%) 82.7 ±1 . 2
Stage 2 (%) 11.6 ±1 . 2
Emitted Dose (mg) 18.9 ±0.17
Emitted Dose (%) 94.3 ± 0.45
Fine Particle Dose (mg) 2.32 ± 0.25
Fine Particle Fraction (%) 12.3 ±1.3
FPL Recovered (%) 100 ±3.1
Table 5.4 The in-vitro aerosol characterisation o f  FPL determined by discharging 
10 x 20 mg powder samples (n = 6). ED and FPD were normalised with 
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Figure 5.6 In-vitro aerosol characterisation o f FPL.
Bars represent the mean + SD o f 6 determinations.
ED and FPD were normalised with respect to a 20 mg capsule fill weight.
176
However, the results give an approximate estimation of the potential fine particle 
deposition of the FPL. Decreasing the particle size of the lactose carrier in the powder 
formulations is one strategy for improving the FPD of NST. However, this formulation 
approach will also increase the fraction of lactose likely to reach the lower RT.
5.3 General Discussion
It has been demonstrated that the introduction of FPL can improve the in-vitro aerosol 
performance of NST (section 4.4). By selecting the appropriate size fraction of lactose 
(FPL) together with an optimised blending protocol (RBB), the deaggregation of the 
NST (FPF) can be increased from approximately 15% for the pure drug system (section 
2.6.2) to >50% for an optimised formulation (section 5.1.1).
It would appear that the excipient particles produce their optimal functional effects 
when a particle size distribution is selected in conjunction with an appropriate mixing 
process to promote optimal intercalation of the lactose particles within the drug/drug 
self agglomerates. Future policies for the formulation of high dose cohesive drug 
systems (small or large molecules) may include: a) further increasing the shear forces 
generated during the mixing process, possibly allowing the more complete intercalation 
of fine excipient material into the aggregated drug system or b) selection of an even 
finer excipient material.
Figure 5.7 is a diagrammatic representation of the possible interactive system that could 
be achieved by formulating the NST with an even finer excipient.
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Excipient particles
Figure 5.7 Theoretical consideration o f a possible future formulation strategy to 
promote the more complete deaggregation o f high dose drug systems.
The effect o f these spacer particles would be to decrease the van der Waals attractive 
forces, forces thought to predominate when considering the interactions dictating the 
aggregation o f the ultrafine NST powder. The fine excipient material may decrease the 
number o f drug/drug contacts and increase the separation distance between 
neighbouring particles.
However, it is recognised that the excipient material itself would need to be efficiently 
deaggregated under the shear forces produced in the appropriate mixing process. 
Toxicological issues would also need addressing since the fine excipient material would 
be capable o f depositing in the deep lung. However, it is conceivable that optimisation 
of the blending process together with selection of an appropriate “intercalating” material 
may reduce the required concentration o f excipient. Provided that the excipient material 
selected was fully deaggregated into discrete particles, it is conceivable that a proportion 
of the material (Dae <1 pm) may be too small to deposit in the deep lung and therefore 
be exhaled (Zanen et al. 1994).
Surface treatment of the drug particles is an alternative technique to decrease the 
cohesive interactions operating within a micronised powder system (Fults et al. 1997; 
Kawashima and Hino, 1996; Kawashima et al. 1998b).
Fults et al. (1997) reported that fatty acid surface-treated DSCG, differed from the non­
treated DSCG in particle size, shape and dispersion properties. They concluded that 
treatment with the fatty acids could improve the FPF of the drug particles either by 
changing the morphology of the drug particles or altering the extent of interaction 
between drug particles.
Another possible strategy to reduce the cohesive drug interactions is to encapsulate the 
drug particles in microspheres, which may provide further benefit by resisting 
hygroscopic growth within the RT and/or showing sustained release characteristics (El- 
Basier et al. 1997). El-Basier et al. (1997) prepared and characterised (physicochemical 
studies) poly(L-lactic acid) microspheres containing either nedocromil sodium or 
budesonide. They concluded that whilst hydrophobic drugs (budesonide) could be 
effectively incorporated into the microspheres, hydrophilic drugs (nedocromil sodium) 




6.1 Aggregated NST Powder Systems
The inclusion of coarse carrier particles has been avoided in aerosol formulations of TS 
(Trofast and Falk, 1996; Wetterlin, 1988) and DSCG (Bell et al. 1971) by the controlled 
aggregation of fine drug particles into free flowing spheres. The energy driving 
agglomerate formation is the surface free energy of individual particles; formation of 
interparticle bonds reduces the exposed surface area and therefore the surface free 
energy of the system (Adjei and Gupta, 1997). NST exhibits spontaneous aggregation 
although it is possible to develop more uniform agglomerates by rolling the powder on a 
metal mesh (spheronisation).
6.1.1 Materials and Methods
The flow properties and in-vitro aerosol performance of the aggregated pure drug 
system were characterised and compared to the non-aggregated drug powder (section 
2 .6.2).
Approximately 10 grams of NST was screened through a metal sieve (1.4 mm aperture 
diameter) onto a finer sieve mesh (63 pm aperture) and spheronised by rolling the 
screened material across the finer mesh for three minutes. The spheres were then size 
classified by placing the loosely aggregated powder on top of a stack of metal process 
sieves and gently hand tapping the sieve stack for approximately 1 minute to fractionate 
the powder sample. More uniform aggregates were produced (visual inspection) by 
rolling the powder aggregates over the smaller sized mesh of each classification stage 
for a further five minutes. Four sieve size fractions of aggregates were collected: 212- 
355, 355-500, 500-710 and 710-1400 pm.
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The aerosol performance of the aggregated micronised NST was characterised using the 
modified Apparatus A. Approximately 8 mg of drug was accurately weighed into a 
hard gelatin capsule and discharged from the Cyclohaler® at 60 litres min'1 (section
2.5.1).
6.1.2 Powder Flow Properties
Materials and Methods
The flow properties of the screened (355 pm) NST powder were compared to the four 
sieve size fractions of aggregates. The powder flow properties were investigated by 
evaluating bulk density and angle of repose measurements.
Bulk Density Measurements
Accurately weighed powder was filled into a 50 ml measuring cylinder using a glass 
funnel. The initial volume was recorded and the cylinder then placed on a jolting 
volumeter (Type STAV 2003, J Engelsmann GmbH, Ludwigshafen, Germany), which 
was operated at approximately 4 Hz. The cylinder was tapped until a constant volume 
was attained (1000 taps). Equations 6.1 and 6.2 were used to determine the Carr’s index 
(Cl) (Carr, 1965) and Hausner ratio (HR) (Hausner, 1967) respectively.
Equation 6.1 Carr’s Index (%) = Tapped Density - Poured Density x 100
Tapped Density
Equation 6.2 Hausner Ratio = Tapped Density
Poured Density
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The Cl defines the type of powder flow as; 5-15% excellent, 12-16% good, 18-21% 
passable, 23-35% poor, 33-38% very poor and> 40% extremely poor. Values less than 
1.25, as defined by the HR, indicate good flow properties whilst values greater than 1.25 
suggest poor flow.
Angle o f Repose
The “poured” angle of repose (AR) was determined using the method described by 
Jones and Pilpel (1966). A powder funnel was fixed using a retort stand so that the 
bottom of the funnel’s orifice was 10 cm from the bench surface (covered with paper). 
The outlet was closed and the funnel carefully filled to the brim with the powder. The 
powder was then allowed to pour out and the AR determined. The AR defines the type 
of powder flow as; <25° excellent, 25-30° good, 30-40° passable and >40° very poor 
(Wells, 1993).
Results and Discussion
Table 6.1 summarises the powder flow measurements obtained by comparing the 
poured and tapped density and measuring the AR. Results for NST indicate that the 
micronised powder exhibits very poor flow properties (Cl > 36% and AR ~ 40°).
One way analysis of variance followed by Fisher’s pairwise comparisons revealed that 
the aggregated NST systems displayed significantly improved flow properties when 
compared to the non-aggregated NST (F = 71.38; p < 0.001). However, only the larger 
three fractions (>355-500 pm) exhibit what would be defined as good/excellent flow 
(AR< 30°). The flow properties of the larger three fractions of aggregated NST are 
comparable to the coarse lactose sieve fraction (63-90 pm) which is generally added to
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aerosol formulations to improve the flow properties of the micronised drug powder 
(Lucas et al. 1998b).
The Cl for the aggregated and non-aggregated systems were in general agreement with 
AR determinations, indicating that the aggregated sieve fractions showed a significant 
improvement in flow compared with the non-aggregated powder (ANOVA: F = 35.48, 
p < 0.001). Fisher’s pairwise comparisons revealed that the aggregated size fraction 
>355-500 pm showed a significant improvement in flow compared with the 212-355 
pm fraction. However, the powder flow even for the three larger fractions of aggregates 
would still be defined as poor using the Carr’s index definitions whereas the coarse 
lactose fraction would again be described as having good flow properties. This was due 
to the partial break-up of the aggregated system upon consolidation, leading to a greater 
volume reduction and subsequent greater measured tapped density than would otherwise 
be expected.
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Material Bulk Density (g cm'3) Carr’s Index (%) Hausner Ratio Angle of Repose (0)
Poured Tapped
A Micronised NST 0.16(0.001) 0.25 (0.004) 36.9(1.4) 1.58 (0.04) 38.1 (1.6)
A Aggregated NST (212-355 pm) 0.12 (0.002) 0.17 (0.001) 27.7 (0.60) 1.38(0.01) 34.7 (2.0)
A Aggregated NST (355-500 pm) 0.14(0.007) 0.17(0.008) 21.3 (0.57) 1.27 (0.01) 23.6(1.0)
A Aggregated NST (500-710 pm) 0.20 (0.02) 0.25 (0.013) 19.5(3.9) 1.25 (0.06) 21.4(1.8)
A Aggregated NST (710-1400 pm) 0.16(0.01) 0.20 (0.003) 23.2(1.8) 1.30 (0.03) 25.6 (0.04)
B Lactose (63-90 pm) 0.70 (0.007) 0.84 (0.000) 16.4 (0.82) 1.20 (0.01) 25.2 (0.76)
B Fine Particle Lactose 0.32 (0.006) 0.60 (0.013) 47.1 (0.86) 1.89 (0.03) Test failed
Table 6.1 Powder flow characteristics of non-aggregated NST, aggregated NST and two lactose size fractions. 
Results are the mean (SD) of three determinations.
A Results were obtained using a 50 ml measuring cylinder.
B Results were obtained using a 250 ml measuring cylinder. 
cTest failed: the fine particle lactose would not pour from the funnel.
6.1.3 In-vitro Aerosol Characterisation o f the Aggregated NST Powder Systems
Table 6.2 and figures 6.1 and 6.2 summarise the in-vitro aerosol performance of the 
aggregated NST systems.
The aerosol performance of the non-aggregated NST sample screened through a 355 pm 
aperture mesh (section 2.6.2) was compared to that of the aggregated systems. One way 
analysis of variance revealed a significant difference in the ED (F = 97.37, p < 0.01), the 
deaggregation (FPF) (F = 24.75, p < 0.001) and subsequent stage-2 drug deposition 
(FPD) (F = 16.51, p < 0.01) between the aggregated and non-aggregated powder 
systems. Fisher’s pairwise comparisons revealed that the two smaller sized aggregate 
fractions (212-355 and 355-500 pm) showed a significant improvement in the ED 
compared with the non-aggregated powder. This may be a result of the aggregated 
systems being entrained and then aerosolised more efficiently than the non-aggregated 
powder (Lord and Staniforth, 1996).
Alternatively, the aggregated system may not adhere to the device wall to the same 
extent as the non-aggregated powder, due to a reduction in the generation of fine 
particles upon powder aerosolisation. Fisher’s pairwise comparisons also revealed that 
the two larger sieve fractions (500-710 pm and 710-1400 pm) showed a significant 
decrease in the ED compared with the non-aggregated system, due to incomplete 
capsule emptying.
The generation of fine particles from both the aggregated and non-aggregated powder 
systems is dependent on the strength of the interparticle cohesive interactions and the 
shear forces generated within the device upon aerosolisation (Lord and Staniforth,
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1996). The process of spheronisation appeared to increase the cohesive interactions, 
presumably by decreasing the interparticle separation distance thereby increasing the 
strength of the van der Waals interactions (Hickey et al. 1994). This was reflected in the 
significant decrease in the deaggregation (FPF) of the smaller aggregate fractions (<500 
pm) compared with the non-aggregated powder (Fisher’s pairwise comparisons).
The significant increase in the deaggregation of the larger aggregate fractions may result 
from the increased shear forces experienced by the larger systems upon aerosolisation. 
These increased shear forces may result from more frequent and intense collisions of the 
larger powder aggregates when delivered from the pierced gelatin capsule. However, 
the improved FPF of the largest aggregate fraction did not translate into an increase in 
the FPD since a greater percentage of the aggregate mass was retained within the 
capsule (-40% of the recovered drug).
An alternative method of assessing the strength of agglomerated powder systems was 
described by Boerefijn et al. (1998). They described an impact testing technique by 




Sieve Size Fraction of NST Aggregates
212-355 pm 355-500 pm 500-710 pm 710-1400 pm non-aggregated
% Capsule 4.18 ±0.94 6.00 ± 2.4 10.1 ±3.9 39.9 ± 5.3 2.95 ±0.31
% Device 15.7 ±2.9 13.6 ±0.97 19.9 ±2.0 15.8 ±2.7 21.7 ± 1.7
% Stage One 70.3 ± 2.6 71.3 ±3.0 57.6 ±4.7 34.6 ±5.0 63.1 ±2.4
% Stage Two 9.87 ± 0.64 9.07 ± 0.90 12.5 ± 0.82 9.76 ± 0.90 12.3 ± 1.1
Emitted Dose (mg) 6.47 ±0.18 6.49 ±0.19 5.68 ± 0.33 3.54 ± 0.42 6.05 ±0.17
Emitted Percent (%) 80.1 ±2.4 80.4 ± 2.2 70.1 ±4.4 44.3 ± 4.9 75.4 ± 1.6
Fine Particle Dose (mg) 0.796 ± 0.052 0.732 ± 0.072 1.01 ±0.067 0.780 ± 0.074 0.985 ± 0.083
Fine Particle Fraction (%) 12.3 ± 0.97 11.3 ± 1.4 17.9 ± 1.9 22.2 ± 3.2 16.3 ± 1.7
Drug Recovered (%) 101 ±2.0 101 ±0.97 101 ±0.98 99.9 ± 2.2 100 ± 1.3
Table 6.2 In-vitro aerosol characterisation of the non-aggregated (355 pm screened) and aggregated sieve size fractions of NST. 
Values are the mean ± SD of 5 determinations
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V777A Aggregate size 212-355 pm 
Aggregate size 355-500 pm 
ES&S& Aggregate size 500-710 pm 
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Modified Apparatus A
Figure 6.1 In-vitro aerosol performance of the size fractions o f aggregated NST.
Each column shows the mean of 5 determinations (bars represent SDs).
r  ■ i Non-Aggregated Powder 
zr/77\ Agrregate Size Fraction 212-355 pm 
ENSS3 Aggregate Size Fraction 355-500 pm 
RSfrXH Aggregate Size Fraction 500-710 pm
fE = = \ Aggregate Size Fraction 710-1400 pm
ED FPD
In-vitro Aerosol Charactersiation
Figure 6.2 In-vitro aerosol performance of the size fractions o f  aggregated NST.
Each column shows the mean of 5 determinations (bars represent SDs).
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6.2 Aggregated NST/FPL Powder Systems
Although the NST/FPL powder systems (section 5.1.1) displayed improved 
deaggregation properties when compared to the pure NST (section 2.6.2) and the coarse 
carrier based systems (section 4.2), the flow properties of the formulations were 
considered poor (Cl > 50%). Therefore, blends of NST and FPL were aggregated in a 
controlled manner to improve the flowability of the cohesive systems.
Improvements in the in-vitro aerosol performance of NST when formulated with FPL 
have been attributed to the ability of the FPL to intercalate within the NST self­
agglomerates, reducing the number and/or strength of the drug/drug interparticle 
interactions. The process of spheronisation whereby the powder formulations are 
aggregated into free flowing systems has previously been shown to improve the flow 
properties of the powder systems (section 6.1). However, the process of aggregation 
may bring the drug particles into closer proximity, possibly increasing the strength of 
the cohesive interactions. Therefore, the effects of aggregation on the aerosol 
performance of the NST/FPL systems were investigated.
6.2.1 Materials and Methods
The binary formulation consisting of 40% w/w NST and 60% w/w FPL was prepared using 
an optimised mixing procedure (section 5.1.1), blending the two components in the 
RBB for 8 minutes. The blend was then aggregated as previously described for the pure 
drug system (section 6.1.1).
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Studies were then performed to investigate the possibility of “over spheronising” the 
powder formulation. The aggregate sieve size fraction (500-710 pm) (lOg) was placed 
in a glass jar with a plastic screw tap and tumbled in the TTM (42 rev. min'1) for 10, 60 
and 180 minutes. The TTM had previously been shown to promote self-agglomeration 
of NST (section 4.2). The 500-710 pm fraction was chosen after consideration of the 
aerosol performance of all the fractions and the ease of preparation of larger quantities 
of aggregates.
In-vitro Aerosol Characterisation o f the Powder Systems
The content uniformity of the sieve size fractions and the powder systems subjected to 
the extended tumbling times was investigated (section 2.2.4). The in-vitro aerosol 
performance of the four sieve size fractions was investigated using the modified 
Apparatus A (section 2.5.1). Subsequent studies assessed the effects of increased 
aggregation time (TTM) on the aerosol performance of the 500-710 pm fraction.
Microscopic Investigations
The powder systems (aggregated and non-aggregated) were photographed 
(Photographic Unit, University of Bath, Bath, U.K.). The aggregated powder system 
was also imaged using the technique of ESEM (3.2.3).
6.2.2 Results and Discussion
In-vitro Aerosol Characterisation
Table 6.3 summarises the drug content uniformity data for the four different sieve size 
fractions of NST/FPL aggregates. All sieve size fractions displayed an acceptable 
degree of mixing (CV <1.2 %) and there was no dramatic difference between the mean
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drug content for the four size fractions indicating that the aggregation process had not 




Mean (mg) RSD (%)
212-355 pm 8.07 1.14
355-500 pm 7.88 0.89
500-700 pm 7.88 1.00
710-1400 pm 7.93 1.06
Table 6.3 Content uniformity data for the different sieve size fractions of NST/FPL 
agglomerates (n = 10 x 20 mg).
Table 6.4 and figures 6.3 and 6.4 summarise the in-vitro aerosol performance of the 
aggregated NST/FPL powder systems.
To investigate the effects of aggregation on the aerosol performance of the NST/FPL 
powder mixtures, data from the non-aggregated powder formulation (section 5.1.1) was 
included in the statistical analysis. The Students t-test revealed that the repeat 
formulations (run 1 and 2) for the non-aggregated systems (RBB: 8 minutes) displayed 
statistical similar aerosol parameters: (ED) t = 1.65, p = 0.14; (FPD) t = 0.89, p = 0.40. 
Therefore, the data from run 1 was incorporated to assess the effects of aggregation.
One way analysis of variance followed by Fisher’s pairwise comparisons revealed a 
significant increase in the ED for the spheronised systems compared with the non- 
spheronised powder (F = 2.90, p = 0.048). However, there was no significant difference 
in the ED for the four sieve size fractions of aggregates. This result is in contrast to data
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obtained for the various sieve size fractions of pure drug aggregates where a significant 
decrease in the ED occurred for the larger size fractions (section 6.1.3). This decrease 
in ED was attributed to the increased capsule retention for the larger sized aggregates.
The intercalation of FPL within the drug agglomerates has presumably increased the 
deaggregation of the agglomerates therefore less drug is retained within the capsule.
One way analysis of variance revealed no significant difference in the deaggregation 
(FPF) (F = 1.90, p = 0.15) and stage-2 drug deposition (FPD) (F = 0.80, p = 0.54) for 
the aggregated and non-aggregated systems. This would suggest that loosely 







Sieve Size Fraction (pm)
212-355 355-500 500-710 710-1400
Capsule (%) Not recorded 1.87 ±0.09 2.17 ±0.48 1.94 ±0.42 2.05 ±0.31
Device (%) Not recorded 13.8 ±0.92 14.3 ± 1.7 15.5 ±3.0 15.3 ±2.8
Capsule + Device (%) 20.2 ± 3.0 15.7 ±0.95 16.5 ±2.0 17.4 ±2.7 17.4 ±3.0
Stage 1 (%) 39.5 ±2.7 44.3 ± 1.7 42.2 ±3.1 41.5 ± 1.2 42.7 ± 2.5
Stage 2 (%) 40.3 + 1.3 40.1 ±1.7 41.3 ± 1.5 41.1 ±2.3 39.9 ± 1.2
Percentage Emitted (%) 79.8 ±3.0 84.3 ± 0.95 83.5 ±2.0 82.6 ±2.7 82.6 ±3.01
Emitted Dose (mg) 6.16 ± 0.18 6.62 ± 0.20 6.42 ± 0.27 6.48 ±0.16 6.43 ± 0.25
Fine Particle Fraction (%) 50.5 ± 1.8 47.5 ±2.0 49.5 ± 2.7 49.7 ±1.5 48.3 ±1.4
Fine Particle Dose (mg) 3.11 ±0.08 3.15 ±0.15 3.17 ±0.076 3.22 ±0.17 3.11 ±0.089
% Drug Recovery 96.9 ± 0.84 97.4 ±1.9 97.6 ± 1.9 99.6 ± 0.85 98.2 ± 1.7
Table 6.4 The effects of sieve size classification on the in-vitro aerosol performance of NST (40% w/w) blended 
with FPL (60% w/w) and loosely aggregated.
Results are the mean ± SD of five determinations.
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Figure 6.3 The in-vitro aerosol performance o f the size fractions o f the 
aggregated and non-aggregated NST/FPL systems.
Each column shows the mean o f 5 determinations (bars represent SDs).
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In-vitro Aerosol Characterisation
Figure 6.4 The in-vitro aerosol performance o f the size fractions o f the aggregated 
and non-aggregated NST/FPL systems.
Each column shows the mean o f 5 determinations (bars represent SDs).
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Increased Tumbling Times
The drug content uniformity data for the 500-710 pm aggregate sieve size fraction 
following extended tumbling times is summarised in table 6.5. Analysis of the drug 
content uniformity data revealed an acceptable drug distribution (CV <2 %) for all the 
powder systems.
The in-vitro aerosol performance of the 500-710 pm aggregate sieve size fraction 
following increased tumbling times is summarised in table 6.6 and figures 6.5 and 6.6,.
One way analysis of variance revealed that increasing the tumbling time (TTM) (500- 
710 pm sieve fraction) had no significant effect on the ED (F = 0.39, p = 0.76). 
However, an increased tumbling time significantly decreased the deaggregation (FPF) 
and subsequent stage-2 drug deposition (FPD) (F = 45.53, p < 0.001). Fisher’s pairwise 
comparisons revealed that tumbling the mixture for 10 minutes had no significant effect 
on the FPD however, a significant decrease in both FPF and the FPD occurred after 60 
minutes. Since no significant difference is observed in the ED, the decrease in the FPD 
is a direct result of the decrease in the deaggregation of the powder system, which 
decreased from an initial value of 49.7 ± 1.5% to 27.1 ± 2.3% after 180 minutes of 
tumbling.
It is clear that when formulating powders for inhalation as aggregated systems, a 
compromise must be reached between the robustness of the aggregates and downstream 
deaggregation. The strength on the interparticle interactions should be such that the 
aggregates remain intact during down stream processing and device/capsule filling but 










Table 6.5 The effect of tumbling time on the drug content uniformity of the 




0 10 60 180
Capsule (%) 1.94 ±0.42 2.97 ±1.1 2.67 ± 0.29 5.31 ±5.2
Device (%) 15.5 ±3.0 14.2 ±2.9 16.1 ±4.4 13.5 ±2.5
Stage 1 (%) 41.5 ±1.2 44.6 ±2.1 53.6 ±7.9 59.1 ±2.5
Stage 2 (%) 41.1 ±2.3 38.2 ±1.2 27.6 ±3.8 22.1 ±2.6
Emitted Dose (%) 82.6 ±2.7 82.8 ±2.5 81.3 ±4.6 81.2 ±4.0
Emitted Dose (mg) 6.48 ±0.16 6.48 ± 0.28 6.54 ± 0.39 6.68 ± 0.41
FPF (%) 49.7 ±1.5 46.2 ±1.3 34.3 ± 6.3 27.1 ±2.3
Fine particle Dose (mg) 3.22 ±0.17 2.99 ±0.12 2.22 ± 0.30 1.82 ±0.24
Drug Recovered (%) 99.6 ± 0.85 97.7 ± 1.9 100 ±0.68 101 ± 1.8
Table 6.6 The effects of extended tumbling times on the in-vitro aerosol behaviour 
of the NST/FPL (500-710 pm) sieve size fraction.
Results are the mean ± SD of five determinations.
ED and FPD were normalised with respect to a 20 mg capsule fill weight.
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Figure 6.5 Effect o f increased aggregation time on the in vitro aerosol performance of  
the 500-710 pm aggregated NST/FPL system.
Each column shows the mean of 5 determinations (bars represent SDs).
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Figure 6.6 Effect o f increased aggregation time on the in vitro aerosol performance of 
the 500-710 pm aggregated NST/FPL system.
Each column shows the mean o f 5 determinations (bars represent SDs).
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Any changes in the size of the aggregated NST/FPL systems during the extended 
mixing period would have little effect on the aerosol performance since the 
deaggregation and subsequent stage-2 deposition of the various aggregated sieve size 
fractions were not statistically different.
It is presumed that increasing the mixing time may increase the van der Waals forces of 
interaction by decreasing the interparticie distance, increasing the area of interparticle 
contact and/or causing a transient increase in the electrostatic forces of attraction.
Microscopic Analysis
Figures 6.7 and 6.8 are photographic images of the aggregated (pre size classification) 
and non-aggregated NST/FPL powder systems. The images indicate that the cohesive 
powder system readily aggregates into spherical agglomerates.
Figure 6.9 is an ESEM image of the surface of one of the aggregates (pre-size 
classification). The image shows that within the spherical agglomerate, larger particles 
of fine lactose can be seen physically disrupting the drug/drug cohesive interactions.
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Figure 6.7 Photographic image o f the non-aggregated NST/FPL powder system.
Figure 6.8 Photographic image o f the aggregated NST/FPL powder system.
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Figure 6.9 ESEM image o f the aggregated NST/FPL powder system.
6.3 Aggregated TS/FPL Powder Systems
Micronised TS is formulated as a dry powder inhalation by Astra Pharmaceuticals, AB 
Draco, Sweden. The micronised drug is transformed by spheronisation into soft 
aggregates to improve powder processing and aerosolisation (Wetterlin, 1988).
The intercalation o f FPL within the aggregated TS system was investigated to see if the 
improved deaggregation observed for NST was material dependent.
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6.3.1 Materials and Methods
Particle Size Characterisation
The particle size of TS was measured using the technique of LALLS as described in 
section 2.3.1.1. The size distribution was determined using the SVC in conjunction 
with the 100 mm optical lens. Cyclohexane + 0.1% w/v lecithin was used as the 
dispersant medium.
A sample of the TS powder was imaged using conventional SEM as described in section 
3.2.1.
Formulation o f the Powder Systems
Micronised TS aggregates were initially crushed in a weighing boat using a metal 
spatula to destroy the drug self-agglomerates. The TS was then hand blended for 15 
minutes with an equal amount of FPL as described in section 2.2.3.
Both the TS/FPL mixture and the TS powder were screened through a metal sieve (1.4 
mm aperture diameter) onto a finer sieve mesh (63 |im) and spheronised by rolling the 
screened material across the finer mesh for three minutes. The spheres were then size 
classified by placing the loosely aggregated powder on top of a stack of metal process 
sieves and gently hand tapping the sieve stack for approximately 1 minute to fractionate 
the powder sample. More uniform aggregates were produced (visual inspection) by 
rolling the powder aggregates over the smaller sized mesh of each classification stage 
for a further five minutes. Four sieve size fractions of aggregates were collected; <125 
pm, 125-500 pm, 500-710 pm and > 710 pm.
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Using this procedure ensured that both the pure TS system and the TS/FPL formulation 
were aggregated following the same protocol Therefore, any differences in the in-vitro 
aerosol performance of the systems could be related to the performance modifying 
effects of the FPL and not the methods of aggregation.
In-vitro Aerosol Characterisation
The in-vitro aerosol performance of the pure TS and the TS/FPL powder formulation 
was characterised using the modified Apparatus A (section 2.5.1). Capsules were filled 
with 10 mg of either pure TS or TS/FPL immediately before in-vitro aerosol assessment 
and discharged from the Cyclohaler® at 60 litres min'1.
6.3.2 Results and Discussion
Particle Size Characterisation
The particle size distribution of TS is shown in Appendix I, figure A6. The VMD 
(±SD) was 1.8 ± 0.03 pm (n = 3). 90% of the particles had an equivalent volume 
diameter < 5.3 ± 0.1 pm (n = 3).
Figure 6.10 is an electron micrograph of the TS particles, obtained using the technique 
of conventional SEM. The image revealed that the micronised TS powder consists of 
irregular shaped, plate-like crystals.
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Figure 6.10 Conventional SEM electron micrograph of micronised TS.
In-vitro Aerosol Characterisation
Table 6.7 summarises the drug content uniformity data for the fractionated TS/FPL 
aggregated systems. The sieve fraction <125 pm did not appear to aggregate therefore 
was not investigated further. The two larger size fractions of spheres, 500-710 pm and 
>710 pm, showed acceptable drug content uniformity (CV <5 %).
Sieve Size Fraction (pm) Content Uniformity
Mean (mg) CV (%)
125-500 pm 4.40 8.57
500-710 pm 4.66 4.09
>710 pm 4.23 4.35
Table 6.7 Content uniformity data for TS blended with FPL (n = 10 x 10 mg).
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The in-vitro aerosol performance of the 500-710 pm aggregated size fraction was 
characterised using the modified Apparatus A and compared to the aerosol behaviour of 





% Capsule 22.5 ± 3.0 15.4 ±4.9
% Device 22.3 ± 3.6 17.6 ±4.8
% Stage 1 22.3 ± 2.6 29.2 ± 3.3
% Stage 2 33.0 ±3.4 37.8 ±2.7
% Emitted 55.2 ±2.1 67.1 ±5.5
Fine Particle Fraction (%) 59.6 ±5.0 56.5 ± 2.0
Drug Recovery (%) 99.7 ±3.1 98.8 ±3.6
Table 6.8 In-vitro aerosol characterisation of TS and TS/FPL powder systems. 
Values are the mean ± SD of 10 determinations.
The Students t-test revealed that the incorporation of FPL into the TS powder system 
significantly increased the percentage of drug emitted from the capsule/device (t = 7.15, 
p < 0.001). However, there was a significant decrease in the deaggregation (FPF) of the 
system (t = 2.32, p = 0.03) although the effects were not considered dramatic, i.e. TS = 
59.6 ± 5.0% compared with TS/FPL = 56.5 ± 2.0%. The functional effects of FPL 
appear to be material dependent.
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6.4 General Discussion
The formulation of agglomerated units of pure drug offers an alternative formulation 
strategy to carrier based systems when attempting to improve the flow, processing and 
entrainment properties of the fine drug particles (Bell et al. 1971; Wetterlin, 1988).
Under carefully controlled processing conditions, spherical agglomerates of NST 
possessing excellent flow characteristics can be formed. However, the in-vitro 
inhalation performance of NST in both the initial powder and the spheronised form is 
poor, presumably due to the strong cohesive interparticle interactions.
Controlled aggregation of the optimised NST/FPL powder systems results in 
agglomerates with excellent aerosol characteristics (deaggregation and subsequent fine 
dose deposition). However, it has also been demonstrated that increased aggregation 
periods can have a detrimental effect on the deaggregation of the systems following 
aerosolisation. Agglomerated powder systems must be sufficiently strong to withstand 
breakage during storage and transport but be weak enough to disintegrate upon patient 
inhalation. Therefore, there is a narrow window in which the agglomerates should be 
tailored (Boerefijn et al. 1998).
No significant clinical differences were observed between two formulations of DSCG, 
either a blend of DSCG (20 mg) plus lactose (20 mg) or a lactose-free pelletised 
formulation of DSCG (20 mg) (Edwards and Chambers, 1989). It is possible that the 
selection of carrier lactose and/or the mixing processes employed failed to deaggregate
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the drug systems. The aerosol performance of both systems may therefore be limited by 
the cohesive drug interactions.
However, the pelletised formulation may have clinical value because it removes the 
possibility of any adverse effects due to lactose intolerance in lactase deficient patients 
and it also removes any possibility of allergenicity to protein contaminants in the lactose 
(Edwards and Chambers, 1989). Since there is half the amount of powder in a capsule 
of pelletised sodium cromoglycate (20 mg), compared to that of the blend formulation 




THE EFFECTS OF RELATIVE 
HUMIDITY ON THE PHYSICAL 
PROPERTIES AND IN-VITRO 
AEROSOL BEHAVIOUR OF 
NEDOCROMIL SODIUM
7.1 Introduction
NST is stable over the RH range 6.4 to 79.5 % (Khankari et al. 1998). However, NST 
may sorb/desorb surface moisture over this humidity range. The soiption/desorption of 
surface moisture may affect both the electrostatic and capillary interactions at low and 
high humidities respectively. Therefore, samples of NST powder were stored near the 
extremes of this stability range (12 and 76% RH) to assess any possible effects on the 
total moisture content and aerosol performance of the system. NSHH was subsequently 
investigated (physicochemical properties and in-vitro aerosol behaviour) and compared 
to NST.
7.2 Effect of RH on the Physical Properties of 
Nedocromil Sodium
7.2.1 Preparation of Nedocromil Sodium Hydrates
Samples of nedocromil sodium were received as the trihydrate (Rhone Poulenc Rorer, 
U.K.). NSHH was obtained by equilibrating NST at 85-86% RH at 25°C for a four 
week period. Total conversion of NST to NSHH has been reported to occur within 10 
days if stored at a RH of 90% (Khankari et al. 1998). The conversion was monitored 
visually since the colours of the hydrates are strikingly different, crystals of NST are 
pale yellow whereas those of NSHH show a more intense yellow colour (Khankari et al. 
1998). It has been reported that the pale yellow monohydrate can be obtained by storing
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the trihydrate over phosphorus pentoxide under vacuum (0 % RH) at 22°C for six 
months (Khankari et al. 1998). However, since the monohydrate is highly unstable, 
rapidly taking up moisture and converting to the trihydrate at RH >6 % (Khankari et al. 
1998), this conversion and associated experimental investigations were not attempted.
The effects of storage humidity on the total water content of the powder samples and/or 




The percentage weight change of NST samples stored at 12, 53-55 and 75-76 % RH was 
investigated. Samples of approximately 400 mg of NST (initially stored at 53-55% RH) 
were accurately weighed using a five figure balance (Mettler AT261 DeltaRange, 
Mettler Toledo, Switzerland) and then spread thinly over the inside of small plastic 
petri-dishes. The powder samples were then placed in an appropriate desiccator (section 
2.2.2).
Changes in the total water content were monitored gravimetrically over a period of eight 
weeks by regularly removing the powder samples from the desiccators and recording 




Table 7.1 summarises the percentage weight changes for the NST powder samples 
stored at the three humidity levels. Negligible weight changes occurred over the eight 
week period for all powder samples. The results suggest that not only is nedocromil 
sodium stable as the trihydrate but that NST does not appear to sorb or desorb large 
quantities of moisture over this humidity range.
% RH % Weight Change




Table 7.1 Summary of the gravimetric study for NST stored over a range of humidities
7.2.3 Karl Fischer Analysis
Materials and Methods
The total water content of the NST powder samples stored at the three humidity levels 
and the NSHH was determined using the Karl Fischer (KF) method of analysis.
Materials and Methods
KF titrations were initially performed by adding a powder sample (5-10 mg) directly 
into the titration vessel (684 KF Coulometer, Metrohom with 728 Stirrer) using a glass 
capsule filler to ensure all the powder was delivered to the titration solution. The glass 
capsule was accurately weighed (Mettler AT261 DeltaRange, Mettler Toledo, 
Switzerland) before and after delivery of the powder sample to the titration vessel to
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ensure an accurate determination of the delivered mass. Powder samples from the four 
defined storage humidities: 12 %; 53-55 %; 75-76 % and 85-86 % were analysed.
Due to concerns regarding adhesion of the cohesive powder to the glass titration vessel 
(near the port of entry), an alternative method of sample preparation and delivery was 
employed. Approximately 200 mg of powder was accurately weighed and made up to 
50 ml in a volumetric flasks using methanol (water content 0.0024% w/w). An accurate 
volume of the solution (1 ml) was injected into the titration vessel using a Hamilton 
syringe (Hamilton Gastight 1700 Syringe, Hamilton Company, Nevada, U.S.A.). The 
source of methanol used in the preparation of the samples was used as a blank 
throughout all investigations. Due to the hygroscopic nature of methanol (Connors, 
1988), a fresh source was obtained and dedicated to the study and its exposure to the 
atmosphere minimised.
Results and Discussion
Results for the KF analysis of the powder samples prepared using the two techniques are 
shown in table 7.2.
The water contents derived for the NST are in agreement with values previously 
reported of; 12 % w/w(Wong et al. 1995b) and 11.72 % w/w (Khankari et al. 1998). The 
method described by Khankari et al. (1998) is based on the addition of the sample as a 
dry powder. Therefore, similar concerns are expressed regarding the suitability of this 
method for such a cohesive material. Theoretical values based on molecular weights are: 
NSHH 24.5% w/w; NST 11.5 % 7 W and 4.2 % 7 W NSM (Khankari et al. 1998). 
However, these values only take into account water of hydration and not the presence of 







( %  W/ w )
12 dry powder 11.5 ± 0.13
53-55 dry powder 11.5 ± 0.10
75-76 dry powder 11.8 ±0.25
85-86 dry powder 24.0 ±0.51
12 powder in solution 12.6 ± 0.24
53-55 powder in solution 12.4 ±0.13
75-76 powder in solution 12.9 ±0.35
85-86 powder in solution 25.2 ± 0.88
Table 7.2 KF determination of the total water content of NS stored at different 
humidity levels. Results are the mean ± SD of 5 determinations.
a) Dry powder method - direct addition of the sample as a powder.
b) Powder in solution - addition of sample dissolved in methanol.
It would again appear that NST does not sorb/desorb large quantities of water over the 
range of humidities the trihydrate is stable.
7.2.4 Differential Scanning Calorimetry
In the DSC method, the sample and reference are maintained at the same temperature 
and the heat flow required to keep equality in temperature is measured. DSC 
thermograms are obtained as the differential rate of heating against temperature.
Materials and Methods
DSC thermal analysis of NST and NSHH powder samples was performed over the 
temperature range 40 to 350°C (Model 2910, TA Instruments Ltd, U.S.A.). Samples of 
powder (3 mg to 5 mg) were accurately weighed, enclosed in crimped aluminium pans 
and then heated at 10°C min'1. An empty crimped aluminium pan was used as a
reference. The calorimeter furnace was continually purged with nitrogen gas at a flow 
rate of approximately 25 ml min'1. The onset of melting of indium (156.6°C) and tin 
(231.9°C) were used to calibrate the calorimeter. Powder samples were prepared and 
analysed in duplicate.
Results and Discussion
Examples of the DSC thermograms for NST and NSHH are shown in figures 7.1 and
7.2. The peak temperatures and specific energies for the principle endotherms are 
summarised in table 7.3.
Material Peak Temperature (°C) AH of each endotherm (J g 1)
Run 1 Run 2 Run 1 Run 2
NST 129.8 130.7 266.2 266.5
207.8 208.8 75.5 76.9
NSHH 70.5 67.3 76.2 82.8
100.9 97.8 140.6 136.2
124.4 125.1 142.4 147.4
202.6 201.2 102.4 108.5
Table 7.3 Summary of the DSC analysis of NST and NSHH.
Nedocromil Sodium Trihydrate
The DSC thermogram for NST stored at 53-55% RH shows a sharp endotherm at 
approximately 130°C and a broad weak endotherm at approximately 208°C (figure 7.1). 
Khankari et al. (1995) correlated similar DSC data with information obtained from 
thermogravimetric analysis (TGA) and hot stage microscopy, confirming that the two 
endotherms relate to processes of dehydration. The first dehydration corresponds to the
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loss of two thirds of the water (loosely bound) and the remaining one third is lost at 
about 208°C (tightly bound).
Nedocromil Sodium Heptahemihydrate
NSHH exhibits four endotherms, a very sharp narrow endotherm at approximately 70°C, 
followed by two broader endotherms at 100°C and 125°C and a still broader weaker 
endotherm at 200°C. The variation in the specific energies associated with the 
endotherms was considered a result of difficulties in integrating the peak areas since 
there is no obvious baseline. This degree of variability is also reflected in published 
data (DSC on NSHH) from two separate studies (Khankari et al. 1992; Khankari et al. 
1995). The peak temperatures associated with each endotherm are in general agreement 
with Khankari et al. (1998) suggesting that the four week storage period was sufficient 
to cause complete conversion of NST to NSHH.
Initially it was reported that the dehydration of NSHH occurred in four steps, 
presumably due to four different binding environments available for the water 
molecules (Khankari et al. 1992). However, in crimped pan DSC and TGA, the 
relatively high water vapour pressures produced changes in the dehydration of NSHH. 
The NSHH melted at 75°C converting to NST, which on further heating converted to 
NSM and eventually the anhydrate (Khankari et al. 1998). More recent studies using 
techniques of open/closed pan DSC, TGA and hot stage microscopy revealed that the 
water molecules in NSHH are linked together to form continuous water channels. DSC 
and TGA of the NSHH in open pans revealed a single dehydration endotherm from 72 
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Figure 7.2 DSC thermogram for NSHH (stored at 85-86 % RH).
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7.2.5 M icroscopic Analysis
LTSEM electron micrographs of NST (figures 3.8 and 3.9) were described in section
3.3.2. LTSEM electron micrographs of NSHH are shown in figures 7.3 and 7.4. The 
techniques used to acquire the images are described in detail in section 3.2.2.
From figures 7.3 and 7.4, it would appear that solid/liquid bridges appear to have 
formed between the previously discrete drug particles, resulting in what can be 
envisaged as agglomerates with poor deaggregating capabilities. The uncharged nature 
of the sample, as seen from the resolution and clarity of the images, again reflects the 
usefulness of LTSEM for imaging highly hydrated pharmaceutical materials.
Ampratum et al. (1997) claim to have imaged both milled and spray dried NST using 
conventional SEM although the images were not presented. They concluded that on 
storage at 76 and 96 % RH, spray dried and milled NST particles appeared to fuse 
having no distinct shape and roughened surfaces. However, the imaging of such 
hydrated particles in the vacuum of a conventional SEM (SEM, Phillips XL20) without 
substantial damage to the conducting gold coating and subsequent sample charging is 
difficult to envisage.
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Figure 7.3 LTSEM electron micrograph o f NSHH.
Figure 7.4 LTSEM electron micrograph o f NSHH.
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7.3 The Effects of Storage Humidity on the In-vitro 
Aerosol Performance of Nedocromil Sodium
The influence of the storage humidity on the interactive forces operating within the pure 
drug system was evaluated by measuring the deaggregation and subsequent fine particle 
deposition of the powder samples (modified Apparatus A and MSLI).
The in-vitro aerosol performance of NST stored over a range of humidities (12 to 76% 
RH) was characterised and compared to NSHH.
7.3.1 Materials and Methods
All powder samples were pre-screened through a 355 pm mesh before storage for four 
weeks at one of four humidities (12, 53-55, 75-76 and 85-86% RH). The conditions 
were chosen to represent a range of humidities throughout which NST is stable (12-76% 
RH) but where sorption/desorption of surface moisture may occur. The powder stored 
at 86% had converted to NSHH.
The modified Apparatus A was initially used to study the in-vitro aerosol properties of 
the drug powder. Data derived from these investigations was supplemented by MSLI 
investigations.
An 8 mg capsule powder fill weight was employed for the modified Apparatus A 
studies and a 20 mg fill weight investigated for the MSLI studies.
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To minimise the effects of gelatin/powder moisture transfer (Bell et al. 1973b; Konty 
and Mulski, 1989) the powders were removed from the dessicators and filled into the 
gelatin capsule immediately before in-vitro aerosol assessment.
7.3.2 Results and Discussion
Table 7.4 and figures 7.5 and 7.6 summarise the in-vitro aerosol performance (modified 
Apparatus A) of NST stored under different humidity conditions.
The deaggregation of the pure drug system investigated immediately after screening 
(355 pm) (section 2.6.2) was compared to the aerosol performance of the sample stored 
at 53-55 % RH for four weeks. The Students t-test revealed no significant differences in 
the ED (t = 1.22, p = 0.260). However, there was a significant decrease in the 
deaggregation (FPF) (t = 2.62, p = 0.030) and subsequent stage-2 deposition of NST 
(FPD) (t = 2.58, p = 0.033).
The decrease in the deaggregation of the pure drug system following storage is 
presumably due to the screened material re-agglomerating. This would suggest that the 
aerosol performance of the optimised formulations (section 4 and 5) may decrease with 




Storage Humidity (% RH)
12 53-55“ 53-55 75-76 85-86
% Capsule 5.41 ± 1.8 3.00 ±0.31 4.02 ± 0.52 4.50 ±0.69 16.5 ±0.95
% Device 26.8 ±3.0 21.7 ± 1.7 19.0 ±0.73 21.3 ±2.1 7.69 ± 0.62
% Stage 1 52.8 ± 4.3 63.1 ±2.4 66.2 ± 1.3 62.5 ±3.0 69.8 ± 0.44
% Stage 2 15.1 ± 1.4 12.3 ± 1.1 10.8 ±0.74 11.7 ±0.92 5.98 ± 0.77
Emitted Dose (%) 67.8 ±4.1 75.4 ±1.6 77.0 ±1.1 74.2 ± 2.2 75.8 ±1.2
Emitted Dose (mg) 5.46 ±0.26 6.05 ±0.17 6.16 ± 0.10 5.94 ±0.19 6.09 ± 0.064
Fine Particle Fraction (%) 22.5 ± 2.2 16.3 ±1.7 14.1 ±0.96 15.7 ± 1.6 7.88 ±0.89
Fine Particle Dose (mg) 1.21 ±0.11 0.985 ± 0.083 0.865 ± 0.059 0.934 ± 0.087 0.479 ± 0.053
Drug Recovered (%) 101 ± 1.7 100 ± 1.4 100 ±2.4 100 ±2.43 100 ±2.0
Table 7.4 In-vitro aerosol characterisation of NST stored under environments of different relative humidities.
Discharged using ambient air as the carrier gas. Values are the mean ± SD of 5 determinations. 
“Powder assessed immediately after screening (no 4 week storage period).
ED and FPD were normalised with respect to a 8 mg capsule fill weight.
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Figure 7.5 Effects o f storage humidity on the in-vitro aerosol performance o f NST 
and NSHH determined using the modified Apparatus A.
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Figure 7.6 Effects o f storage humidity on the in-vitro aerosol performance o f NST 
and NSHH determined using the modified Apparatus A.
Each column shows the mean o f 5 determinations (bars represent SDs).
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One way analysis of variance indicated a significant difference in the ED (F = 17.25, 
p < 0.001) for the powder samples stored at the four different humidities. Fisher’s 
pairwise comparisons revealed a significant decrease in the ED for the powder sample 
stored at 12% RH compared with the powder samples stored at the higher humidities 
(55-86%). This is presumably due to an increase in the adhesive interactions operating 
between NST and the device/capsule walls. The increase in adhesion may be a result of 
an increase in electrostatic interactions (Kulvanich and Stewart, 1988) and/or the more 
complete regeneration of fine particles of NST, possessing greater surface free energy.
As the powder sample is stored at progressively higher humidities, the percentage of 
drug adhered onto the device decreases (table 7.4). Braun et al. (1996) reported that 
micronised DSCG adhered to most surfaces at low moisture contents due to electrostatic 
interactions but when exposed to humid air, the micronised powder became more 
cohesive. A similar situation is observed with the NSHH where the percentage of 
NSHH adhered onto the device walls was <8% compared with >19% for samples of 
NST stored at 53-55% RH. However, the decrease in device adhesion did not translate 
into an increase in the ED since the percentage of NSHH retained in the capsule was 
greater (16.5 %) compared with the other powder samples (<6 %). All values were 
expressed as a percentage of the total drug recovered. The increased capsule retention is 
presumable due to a decrease in the deaggregation of the NSHH system upon 
aerosolisation possibly caused by an increase in capillary interactions or even the 
formation of solid bridges (figures 7.3 and 7.4).
The decreased deaggregation of NSHH (FPF) compared to the samples of NST was 
confirmed using Fisher’s pairwise comparisons (F = 72.9, p < 0.001). However,
Fisher’s pairwise comparisons also revealed a significant increase in the deaggregation 
(FPF) of the NST stored at 12% RH. The FPD followed the same trend (F = 69.0, p < 
0.001), greatest for the powder sample stored at 12% RH (1.21 ± 0.11 mg) and lowest 
for the NSHH (0.48 ± 0.05 mg) (Fisher’s pairwise comparisons). There was no 
significant difference in the aerosol performance, in terms of FPF and FPD for the 
samples of NST stored between 53 and 76% RH.
NST stored at lower humidities deaggregated more completely compared to the powder 
samples stored at 53-55 and 75-76% RH and NSHH. However, the improved 
deaggregation did not translate into a dramatic increase in the FPD since a greater 
percentage of the drug adhered to the device walls.
Multistage Liquid Impinger
Table 7.5 and figures 7.7 and 7.8 summarise the in-vitro aerosol characterisation of the 
powder samples measured using the MSLI. The capsule fill weights were increased to 
ensure adequate NST recovery for quantitative drug analysis using the selected 
analytical techniques. This was considered important for the quantification of drug 
deposition on the lower stages of the MSLI for the poorly deaggregating systems 
(NSHH). With the exception of the NSHH, a single actuation was sufficient to 
discharge the capsule contents; multiple actuations were required to empty the capsules 
containing NSHH.
When operated at a flow rate of 60 litres min'1, the FPD determined using the MSLI 
(stage-2 to the filter) encompassed particles of a size 0-6.8 pm (Dae); the modified- 
Apparatus A (stage-2) captured particles of a size 0.5-5.3 pm (Dae).
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In-vitro Aerosol 12% 53-55% 75-76 % 85-86%
Characterisation single shot “single shot single shot Single shot single shot multiple shots
% Capsule 2.01 ± 0.27 6.88 ±1.4 2.00 ± 0.25 1.79 ±0.65 18.5 ±4.9 1.87 ±0.19
% Device 22.6 ± 0.83 16.4 ±1.5 13.5 ±2.2 9.35 ±2.0 3.09 ±0.41 3.24 ± 0.54
% Throat 43.5 ±0.72 26.2 ±2.1 39.5 ± 1.7 35.2 ± 11 25.7 ±4.7 37.7 ±8.9
% Stage 1 17.0 ± 1.8 36.8 ±0.71 33.1 ±3.4 40.1 ±7.4 40.7 ±1.7 46.8 ± 9.6
% Stage 2 2.82 ± 0.067 3.42 ± 0.42 2.12 ±0.48 2.25 ± 0.56 5.23 ± 0.86 5.32 ± 0.24
% Stage 3 4.62 ±1.1 4.98 ± 0.27 3.84 ±0.30 4.05 ± 0.24 4.33 ± 0.23 3.42 ±0.52
% Stage 4 5.81 ±0.57 4.02 ± 0.44 4.64 ± 0.96 4.65 ±0.31 1.40 ±0.17 1.24 ±0.23
% Filter 1.69 ±0.094 1.37 ±0.20 1.21 ±0.27 1.69 ±0.50 0.774 ± 0.52 0.417 ±0.067
ED (%) 74.6 ±1.8 78.2 ±3.8 86.3 ± 2.9 89.1 ±0.97 77.2 ±4.3 95.9 ± 1.1
ED (mg) 14.9 ±0.35 6.25 ± 0.30 17.3 ±0.58 17.8 ±0.19 15.4 ±0.86 19.2 ±0.22
*FPF (%) 16.1 ±2.0 13.5 ±0.44 11.5 ± 1.5 11.8 ± 1.1 8.31 ±0.24 5.35 ±0.68
*FPD (mg) 2.40 ± 0.35 0.845 ± 0.062 1.98 ±0.29 2.16 ± 0.18 1.35 ±0.071 1.01 ±0.13
Extra FPF (%) 9.95 ±0.55 7.01 ±0.58 6.91 ± 1.3 7.23 ±1.1 2.77 ± 0.50 1.75 ±0.19
Extra FPD (mg) 1.48 ±0.12 0.439 ± 0.058 1.20 ±0.26 1.29 ±0.19 0.438 ± 0.090 0.334 ± 0.032
% Drug Recovered 98.9 ± 1.6 102 ±1.9 102 ±0.80 100 ±3.2 98.5 ±1.0 101 ±0.77
Table 7.5 In-vitro aerosol deposition data for NS stored at various humidities determined using a MSLI.
Capsule fill weight = 20 mg except “capsule fill weight = 8 mg.
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igure 7.7 Deposition data for NS stored at various RH determined using a MSLI.
Each column shows the mean of 3 determinations (bars represent SDs). 
Capsule fill weight = 20 mg.
20  -  
18  -  
1 6  -  
1 4  -  
1 2  -  
10  -  
8 -  
6 -  
4 -  
2 -  
0 -
Figure 7.8 Deposition data for NS stored at various RH determined using a MSLI.
Each column shows the mean of 3 determinations (bars represent SDs). 
Capsule fill weight = 20 mg.
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Initially, the aerosol performance of the 8 mg capsule fill weight was assessed, 
comparing the modified Apparatus A data with that obtained from the MSLI 
investigations. The Students t-test revealed no significant differences between the ED (t 
= 0.65, p = 0.54), the deaggregation (FPF) (t = 0.50, p = 0.63) and subsequent stage-2 
drug deposition (FPD) (t = 0.92, p = 0.39).
However, there was a significant decrease in the percentage of drug emitted (NST stored 
at 53-55% RH) for the 8 mg capsule fill weight (78.2 ± 3.8%) compared with the 20 mg 
capsule fill (86.3 ± 2.9%) (t = 2.96, p = 0.04). The reduced powder mass may 
experience increased shear forces upon aerosolisation, deaggregating the powder system 
into smaller sized aggregates. These smaller aggregates would have a greater surface 
area and therefore possess an increased surface free energy (Adjei and Gupta, 1997), 
causing them to adhere more readily to the device and capsule walls. However, the 
increased percentage of drug emitted from the 20 mg capsule fill weight did not 
translate into an increased percentage reaching the lower stages of the MSLI since the 
pre-separator collected a large percentage of the ED (table 7.5).
Generally the data obtained from the MSLI investigations supports the information 
derived from the modified Apparatus A studies in terms of the effects of storage 
humidity on the aerosol performance of NST and NSHH.
The MSLI studies again revealed significant differences in the aerosol performance of 
the NST compared with the NSHH samples. However, no dramatic effects on the 
aerosol performance were observed after storage of the NST at humidities ranging from 
12 to 76% RH.
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The results from the MSLI investigations suggest that the deaggregation of the pure 
drug systems does not result in discrete particle re-generation since <2 % of the 
recovered dose was collected On the final filter (Dae: 0 to 1.7 pm).
From LALLS investigations, it was concluded that a large percentage of the NST 
particles had an equivalent volume diameter <1 pm. Miller et al. (1992) reported that 
consideration must be given to the possibility of a percentage of particles (Dae <1 pm) 
penetrating stage-2 of Apparatus A. However, from the MSLI investigations the Dae of 
the aerosolised aggregates would appear to be >1 pm therefore, penetration of the stage- 
2 liquid trap should be minimal.
Investigations into the aerosol performance of NSM were not performed since because 
the monohydrate is difficult to attain and is extremely hygroscopic, rapidly converting 
back to the trihydrate at RH >6.4% (Khankari et al. 1998).
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7.4 General Discussion
It is recognised that the methods employed to determine the total water content of the 
powder system might only detect gross changes in the moisture content. Alternative 
methods may be employed in future studies to assess changes in the surface energetics 
of the interacting particles. These methods may include contact angle measurements 
(Chawla et al. 1993), isothermal microcalorimetry (Buckton, 1997) and inverse gas 
chromatography (Djordjevic et al. 1992; Dove et al. 1996; Ticehurst et al. 1994). 
Applications of inverse gas chromatography to pharmaceutical systems include a study 
on water adsorption by cyclosporin (Djordjevic et al. 1992) and of organic vapours by 
SS (Ticehurst et al. 1994) and xanthine bronchodilators (Dove et al. 1996).
Alternatively, the influence of storage humidity on the adhesion and cohesion drug/drug 
and drug/carrier could be studied using the centrifugal techniques (Podczeck et al. 1995, 
1996 and 1997).
Numerous studies have investigated the effects of storage humidity on the in-vitro 
aerosol performance of dry powder systems formulated for inhalation (Braun et al. 
1986; Genus et al. 1997; Jashnani and Byron, 1996; Vidgren et al. 1989).
Jashnani and Byron (1996) studied the aerosol performance of powders composed of
three salts and the free base of salbutamol after storage at varying conditions of
temperature and humidity. It was concluded that hydrophobic powders were less
sensitive to high storage humidities than hydrophillic powders with respect to their in-
vitro aerosol performance (Jashnani and Byron, 1996). This was in agreement with
Padmadisastra et al. (1994a) who reported that the type of drug and carrier influenced
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the degree of interaction; carriers with a higher capacity to adsorb water facilitated 
greater interaction by capillary and solid bridge formation.
For non-hydrating, crystalline solids, water is mainly adsorbed onto the particle surface 
at low humidities and as the RH is increased, multi-layer condensation of water vapour 
onto the particle surface may occur (Coelho and Hamby, 1978a).
However, for hydrating particles, condensation of water vapour onto the particle surface 
may not result in the formation of a multi layer. Instead, the sorbed water may be 
employed to convert the non-hydrated particle to the hydrated particles (Ahlneck and 
Zografi, 1990). Relatively large quantities of water vapour may penetrate or diffuse into 
the particles before any significant liquid bridges can be formed on the surface of the 
particle (Chan and Pilpel, 1983). In the case of NST, it is suggested that at increasing 
humidities, the majority of the sorbed moisture may be absorbed, converting the 
trihydrate to the heptahemihydrate. This may explain why NST samples stored at 76% 
RH, deaggregated as efficiently as the powder samples stored under ambient conditions 
(55% RH).
Investigations into the effects of storage humidity on the physical stability and in-vitro 
inhalation performance of micronised DSCG have been performed (Braun et al. 1986; 
Vidgren et al. 1989). Both studies assessed the influence of storage humidity on the 
mixture by measuring the in-vitro dispersibility of the systems after storage at fixed 
humidities.
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Vidgren et al. (1989) found that the water content of mechanically micronised DSCG 
had no significant effect on the mechanical properties of the blend. Storing of the 
mixtures at elevated humidity affected neither the emptying of the capsules in the 
inhaler nor the liberation of micronised drug particles from the carrier particles. Chan 
and Pipel (1983), who reported no change in the binding properties of DSCG 
agglomerates with changing storage humidity supported these findings. DSCG was 
found to accommodate most of the absorbed moisture within its particles and only a 
small amount of water was adsorbed on to the particle surface (Chan and Pilpel, 1983),.
These findings are in contrast to observations made by Braun et al. (1996) and Maggi et 
al. (1999). Braun et al. (1996) compared several formulations containing lactose or 
dextrose as a carrier and 20 mg of mechanically micronised DSCG. They found that the 
deaggregation (FPF) of DSCG increased markedly from 22.3 ± 1.86% to 34.4 ± 3.32% 
after storage at decreased humidities (33% compared to 55 % RH). Braun et al. (1996) 
explained the contradictory results by suggesting that the formation of soft agglomerates 
during their preparation process may change the binding properties acting between the 
powder particles. However, the mixing process employed by Vidgren et al. (1989) may 
also promote self-aggregation of the drug system (section 4.2.1) although this was not 
reported. It is believed that a consideration of the forces governing the aerosol 
performance of the interactive systems may provide a more feasible explanation as to 
the differing effects of humidity the aerosol performance of the DSCG formulations. 
Vidgren’s work was based on the formulation of DSCG blended with an equal amount 
of coarse carrier lactose in a TTM, whereas Braun et al. (1996) and Maggi et al. (1999) 
employed a finer grade of lactose. Based on mixing experiences with NST (section 
4.2.1) it is suggested that the aerosol performance of formulations prepared by Vidgren
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et al. (1989) may be governed by the drug/drug interactions. However by the selection 
of a finer excipient (Braun et al. 1996; Maggi et al. 1999), the formulations may be 
influenced to a greater extent by the weaker drug/carrier adhesive interactions. The 
effects of humidity on the strong cohesive drug interactions may be minimal. However, 
adsorbed moisture may have a detrimental effect (in terms of subsequent deaggregation) 
on the weaker drug/carrier interactions. Future studies may assess the effects of storage 
humidity on the in-viti'o aerosol performance of the optimised NST/FPL aggregated 
system (section 5.1).
Environmental chambers have also been used to assess the importance of carrier air 
temperature and/or humidity on the aerosol performance of powder systems (Byron et 
al. 1977; Hickey, 1988; Martin et al. 1988; Vidgren et al. 1992). The importance of 
both parameters was demonstrated by Bryon et al. (1977), who placed a cascade 
impactor in a climatic chamber at 37°C and monitored changes in the aerosol 
performance as a function of RH. Byron et al. (1977) found a large and significant 
decrease in the dose fraction of drug contained in particles below 5 pm when the RH 
was varied between 40 and 100 % for powder systems containing DSCG (Intal® 
Spincaps).
When considering dry powder systems, the decrease in the fine particle deposition can 
be attributed to; a) hygroscopic growth of the drug particles and/or b) a decrease in the 
deaggregation of the drug/carrier or drug/drug components (Jashnani and Byron, 1996; 




DIFFERENT PHYSICAL FORMS OF 
NEDOCROMIL SODIUM.
8.1 Introduction
Fine powders for inhalation can be prepared either by particle size reduction (milling 
and micronisation) or by particle construction (condensation, evaporation or 
precipitation) (Chawla et al. 1994; Hickey et al. 1994; Hindle et al. 1998; York and 
Hanna 1996; York et al. 1998).
Hammer mills decrease the particle size by impacting the powder with rotating 
hammers. Clark and Hollingworth (1993b) claim to have used a hammer mill to 
manufacture potentially respirable particles of NST, although the majority of drug 
particles for inhalation are prepared using a jet mill in a process known as micronisation 
(Hallworth, 1987). In a jet mill, size reduction is obtained by interparticle collisions and 
attrition, producing particles with sizes ranging from 1-20 pm (Johnson, 1997).
It was considered that the strong cohesive interactions binding the NST particles within 
the pure powder system may be a result of the ultrafine nature of the micronised NST 
(LTSEM and LALLS analysis). Therefore, an alternative size distribution of NST 
(milled) was characterised and the aerosol performance of the pure drug system 
compared to that of the micronised NST.
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8.2 Materials and Methods
Two batches of NST, micronised (Bn. GMR 5019G) and milled (Bn. 3834E/A), were 
supplied by Rhone Poulenc Rorer (Cheshire, U.K.) and used as received.
Re-crystallised nedocromil sodium was passed through a hammer mill (Model TBEP, 
Apex Construction Ltd, Dartford, U.K (Clark and Hollingworth, 1993b). This material 
is referred to as milled NST. The micronised material was prepared by fluid energy 
micronisation of the milled NST (Wong et al. 1995b). This material, referred to as 
micronised NST, has been investigated throughout the study.
8.3 Physicochemical Characterisation
The milling process has the potential to change more than just the particle size of the 
feed material. The heat generated during interparticle collisions can cause changes in 
the solid state properties of the material (Johnson, 1997). Therefore, the particle size 
and shape, the water content and the degree of crystallinity of the two samples was 
characterised in an attempt to correlate differences in the aerosol performance of the 
systems with the physicochemical properties of the powders.
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8.3.1 Particle Size Analysis
Materials and Methods
The particle size distribution of milled NST was determined using the technique of 
LALLS and compared to measurements obtained for micronised NST (section 2.3.1.1). 
Section 2.3.1.1 details the methods and equipment used to prepare and then analyse 
NST by LALLS.
Results and Discussion
The effects of extended sonication periods and the use of a saturated or non-saturated 
dispersant on the particle size distribution of milled NST are summarised in tables 8.1 
and 8.2 and figure 8.1. The particle size distribution of micronised NST, determined by 
LALLS investigations, was described in section 2.3.1.1 and is summarised in table 8.2. 
The particle size distributions for the two forms of NST are shown in Appendix I: 
micronised NST (figure Al) and milled NST (figure A2).
Clark and Hollingworth (1993b) and Wong et al. (1995b) have previously determined 
the particle size distribution of milled and micronised NST samples. Clark and 
Hollingworth (1993b) determined the VMD of a sample of milled NST to be 8 pm. 
Particle size determination was performed using LALLS (Malvern 2600, Malvern 
Instruments) with the sample suspended in propan-2-ol and the scattered light focused 
using a 63 mm lens. Prior to analysis, the sample was dispersed for 2 minutes using an 
ultrasonic water bath. Wong et al. (1995b) determined the VMD of milled and 
micronised NST in liquid suspension by LALLS to be 10.17 and 5.0 pm respectively. 
Details regarding the preparation of the samples prior to particle sizing were not 
provided.
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Based on LALLS investigations, Wong et al. (1995) determined what they considered to 
be the potentially respirable fraction (0.5 to 7 pm, Dae) of the milled and micronised 
NST to be 37.6 and 67 % respectively.
In the present study, the measured particle size distribution of both milled and 
micronised NST is smaller than that determined by Wong et al. (1995b) and Clark and 
Hollingworth (1993b). The milled and micronised NST samples have a VMD of 
approximately 1 pm with 90% of the milled material having an equivalent volume 
diameter <13 pm and 90% of the micronised NST having a diameter <5 pm. The 
measured difference may be due to the use of different batches of NST or a result of 
differences in the preparation of the samples prior to LALLS analysis. The present 
study has demonstrated the importance of optimising sample presentation prior to 
particle sizing. It is considered that the degree of deaggregation in both previous studies 
may have been insufficient to regenerate discrete NST particles and both Wong et al. 
(1995b) and Clark and Hollingworth (1993b) may have measured the particle size 
distribution of drug agglomerates.
Results obtained using the 45 mm lens to collate the scattered light suggest that the 





Dispersant d(0.1) (|im) d(0.5) (pm) d(0.9) (pm)
Run 1 Run 2 Run 1 Run 2 Run 1 Run 2
1 Non-saturated 0.63 0.73 3.33 6.03 12.53 16.65
3 Non-saturated 0.63 0.69 3.23 5.52 12.06 12.35
5 Non-saturated 0.63 0.69 3.19 4.50 11.99 12.27
10 Non-saturated 0.62 0.64 3.06 3.59 11.28 9.28
15 Non-saturated 0.63 0.66 2.93 3.57 10.92 9.04
30 Non-saturated 0.62 0.63 2.80 2.72 10.34 7.81
1 Saturated 0.64 0.62 3.75 3.28 13.33 13.95
3 Saturated 0.63 0.62 3.46 3.18 11.66 13.04
5 Saturated 0.62 0.62 3.32 3.17 11.21 12.97
10 Saturated 0.62 0.62 3.24 3.19 10.88 12.48
15 Saturated 0.62 0.62 3.11 3.15 10.60 12.72
30 Saturated 0.62 0.62 2.97 3.10 10.62 10.07
Table 8.1 Particle size analysis of milled NST suspended in cyclohexane + 0.1% w/v 
lecithin. Investigations were performed using the 100 mm 
lens in conjunction with a SVC.
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Figure 8.1 The effect of deaggregation time and suspending medium on 
the particle size distribution of milled NST.
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NST d (0.1) pm d (0.5) pm d (0.9) pm
< Run 1 Run 2 Run 1 Run 2 Run 1 Run2
Micronised 0.20 0.24 0.83 0.89 3.89 4.99
Milled 0.22 0.23 0.86 1.08 12.84 20.34
Table 8.2 Particle size distribution of the milled and micronised NST.
The 45 mm lens was used in conjunction with the LVC.
8.3.2 Microscopic Investigations
Materials and Methods
Relying on particle size information from one method of analysis was again deemed 
scientifically unwise. Therefore, the particle size of the milled NST was studied using 
LTSEM and compared to previous images obtained for the micronised NST (figures 3.8 
and 3.9). The techniques used to prepare and analyse the samples have previously been 
described in section 3.2.2.
Results and Discussion
LTSEM images of the milled NST are shown in figures 8.2 and 8.3.
From the samples analysed, the particle size would appear to correlate with particle size 
measurements obtained using the technique of LALLS. Visual assessment of the 
images, suggest that the particle size of the discrete particles of milled NST are of a 
similar size to the micronised particles. A large percentage of the milled and micronised 
particles appear to be approximately 1 pm with the majority of particles below 5 pm.
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Figure 8.2 LTSEM electron micrograph of the milled NST.
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Figure 8.3 LTSEM electron micrograph of the milled NST.
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As the particle size decreases, dispersion becomes increasingly difficult due mainly to 
an increase in van der Waals interparticle interactions (Hickey at al. 1994). The flat, 
irregular crystals of both materials may further increase the interparticle interactions 
operating within both systems due to an increase in contact area.
8.3.3 Characterisation of the Water Content
Materials and Methods
The water content of the milled NST was investigated using KF analysis and then 
compared to measurements obtained for the micronised NST (section 7.2.3). Methods 
for KF investigations have previously been described in section 7.2.3. Sample 
preparation involved dissolving the powder samples in methanol (section 7.2.3).
Results and Discussion
Data from KF analysis on the milled NST are summarised and compared with that of 
micronised NST in table 8.3.
Material Mean SD
Micronised nedocromil sodium 12.38 0.11
Milled nedocromil sodium 12.34 0.09
Table 8.3 Total water content of milled and micronised NST determined using KF 
analysis (n = 5).
The Students t-test revealed no significant difference between the total water content of 
the milled and micronised NST (t = 0.73, p = 0.48).
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8.3.4 Surface Area Investigations
Materials and Methods
Methods for surface area investigations have previously been detailed in section 2.3.2.
Results and Discussion
Table 8.4 summarises the surface area measurements obtained for the milled and 
micronised NST. The Students t-test revealed that the specific surface area of the milled 
NST is significantly less than that measured for the micronised NST (t = 8.56, p < 
0.001). This could be due to the constituent particles of the micronised NST having a 
smaller particle size. Alternatively, the constituent particles of the milled NST may be 
more firmly agglomerated, preventing the nitrogen permeating all the particle surfaces.
NST Run Adsorption Parameters Specific Surface 
Area 
(m2 g'1)C Intercept Correlation
Coefficient
1 61 0.01 0.9999 7.2
Micronised 2 60 0.01 0.9999 6.9
3 59 0.01 0.9993 7.3
1 57 0.01 0.9999 5.6
Milled 2 61 0.01 0.9999 5.5
3 55 0.01 0.9999 5.9
Table 8.4 Surface area measurements for the milled and micronised NST.
8.3.5 X-Ray Powder Diffraction
Materials and Methods
X-ray powder diffraction (XRPD) was performed to assess the degree of crystallinity of 
both the milled NST and micronised material. The X-ray diffraction patterns were 
scanned between 5.00 and 59.62 in 0.02 degree steps.
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Instrumentation
Philips PW 1730/00 4kW generator
Philips PW 2273/20 long fine focus 2kW copper target X-ray tube, operated at 40 kV, 
25 mA.
Philips PW 1820/00 computer controlled vertical diffractometer goniometer.
Philips PW 1711/10 Xenon proportional counter with PW 1752/00 graphite 
monochromator and PW 1368/55 automatic divergence slit assembly.
Philips PW 1710/00 microprocessor diffractometer control Philips PW 1877 PC-APD, 
version 3.5b diffraction software.
Results and Discussion
Figure 8.4 shows the X-ray diffractogram for the milled NST superimposed on the X- 
ray information obtained for the micronised NST.
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Figure 8.4 X-ray diffractograms for micronised and milled NST.
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Figure 8.4 suggests that there is no difference in the degree of crystallinity between the 
milled and micronised NST.
The X-ray pattern of both materials show a series of sharp diffraction peaks indicating 
that these hydrates are crystalline.
8.4 In-vitro Aerosol Characterisation
Wong et al. (1995b) concluded that the in-vitro aerosol performance of milled NST was 
superior to that of the micronised NST. They reported that although the milled NST 
contained a smaller proportion of potentially respirable material when compared with 
the micronised material, a better in-vitro dispersion performance was obtained for 
blends containing the milled drug. The difference in dispersion was attributed to the 
cohesive interactions of the drug particles as a result of the differences in the particle 
size distributions. To more fully characterise the cohesive interactions governing the 
deaggregation and dispersion of milled and micronised samples of NST, a range of flow 
rates was employed to characterise the aerosol cloud.
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8.4.1 M aterials and M ethods
The in-vitro aerosol performance of the milled and micronised NST was investigated 
using the modified Apparatus A at four different flow rates; 30, 60, 80 and 100 litres 
min'1. Increasing the flow rate will reduce the ECDso% for the stage-1 jet of Apparatus 
A (Hallworth and Westmoreland, 1987). Therefore, based on impactor theory 
(Hallworth and Westmoreland, 1987), modified stage-1 jets of known internal diameter 
were manufactured (section 2.5.1) and employed at the respective flow rate to maintain 
an ECDso% of approximately 5 pm. Table 8.5 details the calculated and measured (if 
applicable) ECDso% of the four stage-1 jets employed in the study. The modified stage- 







9.7 5.20 at 30 litres min’1 6.6 (± 0.4)
11.6 4.80 at 60 litres min’1 5.3 (±0.3)
13.4 5.20 at 80 litres min'1 5.4 (± 0.3)
14.2 5.08 at 100 litres min'1 not measured
Table 8.5 Internal diameters for the stage-1 jets of the modified Apparatus A 
and the corresponding ECDso% at the specified flow rate.
*Measured by AEA technology, Aerosol Science Centre, Oxfordshire, U.K. 
±value in parenthesis is an estimate of precision (AEA data base).
8.4.2 Results and Discussion
For the 9.7 mm jet, the calibration value of 6.6 was higher than obtained from equation 
2.3. Calculation of the Stokes number for the four jet sizes using equation 2.2 gives 
values of 0.115 -  0.118. However, for Reynold’s numbers in the range 500-3000, the 
Stokes number for round impactor jets is quoted as 0.24 (Hinds, 1982). The calculated
245
Reynold’s number for the 9.7 mm jet is 3500, which is not too far removed from the 
quoted range. Recalculation of the ECDso% from equation 2.2 using a Stokes number of 
0.24, gives a value of 7.3 pm. The measured value thus lies between the two estimates 
and can therefore be considered reasonable.
ribCapsules of fill weight 8 mg were discharged from the Cyclohaler at the respective 
flow rate. Table 8.6 and figures 8.5 to 8.7 detail the aerosol performance of the milled 
and micronised NST at various flow rates.
One way analysis of variance revealed that increasing the flow rate produced a 
significant increase in the ED for the milled NST (F = 98.4, p < 0.001) but a significant 
decrease in the ED for the micronised NST (F = 144.01, p < 0.001). Fisher’s pairwise 
comparisons revealed that the significant difference for both systems occurred when the 
flow rate was increased from 30 to 60 litres min'1, with no significant differences in the 
ED observed thereafter. For both materials the capsule emptied efficiently and 
reproducibly (< 4% of the recovered drug retained) at all flow rates. However, when 
the flow rate was increased from 30 to 60 litres min'1, there was a large increase in the 
percentage of micronised NST adhering to the device (5.04 ± 0.84% to 20.8 ± 2.2 % of 
the recovered drug).
It has been shown that increasing the flow rate generally increases the ED for carrier 
based DPI systems (Hindle and Byron, 1995b; Zanen et al. 1992). However, increasing 
the flow rate can also improve the deaggregation of the powder system leading to an 
increased generation of fine particle material (Newman et al. 1991a; Pitcairn et al. 
1997). The increased surface area and hence surface free energy of the deaggregated 
systems may cause an increase in drug adhesion onto the device wall.
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In-vitro Aerosol Characterisation
Parameter Flow Rate Micronised Milled
(litres min'1) NST NST
% Capsule 30 2.09 ± 0.70 2.87 ± 0.49
% Device 30 5.04 ± 0.84 13.3 ±2.0
% Stage 1 30 90.2 ±1.4 69.5 ±2.0
% Stage 2 30 2.66 ±0.31 14.3 ± 0.89
Emitted Dose (mg) 30 7.53 ±0.19 6.79 ±0.18
Emitted Dose (%) 30 92.9 ±1.4 83.8 ±1.9
Fine Particle Dose (mg) 30 0.22 ± 0.024 1.16 ±0.07
Fine Particle Fraction (%) 30 2.87 ± 0.34 17.1 ±1.1
Drug Recovery (%) 30 101 ±1.2 101 ± 1.2
% Capsule 60 3.73 ±1.0 2.45 ± 0.20
% Device 60 20.8 ± 2.2 9.84 ±2.6
% Stage 1 60 63.6 ±3.7 66.2 ± 2.9
% Stage 2 60 11.9 ± 1.5 21.5 ±2.6
Emitted Dose (mg) 60 6.06 ±0.19 7.10 ±0.26
Emitted Dose (%) 60 75.5 ± 2.4 87.7 ± 2.7
Fine Particle Dose (mg) 60 0.95 ±0.12 1.85 ±0.27
Fine Particle Fraction (%) 60 15.8 ±2.5 24.5 ± 2.84
Drug Recovery (%) 60 100 ±1.7 101 ±0.96
% Capsule 80 3.42 ± 0.65 2.25 ± 0.39
% Device 80 19.3 ±1.7 6.70 ± 0.75
% Stage 1 80 58.6 ± 2.4 67.9 ± 0.96
% Stage 2 80 18.7 ± 1.3 23.2 ± 0.72
Emitted Dose (mg) 80 6.28 ±0.17 7.40 ±0.12
Emitted Dose (%) 80 77.3 ±1.7 91.1 ±1.01
Fine Particle Dose (mg) 80 1.52 ±0.10 1.88 ±0.064
Fine Particle Fraction (%) 80 24.2 ± 1.9 25.5 ± 0.72
Drug Recovery (%) 80 102 ±1.1 101 ± 1.27
% Capsule 100 3.65 ± 0.68 2.67 ± 0.33
% Device 100 19.3 ± 1.5 8.03 ± 0.95
% Stage 1 100 55.4 ±2.8 67.1 ±3.2
% Stage 2 100 21.6 ± 1.3 22.3 ± 2.2
Emitted Dose (mg) 100 6.23 ±0.14 7.29 ±0.18
Emitted Dose (%) 100 77.1 ±1.8 89.3 ±1.25
Fine Particle Dose (mg) 100 1.75 ±0.10 1.82 ±0.18
Fine Particle Fraction (%) 100 28.1 ±2.1 24.9 ± 2.8
Drug Recovery (%) 100 101 ±0.61 102 ±1.7
Table 8.6 In-vitro aerosol characterisation of the milled and micronised NST
at various flow rates. Values are the mean ± SD of ten determinations. 
ED and FPD were normalised with respect to an 8 mg fill weight.
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Capsule Device Stage One Stage Two
Modified Apparatus A
Figure 8.5 The effects o f flow rate on the in-vitro aerosol performance of 
micronised NST.
Each column shows the mean o f 10 determinations (bars represent SDs).
t l Flow Rate - 30 I min"1 
Flow Rate - 60 I min"1 
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Capsule Stage One Stage TwoDevice
Modified Apparatus A
Figure 8.6 The effects o f flow rate on the in-vitro aerosol performance of 
milled NST.
Each column shows the mean o f 10 determinations (bars represent SDs).
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Flow Rate ( I min"1 )
Milled NST (Emitted D ose) 
M icronised NST (Emitted D ose) 
Milled NST (Fine Particle D ose) 
M icronised NST (Fine Particle D ose)
Figure 8.7 The effects of flow rate on the in-vitro aerosol performance of
milled and micronised NST.
ED values are the mean ± SD of ten determinations.
FPD values are the mean + SD of ten determinations.
At flow rates >60 litres min'1, the milled NST showed a decreased tendency to adhere to 
the device wall. This suggested that the deaggregation of the milled NST did not result 
in the regeneration of discrete particles. Instead, the milled powder system may 
deagglomerate into aggregates of milled NST with a larger effective size and therefore, 
a decreased surface free energy.
Fine Particle Drug Deposition
The deaggregation (FPF) and subsequent stage-2 deposition (FPD) of the pure drug
systems was characterised over the range of flow rates. The micronised NST displayed
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a continual increase in both the FPF and FPD with increasing flow rates. However, one 
way analysis of variance in conjunction with Fisher’s pairwise comparisons, revealed 
that the milled NST only showed an increase in drug deaggregation (FPF) when the 
flow rate was increased from 30 to 60 litres min'1 (F = 34.72, p < 0.001). However, the 
milled system showed no significant increase in the deaggregation of the system 
thereafter.
The Students t-test revealed that the milled NST is deaggregated more completely (FPF) 
into discrete particles and/or potentially respirable aggregates (<5 pm, Dac) at flow rates 
of 30 litres min*1 (t = 40.59, p < 0.001) and 60 litres min"1 (t = 7.24, p < 0.001) when 
compared with the micronised NST. However, there is no significant difference 
between the FPF of the micronised or milled NST when the systems are deaggregated at 
80 litres min*1 (t = 2.06, p = 0.055) and at 100 litres min*1, the deaggregation of the 
emitted drug is significantly greater for the micronised material (t = 2.17, p = 0.044).
The results suggest that the cohesive interactions operating within the micronised NST 
powder system are greater than those operating within the milled NST system. 
However, from both LTSEM and LALLS studies, the particle size distributions of the 
two materials do not appear to differ dramatically.
It is proposed that the milling and micronisation stages, employed in the manufacture of 
the fine particle NST (Clark and Hollingworth, 1993b), are not in fact size reduction 
stages but instead deaggregation stages. The VMD of both materials is approximately 1 
pm however, the micronised NST requires a greater input of energy (increased flow 
rate) to achieve the same degree of deaggregation. The initial process of crystallisation
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produce particles with a VMD of approximately 1 pm, which due to their large surface 
area and excess surface free energy experience strong cohesive interactions (Adjei and 
Gupta, 1997). It is considered that the cohesive interactions operating within this 
system would not be overcome by the shear forces generated upon aerosolisation of the 
powder system from a DPI device.
Re-ciystallised NST Milled NST Micronised NST
t 6b 9 \  /
( a ) ( b ) (C)
Figure 8.8 Diagrammatic representation of the cohesive interactions thought to be
operational in the initial crystallised material and the milled and 
micronised NST systems.
The milling process may partially deaggregate the system into smaller sized 
agglomerates, of which a fraction may be potentially respirable (figure 8.8b). The 
cohesive interactions operating between agglomerates are considered to be reduced due 
to their larger effective size. However, the constituent particles within these milled 
agglomerates are still considered bound by strong cohesive interactions. Therefore, 
upon aerosolisation the system can be partially deaggregated (at relatively low shear 
forces) into the smaller agglomerates, some of which possess an Dae <5 pm. However, 
deaggregation will not be complete since the shear forces generated will only be 
sufficient to overcome the forces binding the agglomerates and not to deaggregate the
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system into its constituent particles. Since only a fraction of the agglomerates have an 
Dae <5 pm, the efficiency of the system is compromised.
The air jet milling employed to produce the micronised NST may further deaggregate 
the milled NST. The micronised system (figure 8.8c) is considered to consist of a 
greater percentage of discrete particles together with smaller sized, potentially respirable 
agglomerates. Due to the increased surface area and surface free energy, the cohesive 
interactions binding the micronised NST particles/agglomerates are considered to .be 
greater than the forces binding the agglomerates produced by milling. However, due to 
the deaggregation stages, the interparticle interactions are less than those acting within; 
a) the original crystallised material or b) the agglomerates of the milled system.
Therefore, a greater force is required to regenerate potentially respirable particles from 
the micronised system but there is an increased potential for fine particle deposition 
compared with the milled material; an optimum FPD is not attained even at 100 litres 
min'1 for the micronised NST. The increased regeneration of discrete NST particles is 
possibly reflected by the increase in adhesive interactions at the higher flow rates 
(increased device deposition).
At 100 litres min'1, the micronised NST shows a significant improvement in the FPF 
compared with the milled material (t = 2.17, p = 0.044). However, this improved 
deaggregation does not translate into a significant improvement in the FPD (t = 1.25, 
p = 0.23 ) due to the increased adhesion of the micronised NST particles onto the device 
walls. The flow rate corresponding to a pressure drop of 4 kPa was measured (section
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2.5) at 96 litres min'1. Therefore, the difference in deaggregation properties of the two 
samples may not transfer into any improved performance in clinical practice.
Unfortunately, the unprocessed NST could not be obtained for characterisation.
8.5 General Discussion
It is recognised that the techniques employed to assess the total water content (KF and 
DSC) and the degree of crystallinity (XRPD) may not be sensitive enough to detect 
surface changes that may influence the physical properties of the two power samples. 
XRPD has been shown to only be able to detect 10% or more of amorphous material in 
powders (Saleki-Gerhardt et al. 1994). Stresses induced during processing may result in 
considerably less than 10% of the material becoming amorphous (Buckton, 1995). 
Furthermore, the disruption will not be distributed uniformly throughout the powder 
mass but will predominate at the surfaces that have been subjected to the processing 
stress (Elamin et al. 1994). Therefore, small quantities of amorphous material may be 
very significant with respect to surface interactions. Future experimental work may 
utilise techniques that can obtain a thermodynamic assessment of the powder surface 
properties of the milled and micronised NST (Buckton, 1997; Feeley et al. 1998; 
Ticehurst et al. 1994).
The cohesive interactions governing the aerosol performance of NST powder 
formulations would appear to result from the ultrafme nature of the constituent particles. 
The importance of formulating systems for inhalation, containing drug particles with an
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Dae <5 jim is widely recognised. However, the cohesive interactions operating within 
systems containing particles at the lower end of this particle size range may be too great 
for the efficient deaggregation and regeneration of discrete particles.
In agreement with Wong et al. (1995b), the milled NST demonstrates improved aerosol 
characteristics (increased ED and FPD) at lower flow rates (<60 litres min'1). However, 
the potential for complete deaggregation from a DPI formulation/device system at 
attainable flow rates would appear unattainable due to the strong interparticle forces 
acting within the aggregates.
It is considered, based on the aerosol performance of the milled and micronised NST, 
that to improve the performance of the micronised NST, the crystallisation of the 
original material needs optimising to produce potentially respirable particles but with a 
larger particle size. This may lead to a decrease in the surface free energy of the system 




The interparticle interactions governing the mixing and aerosol properties of powder 
systems containing a high mass of NST were investigated. By correlating the 
deaggregation of the powder system following various formulatory procedures, it was 
hoped that the contributions of cohesive (drug/drug) and adhesive (drug/carrier) 
interparticle interactions to the performance of NST as a high mass aerosol system could 
be established. To supplement these formulation studies, LTSEM and ESEM 
investigations were performed on the powder formulations since NST was not amenable 
to characterisation by conventional SEM techniques.
Optimisation of particle sizing procedures (LALLS), revealed that the micronised NST 
was an ultrafine powder with a VMD of approximately 1 pm and with 90% of the 
particles having an equivalent volume diameter <5 pm. LTSEM, a novel technique for 
studying hydrated pharmaceutical material, confirmed this particle size distribution.
Preliminary investigations studied the deaggregation and subsequent stage-2 deposition 
(modified Apparatus A) of pure NST (no carrier) to assess the extent of the cohesive 
interactions governing the aerosol performance of the system. Generally, the 
deaggregation and subsequent stage-2 deposition were considered to be poor; FPF <15 
% and FPD <1 mg when an 8 mg capsule fill weight was discharged from the 
Cyclohaler® at 60 litres min*1.
Therefore, the aerosol performance of NST formulated with lactose as a high mass drug 
system was assessed. Information regarding the inteiparticle forces of adhesion and 
cohesion governing the aerosol performance of high mass carrier based formulations of 
NST was inferred from these studies.
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It has previously been reported that the TTM can be used to prepare carrier based 
systems for inhalation containing a high mass of both NST and DSCG (Braun et al. 
1996; Vidgren et al. 1987b, 1988a, 1988b, 1989 and 1990; Wong et al. 1995a and 
1995). Therefore, coarse carrier lactose based formulations (63-90 pm) were initially 
assessed, blending the drug and excipient materials for various time periods in the TTM 
with and without the inclusion of screening stages.
An acceptable homogeneity of drug within the blend (CV <5 %) was achieved by 
careful control of the mixing time and the inclusion of screening stages. However, it 
was considered that due to the high percentage of NST present within the formulation, 
the quality of the mix was governed by interactions operating between the ordered units 
of NST and the carrier component (lactose particles with either minimal, mono- or 
multi-particle layer coverage) and the agglomerates of pure drug. Formulations 
produced using the TTM with a 63-90 pm coarse carrier sieve fraction of lactose did not 
improve the deaggregation or subsequent fine particle deposition of NST when 
formulated as a high mass (40 % w/w) drug system. Although an acceptable drug content 
uniformity was obtained it was considered that the selection of the coarse carrier 
fraction and/or the mixing technique employed, failed to effectively deaggregate the 
pure drug agglomerates and promote the subsequent distribution of NST onto the 
carrier. Despite its extensive use in previous studies investigating high mass drug 
systems, the TTM is considered inappropriate for the formulation of high mass NST 
powder systems (and possibly other high dose compounds) when formulated as a coarse 
carrier based system. It was considered that despite the inclusion of a coarse carrier 
component, the aerosol performance of the powder systems was still governed by the 
cohesive drug/drug interactions.
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Attempts were made to improve the aerosol performance of the coarse carrier 
formulations by blending the components using alternative mixing techniques, capable 
of producing increased shear forces (HB and RBB). However, the aerosol performance 
of the systems was still considered to be poor; FPF <11 % and FPD <0.7 mg.
Therefore, the use of alternative lactose size fractions was investigated. The addition of 
5% w/w FPL to the carrier component, a procedure which has previously been shown to 
improve the aerosol performance of low dose powder systems (Lucas et al. 1998a and 
1998b) failed to improve the aerosol performance of the high mass NST systems. It was 
considered that although the FPL may promote drug liberation from the carrier surface 
(Hersey, 1975; Lucas et al. 1998a), the interparticle forces governing the aerosol 
performance of NST are the cohesive drug/drug interactions.
By decreasing the particle size of the carrier (<45 pm sieve size fraction or the use of 
FPL), the deaggregation and subsequent fine particle drug deposition was improved 
dramatically. Further improvements were made by selecting and then optimising high 
shear mixing procedures (RBB), resulting in efficient drug deaggregation FPF >50 % 
which translated into an improved FPD >3 mg. It was concluded, based on these 
findings together with the evidence from LTSEM and EDAX images, that the FPL is 
producing its functional effects by intercalating within the drug self-agglomerates and 
physically disrupting the cohesive drug/drug interactions. The use of a smaller sized 
lactose size fraction in conjunction with a blending procedure capable of disrupting the 
drug self-agglomerates allowed the optimum intercalation of the excipient material 
within the self agglomerates. It was concluded that the adhesive NST/FPL interactions 
were weak compared to the cohesive NST/NST particle interactions; cohesive
258
interactions that would normally govern the aerosol performance of high mass NST 
powder systems.
The optimised formulation was aggregated into free flowing spheres, which displayed 
the same improved aerosol properties as the non-aggregated system. However, it was 
demonstrated that a compromise must be attained between the robustness of the sphere 
and the efficient regeneration of discrete particles or potentially respirable drug 
aggregates upon aerosolisation.
The intercalation of FPL within systems containing TS failed to produce an 
improvement in the deaggregation of the powder system upon aerosolisation, suggesting 
that the functional effects of the FPL are material dependent.
It was subsequently decided to investigate possible causes of the strong cohesive 
interactions operating within the pure NST drug system. Since NST is a highly hydrated 
compound, the effects of storage humidity on the extent of water sorption and its 
subsequent effects on the aerosol performance of the drug system were assessed.
Nedocromil sodium is stable as the trihydrate over the relative humidity range 6.4 to 
79.5% (Khankari et al. 1998). Over the humidity range 12% to 76% RH, no dramatic 
effects on the deaggregation and fine particle deposition were observed for the NST 
powder system. Particles stored at 12% RH showed an improved deaggregation (FPF 
-20%) however, this did not translate into a dramatic improvement in the FPD (<1.2 
mg) due to the increased adhesion of the system causing a greater device retention. 
However, conversion to the heptahemihydrate dramatically decreased the deaggregation 
(FPF < 8%) and subsequent fine particle deposition (FPD < 0.5mg). Liquid and/or solid
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bridge formation, as suggested by LTSEM investigations, were believed to be the cause 
of the difficulty in deaggregating the NSHH system.
It was considered that the fine nature of the material might be responsible for the strong 
cohesive interactions governing the aerosol performance of NST containing systems. 
Therefore, based on reports in the literature (Wong et al. 1995b), a sample of milled 
NST was extensively characterised and its physicochemical and aerosol properties 
compared to the micronised material.
Both LTSEM and LALLS suggested that the particle size distributions of the two 
materials did not differ dramatically. However, the in-vitro aerosol characterisation of 
both materials suggested that the cohesive interactions operating within the micronised 
NST powder system were greater than those operating within the milled NST system.
It is suggested that the milling and micronisation stages, employed in the manufacture of 
the fine particle NST, are not in fact size reduction stages but instead deaggregation 
stages. Due to the increased surface area and surface free energy, the cohesive 
interactions binding the micronised NST particles/agglomerates are considered to be 
greater than the forces binding the agglomerates produced by milling.
The cohesive interactions governing the aerosol performance of NST powder 
formulations would appear to result from the ultrafine nature of the constituent particles. 
It is considered, based on the aerosol performance of the milled and micronised NST, 
that to improve the performance of the micronised NST the crystallisation of the original 
material needs optimising to produce potentially respirable particles but with a larger 
particle size. This may lead to a decrease in the surface free energy of the system and 
therefore, the more efficient regeneration of discrete particles upon aerosolisation.
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The importance of formulating systems for inhalation containing drug particles with an 
Dae ^5 pm is widely recognised. However, the cohesive interactions operating within 
systems containing particles at the lower end of this particle size range may be too great 





By assessing the mixing behavior and the in-vitro aerosol performance of high dose NST 
powder systems, information regarding the interparticle interactions governing the 
powders’ properties was gained.
LTSEM, a technique considered novel to the characterisation of pharmaceutical particles, 
was developed. By freezing and thus stabilising sorbed moisture, LTSEM enabled the 
micronised and milled samples of NST and NSHH to be imaged. LTSEM and ESEM were 
both used to characterise the drug particles’ distribution within powder systems containing 
coarse and/or fine lactose material.
The re-generation of potentially respirable NST particles from carrier based and self- 
agglomerated drug systems was considered poor due to the strong cohesive interactions 
operating within the drug system. Formulation studies revealed that the inclusion of a 
coarse lactose carrier in high dose drug systems containing NST, had no significant effect 
in disrupting the drug/drug cohesive interactions. It was also concluded that the use of 
tumbling action mixers should be avoided when formulating NST and possibly other fine 
material due to the increased chance of self-aggregation of the drug system.
An improved deaggregation of the pure drug system was achieved by selecting fine 
excipient material in conjunction with a mixing procedure capable of producing increased 
shear forces. The two formulatory procedures initially enabled the physical disruption of 
the cohesive drug interactions, which subsequently allowed the finer excipient particles to 
intercalate within the drug self-aggregates. By physically disrupting the drug/drug
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interparticle interactions, more complete deaggregation of the drug system was achieved 
with a subsequent three-fold increase in the fine particle deposition of NST.
LTSEM in conjunction with ED AX confirmed the intercalation of FPL within the cohesive 
drug system. This combination of techniques is considered novel to the analysis of 
pharmaceutical particle systems.
The inclusion of the fine excipient material did not adversely affect the tendency of NST to 
self-agglomerate, a property considered useful when trying to formulate a powder for 
inhalation with acceptable flow properties.
Storage humidity does not have a dramatic effect on the deaggregation and subsequent fine 
particle deposition of NST.
LALLS and LTSEM characterisation of the milled and micronised NST revealed that both 
materials are ultrafine powders. The cohesive interactions dictating the performance of 
NST powder systems were considered to result from the ultrafine nature of the material. In 
this system, producing drug particles of too small a particle size compromised the DPI 
formulations without improving the fine particle dose.
Alternative methods of producing potentially respirable drug particles, e.g. supercritical 
fluid technology or spray drying, may result in the generation of fine particles with reduced 
surface energies. These particles may deaggregate more completely upon aerosolisation 





Particles size within the Dae range 1-5 pm needs to be investigated especially when 
considering high dose drug systems where cohesive interactions may govern the mixing 
and aerosol performance of the powder system.
Future work should concentrate on assessing the surface energetics of NST particles in 
discrete size channels between 1 and 5 pm. The atomic force microscope (AFM) may 
provide an ideal tool with which to further these investigations (Bowen et al. 1998). 
Additionally, the effects of triboelectrification on the deaggregation of the powder 
system should be assessed and correlated with electrostatic measurements on the bulk 
powder system (Peart, 1996). Assessment of the surface energetics of the milled and 
micronised NST as well as powder systems stored at various humidities might also 
provide useful information.
Optimisation of the aggregated drug systems by the inclusion of an even finer excipient 
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Appendix II Statistical Analysis
To Determine the Equality of More than Two Estimates of a Parameter (P)
The Bartlett test was used to compare calibration graphs (slopes) for nedocromil sodium 
trihydrate (stored under various conditions of humidity), nedocromil sodium 
heptahemihydrate and terbutaline sulphate.
2
Z  = — £3—
where a 2 is given by,
±2 nls1l + n 2s 12+ n„s2n
< 7  — -------------------------------------------------------------------------------------------------------------
nx +n2+  nn
where S1? S2 etc. are the standard deviations associated with the estimates P 1> 2̂> etc. and 
nj and n2 are the number of observations used in determining the estimates.
If the estimates all come from the same normal distribution,
^ 2 will have %2 distribution with N-l degrees of freedom,
(J
where N is the number of estimates.
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Appendix in  
Determination of the Test Flow Rate for the 
Evaluation of the Cyclohaler at 4 kPa
Equipment
• Hastings Mass Flow Meter model HFM 201, Transducer and model CPD-100 
Display Unit (range 1-150 lires min'1).
• 5-Stage Liquid Impinger.
• Differential Pressure Manometer (Digitron P200 H.is).
• Absolute Pressure Manometer (Digitron P200 HA).
• Flow Rate Regulator Unit incorporating regulator valve, timer and solenoid.
• Gast Vacuum Pump Model No. 1023.
Procedure
1. The apparatus was assembled as shown in Figure A7. Rubber bungs were inserted 
into the MSLI sampling ports in stages 2, 3 and 4. A “special” bung, which allowed 
connection of the differential pressure meter to the stage 1 sampling port, was also 
employed.
2. The Cyclohaler® was inserted into the silicone rubber adaptor.
3. The vacuum pump was switched on, the timer-solenoid unit opened and the 
regulating valve adjusted until the differential pressure at the sidearm was 4 kPa. 
Two Gast Vacuum Pumps, connected in parallel, were required to achieve the
4 kPa pressure drop across the Cyclohaler®. The pump was then switched off, the 
manometer, Cyclohaler® and silicone adapter removed and stage-1 sealed with a 
“normal” bung.
4. The flow rate (litres min'1) was determined by connecting the flow meter to the 
MSLI.
5. The silicone rubber adaptor and Cyclohaler® were replaced and with the pump 
running the absolute pressure either side of the timer solenoid (P2, P3) measured with 






5 -S ta g e
Liquid Impinger
Tim er/so leno id
R egu la t ing  ValveV acu u m  P u m p
P3 P2
Figure A7 Schematic of apparatus for determination of Cyclohaler® flow rate for 4 
kPa pressure drop.
S = CDFS Solenoid/timer control (CDFS, University of Bath, Bath, U.K.) 
V = Regulating valve.
API = Differential pressure to atmosphere, Digitron P200 H.is.
P2/P3 = Absolute pressure, Digitron P200 HA.
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Appendix IV Drug Monolayer Coverage
An approximate concentration (% w/w) of micronised NST required to form a theoretical 
monolayer of particles on the surface of the coarse carrier lactose was calculated based 
on the assumptions and conclusions of Hersey (1975). Values were obtained based on 
true density and specific surface area values.
Material Median True Density Specific surface Area
Diameter (pm) (kg m'3) (m2 g 1)
63-90 pm Lactose 96.5 1.54 0.12
NST Micronised 0.86 1.63 7.1
Table Al. Experimental Data
From surface area data, concentration of NST required for theoretical mono particle 
layer coverage = 6.0 % w/w
From true density data, concentration of NST required for theoretical mono particle 
layer coverage = 3.5 % w/w
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